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General introduction | 9 
From ancient times on mankind has searched for ways to cure diseases. The first written 
records originate from the Mesopotamians and Egyptians who already had a keen interest 
in the causes and the healing of diseases.1, 2 In these times healing was strongly tied to 
religion and superstition, and diseases were mainly ascribed to supernatural powers. Still, 
the basics of objective and empirical medicine started to emerge, including the description 
and use of natural products to cure diseases.3 This mixture of superstition and rationalism 
in the approach to medicine remained more or less the same until the advent of scientific 
experimental methods in the 16th and 17th centuries. The field of pharmacology emerged 
as late as the 19th century, when the concept of chemical structures and their relationship 
with their pharmacological action became a subject of study.4 In the following period 
impressive advancements were made with the formulation of receptor theory and  
the discovery of numerous receptor types and their endogenous ligands.5, 6 Today, 
pharmacology is a very diverse field with elements of molecular biology, genetics, 
chemistry, and bio-informatics, to name but a few disciplines. Together, these disciplines 
help to understand why a drug works and give exciting opportunities to develop new 
drugs.  
G protein-coupled receptors 
Of the many drug targets currently identified the G protein-coupled receptors (GPCRs) 
constitute a large fraction. The family of GPCRs encompasses more than 800 different cell 
membrane-bound receptors,7 which regulate many different aspects of human physiology, 
such as vision, homeostasis, and the immune system. This makes it no surprise that they 
are targeted by 30% to 40% of all drugs on the market.8 The general role of GPCRs is to 
relay a diverse collection of extracellular signals, such as photons, hormones, odorants, 
and neurotransmitters, to the intracellular environment. At the intracellular side GPCRs 
interface with G proteins that can further transduce the signal. GPCRs share a common 
structure of seven transmembrane alpha-helices connected by extra- and intra-cellular 
loops (Figure 1). According to their structural architecture, GPCRs can be subdivided in five 
different families: rhodopsin-like (class A), secretin-like (class B), glutamate-like (class C), 
adhesion-like, and frizzled/taste2-like receptors.7 Of these, the class A rhodopsin-like 
receptors constitute by far the largest group. 
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Allosteric modulation and the sodium ion site 
The ligands that can activate GPCRs know a wide variation in both size and chemical 
structure, from large proteins and peptides to small molecules and ions. The binding sites 
on GPCRs can be categorized as orthosteric sites, where endogenous ligands bind and 
activate the receptor, and allosteric sites, where ligand binding can modulate receptor 
activation (Figure 1). Most drugs target the orthosteric site as antagonists thereby 
blocking endogenous ligand binding and subsequent activation of the receptor, or as 
agonists that activate the receptor. Drugs that target the allosteric site may have a less 
‘blunt’ effect, as they enhance or dampen the activation by endogenous ligands.9-11 This 
has the advantage that the action is more localized in both time and space, as these 
allosteric modulators in the most stringent definition only have an effect when the 
endogenous ligand is present at the orthosteric site.  
 
Figure 1. Schematic representation of a GPCR embedded in the cell membrane. Seven 
transmembrane alpha-helices cross the cell membrane, with an extracellular N-terminus, an 
intracellular C-terminus, and six intra- and extra-cellular loops that connect the transmembrane 
regions. The orthosteric binding site is represented by an oval and the allosteric binding sites by 
circles. The middle circle approximates the location of the sodium ion site, in the central region of 
the receptor just below the orthosteric site. Note that the situation may be different for each GPCR 
considering the location and the number of binding sites. 
 
The concept of allosteric modulation is a promising one for the discovery of new 
drugs, and quite a few allosteric modulators have been found for GPCRs.12 However, the 
molecular basis of allosteric activity is still largely unknown. The increasing availability of 
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binding and GPCR activation.13-15 Recently, crystal structures have been solved with 
sufficiently high resolution to be able to spot a sodium ion in an allosteric site of several 
GPCRs, bound by the highly conserved amino acid Asp2.50 (Numbering according to 
Ballesteros and Weinstein16).17-21 Next to these solved crystal structures, sequence 
alignment indicates that this sodium ion site is very conserved and present in almost all 
class A GPCRs.22 This affirmed the results of earlier studies in which sodium ions were 
described as allosteric modulators of GPCRs.23 
The small molecule amiloride has been found to be an allosteric modulator for GPCRs 
as well. Amiloride is used therapeutically as a potassium sparing diuretic by blocking renal 
epithelial sodium channels (ENaCs).24 For GPCRs, amilorides have been found to compete 
with sodium ions for the same allosteric site.25 The feature of the sodium ion binding site 
to bind both small ions and small molecules is intriguing. Moreover, sodium ions and 
amilorides exhibit different allosteric modulation patterns, relative to each other but also 
between the different GPCRs, as discussed for sodium ions by Katritch et al.22 and for 
amilorides in Chapter 2 of this thesis. This makes the sodium ion site an excellent 
candidate of research to further understand the mechanisms behind allosteric 
modulation. 
Adenosine receptors 
The first crystal structure in which a sodium ion binding site was identified was of the 
adenosine A2A receptor.
17 Adenosine receptors belong to the class A rhodopsin-like GPCRs, 
and as the name suggests adenosine is the endogenous ligand. Caffeine and theophylline 
are antagonists and have a wide-spread use as a stimulant due to their ability to block 
adenosine receptors. The group of adenosine receptors encompasses four different 
subtypes with different structural features and physiological roles, named the adenosine 
A1, A2A, A2B, and A3 receptors. These receptors are well-documented by a few decades of 
research yielding a good understanding of their physiological role and a considerable 
number of selective agonists and antagonists is available.26, 27  Adenosine A2A receptors 
couple to Gs and Golf proteins and activation stimulates intracellular cAMP production.
28 
Adenosine A2A receptors are found in many different tissues, such as the brain striatum, 
leukocytes, the lung, and the heart. For their wide presence in the body adenosine A2A 
receptors regulate many different physiological processes, amongst which psychiatric 
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behavior, the sleep-wake cycle, the immune system, myocardial oxygen consumption, and 
angiogenesis. With these diverse roles the adenosine A2A receptor attracts substantial 
clinical interest for the development of drugs. Selective antagonists have been or are 
currently in clinical trials for treatment of Parkinson’s disease and cocaine addiction, and 
the same is true for selective agonists to replace adenosine as a coronary vasodilator in 
myocardial perfusion imaging and treatment of sickle cell anemia.28  
 
 
Figure 2. The sodium ion site in the crystal structures of the inactive (A) and the active state (B) of 
the adenosine A2A receptor. In A the sodium ion is shown as a dark grey sphere, coordinated by 
D522.50 through a salt bridge (dotted lines) and by waters (small solid spheres) and residue S913.39 
through hydrogen bonds (dotted lines). In B the pocket is collapsed leaving no room for the sodium 
ion to bind (hatched sphere). The receptor backbone is shown as ribbons, residues lining the sodium 
ion site are shown as sticks, and carbon and oxygen atom spheres are transparent. The crystal 
structure A was co-crystallized with antagonist ZM-241,385 and B with agonist UK-432,097.29 The 
binding site of these orthosteric ligands is located above residue W2466.48 and is clipped from this 
detailed view. From Liu et al.17 Reprinted with permission from AAAS. 
 
For the adenosine A2A receptor several crystal structures bound to agonists and 
antagonists have been solved.30, 31 The recently solved crystal structure with a bound 
sodium ion added substantially to our understanding of the molecular mechanism of 
adenosine A2A activation.
17 This crystal structure was co-crystallized with the selective 
antagonist ZM-241,385 and was hence a snapshot of the ‘inactive state’ of the receptor. 
Comparison with the ‘active state’ of the receptor co-crystallized with an agonist made 
clear that the sodium ion site undergoes substantial changes between the active and the 
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inactive states of the receptor (Figure 2). The apparent central role of the allosteric 
sodium ion site in the activation of the adenosine A2A receptor urged us to further 
investigate it in Chapters 3-5 of this thesis.  
Ligand binding assays 
To further explain the information derived from crystal structures the ‘wet lab’ is still 
indispensable. The field of pharmacology provides a multitude of different experimental 
setups to probe receptor and ligand characteristics. Most of these methods are dependent 
on labeled probes, for example radioligands and fluorescent ligands. Radioligand binding is 
a robust and well-tried method to probe pharmacological properties of ligands,32 and this 
method served us well in this thesis. However, the use of radiolabeled ligands is expensive 
and requires careful handling regarding safety and waste disposal. Therefore new 
methods to assess ligand binding are being developed, such as fluorescent labeling.33 
Labeling with bulky fluorescent moieties brings however its own risk of changing the 
pharmacological properties of a ligand. A label-free alternative for ligand binding assays is 
offered by mass spectrometry (MS).  
Advancements in mass spectrometry have made it possible to accurately measure the 
small quantities of ligand usually found in ligand binding assays. The use of mass 
spectrometry in ligand binding assays was coined ‘mass spectrometry binding’ (MS 
binding) by the group of Wanner. They developed it for several targets, amongst which 
the dopamine D2 receptor,
34 the GABA transporter mGAT1,35 and the serotonin 
transporter.36, 37 MS binding essentially follows a similar protocol as radioligand binding up 
to the point of the quantification of bound ligand, except for the use of an unlabeled 
ligand instead of a radioligand.  
In both radioligand and MS binding assays the ligand is allowed to bind to a crude 
membrane extract of cells expressing the target receptor. Then the reaction mix consisting 
of the ligand and receptor is filtered over a glass fiber filter, which only retains the 
membrane with the ligands bound to the receptor, while the unbound ligand is separated. 
After the filtration step radioligand and MS binding assays diverge. In the radioligand 
binding assay a scintillation fluid is applied to the filter after which the amount of 
radioligand can be quantified by scintillation counting. In the MS binding assay the bound 
ligand is first eluted from the filter by an organic solvent after which the ligand amount in 
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the solvent is quantified by a mass spectrometer. Before the detection by the mass 
spectrometer the ligand and remaining membrane content is separated by liquid 
chromatography (LC). Both the LC method and the MS detection method have to be 
developed for every ligand specifically, as each ligand has a different molecular mass and a 
different retention time on an LC column. A ligand for which the LC-MS method is 
developed is also called a marker ligand, and can be used in the same manner as a 
radioligand in radioligand binding assays to determine pharmacological binding properties 
of other, unlabeled ligands.  
The types of radioligand binding assays of which equivalents have been applied to MS 
binding by the group of Wanner are ligand saturation, displacement, association, and 
dissociation assays. Another type of radioligand binding assay is the competition 
association assay, in which the kinetic properties of a ligand can be determined without 
measuring binding of that ligand directly. Instead the ligand of interest competes for 
binding to the target with a radioligand of which binding can be followed directly.  Fitting 
the resulting association data of the marker ligand to a model describing competition 
association derives the kon and koff for the competing ligand.
38 In this thesis, we describe 
the development of an MS binding assay for the adenosine A1 and A2A receptors and its 
validation for the different types of ligand binding assays, including for the first time the 
competition association assay. 
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This thesis 
In Chapter 2 the current knowledge of allosteric modulation of class A GPCRs by 
amilorides is reviewed. We describe how the allosteric effects of amiloride and its 
analogues can be very different, depending on the GPCR and the orthosteric ligand in 
question. In Chapter 3 we focus on the mechanism of allosteric modulation by sodium 
ions in the adenosine A2A receptor by integrating the results of molecular dynamics, 
radioligand binding, and thermostability experiments. This approach allowed us to further 
explore the difference in allosteric modulation by sodium ions and amilorides between 
agonists and antagonists. In Chapter 4 we combine molecular dynamics, radioligand 
binding, and functional assays in a mutagenesis study to investigate the role of the amino 
acids that form the sodium ion site of the adenosine A2A receptor in ligand affinity and 
receptor signaling. We found that the sodium ion site was not only important for sodium 
ion and amiloride binding, but also for the overall receptor conformation and signal 
transduction. In Chapter 5 we describe the synthesis and biological evaluation of a 
number of amiloride analogues for the adenosine A2A receptor. We found novel potent 
amiloride analogues that all displace orthosteric ligands, but by different allosteric 
mechanisms. 
In these studies radioligands have been indispensable. Yet, the use of radioactively 
labeled ligands in the lab has its drawbacks, and hence Chapter 6 is dedicated to the 
development of a non-radioactive ligand binding protocol based on mass spectrometry 
(MS binding) for the adenosine A2A receptor and its close homolog the adenosine A1 
receptor. We validated that the MS binding assay works for different types of radioligand 
binding assays, and in addition we combined it for the first time with the competition 
association method to determine ligand binding kinetics. 
To conclude, we discuss in Chapter 7 the results of the research presented in this 
thesis in general together with the further implications for the field of GPCR 
pharmacology. 
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Abstract 
The function of G protein-coupled receptors (GPCRs) can be modulated by compounds 
that bind to other binding sites than the endogenous orthosteric site, called allosteric 
sites. Recent crystal structures revealed a bound sodium ion in a conserved allosteric site 
of multiple GPCRs. Amiloride and its analogues have been proposed to bind in this same 
sodium ion site. This review seeks to recapitulate the current knowledge of allosteric 
effects by amilorides and its analogues on class A GPCRs. Amilorides are known to 
modulate adenosine, adrenergic, dopamine, chemokine, muscarinic, serotonin and 
gonadotropin-releasing hormone receptors. Amiloride analogues with lipophilic 
substituents are more potent modulators than amiloride for several GPCRs. Some 
receptors, like adenosine, α-adrenergic, and dopamine receptors, are strongly modulated 
by amiloride analogues. In addition, for a few GPCRs more than one binding site for 
amilorides has been postulated. Interestingly, the allosteric effects by amiloride binding 
vary considerably between GPCRs, from acting as negative allosteric modulators to in 
some cases as positive allosteric modulators. Since the sodium ion site is strongly 
conserved amongst GPCRs it is to be expected that amilorides also bind to GPCRs not yet 
evaluated for their sensitivity, but with different modulating effects. Investigating this 
typical amiloride-GPCR interaction further may yield general insight on the allosteric 
mechanisms of GPCR binding and function. 
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Introduction 
G protein-coupled receptors (GPCRs) form a family of receptors with approximately 800 
members that are responsible for many different physiological functions such as 
regulation of sleep, vision, blood pressure, CNS activity, taste, and olfaction.1 This is 
reflected by the fact that they are targeted by 30% to 40% of therapeutic drugs currently 
on the market.2 GPCRs are grouped according to their structural and genomic 
characteristics in five main groups: rhodopsin-like (class A), secretin-like (class B), 
glutamate-like (class C), adhesion, and frizzled/taste2, with class A being the largest 
group.3, 4  
The precise mechanisms of these receptors have been studied for a long time, but due 
to the complexity of their structures they are not yet fully understood. The recent increase 
in availability of high resolution GPCR crystal structures allow a better understanding of 
how GPCRs function.5, 6 Co-crystallization with orthosteric ligands allows the study of 
endogenous orthosteric binding sites. However, to study allosteric binding sites co-
crystallization with allosteric modulators is necessary, which is a challenge due to their 
relatively low affinities. Adding high concentrations of sodium ions is a common procedure 
in the crystallization of GPCRs to stabilize the protein, which makes it possible for them to 
bind to even low affinity sites. However, sodium ions are relatively small and will need a 
high resolution (< 2 Å) to be visualized. In recent crystal structures of several GPCRs the 
resolution was sufficiently high to locate a sodium ion bound in a site which is highly 
conserved amongst GPCRs.7 Currently solved crystal structures with a sodium ion bound in 
its allosteric site are of the human adenosine A2A receptor,
8 the β1-adrenergic receptor,
9, 10 
the human δ-opioid receptor,11 and the human protease activated receptor 1.12 The 
common residues that interact with the sodium ion in these crystal structures, either 
directly or through water mediated hydrogen bond interactions, are Asp2.50, Ser3.39 Trp6.48, 
Asn7.45, and Asn7.49 (numbering according to Ballesteros-Weinstein13). The negatively 
charged amino acid Asp2.50 makes a strong salt bridge with the positively charged sodium 
ion and is essential for its binding in this site, which confirmed previous ‘pre-crystal 
structure’ research.14 It is also the most conserved residue of the sodium ion site amongst 
GPCRs. The high conservation of the sodium ion pocket amongst GPCRs makes it probable 
that more crystal structures with sodium ions bound in this site are to be expected. 
22 | Chapter 2 
 
Figure 1. Chemical structures of amiloride and its 5’-amino substituted analogues DMA, EIA, MIBA, 
MBA, HMA, and MGCMA. 
 
Amiloride is primarily known as a potassium sparing diuretic drug, acting through the 
blockade of renal epithelial sodium channels.15 Amiloride and its analogues have also been 
found to bind to the sodium ion site of several GPCRs, modulating orthosteric ligand 
binding.16 The negatively charged carboxylate of sodium ion site residue Asp2.50 interacts 
with the positively charged guanidinium group present on all amilorides, which makes it 
important for amiloride binding as discussed in Chapters 3 and 4 of this thesis. The binding 
of amilorides into the sodium ion site of GPCRs renders these compounds potential 
pharmacological tools to probe molecular mechanisms of GPCR allosteric modulation. This 
review summarizes the current knowledge of modulation by amiloride and its analogues 
on class A GPCRs, which primarily occurs through binding in the sodium ion site. The 
chemical structures of amiloride and its analogues discussed in this review are depicted in 
Figures 1 and 2. Effects of the amilorides are represented in Table 1 categorized per GPCR 
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and orthosteric ligands used. Most of the receptors in Table 1 are discussed in the main 
text, except for the histamine H1 and the opioid receptors which have been studied little 
for amiloride effects.  
 
 
Figure 2. Chemical structures of 2-guanidino substituted amiloride analogues phenamil, benzamil, 
DCB, CBDMB, and A-EIA-AS. 
 
Adenosine receptors 
Adenosine receptors have been studied extensively, and as a result many orthosteric17 
and allosteric18 ligands have been discovered. Amiloride interactions with adenosine 
receptors were discovered in the early days of adenosine receptor research.19 Since the 
effects of amiloride binding to adenosine receptors appeared to be closely tied to sodium 
ion interactions, it was necessary to investigate and exclude the involvement of Na+/H+ 
exchangers (one of the main targets of amiloride) in these interactions.16 In this study, 
Garritsen et al. found inhibition of antagonist [3H]DPCPX and agonist [3H]PIA at the calf 
adenosine A1 receptor by amiloride,  its 5’-amino substituted analogues 5-(N,N-
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hexamethylene)amiloride (HMA), 5-(N-methyl-N-butyl)amiloride (MBA), 5-(N-methyl-N-
guanidinocarbonyl-methyl)amiloride (MCGMA), and 5-(N-methyl-N-isobutyl)amiloride 
(MIBA), and its 2-guanidino substituted analogues benzamil, 5-(N-4-chlorobenzyl)-2’,4’-
dimethylbenzamil (CBDMB), 3’,4’-dichlorobenzamil (DCB), and phenamil. 
Gao and IJzerman found that amiloride analogues benzamil, HMA, MCGMA, MIBA, 
and phenamil increased the dissociation rate of the antagonist [3H]ZM-241,385 at the rat 
A2A receptor, and that they were more potent than amiloride itself (Figure 3).
20 However, 
the affinity (defined by radioligand displacement in equilibrium) and the allosteric potency 
(defined by the concentration-dependent effect on the radioligand dissociation rate) did 
not correlate. This indicated a mixed competitive (i.e., mutually exclusive displacement) 
and noncompetitive (i.e., amilorides and orthosteric ligands can bind to the receptor at 
the same time, and amiloride influences the orthosteric ligand’s dissociation rate) 
behavior of amilorides. The amiloride analogues HMA and MIBA, with a lipophilic moiety 
on the 5’-position, proved to be the most potent compounds in increasing the dissocation 
rate of the orthosteric ligand, while they had equal affinities to benzamil and phenamil in 
displacing it. In contrast to the effect of amilorides, sodium ions decreased the 
dissociation rate of [3H]ZM-241,385. Still, sodium ions and HMA appeared to compete for 
the same allosteric site. 
 
Figure 3. Concentration dependence of amiloride and its analogues for increase of [3H]ZM-241,385 
dissociation (A) and displacement of [3H]ZM-241,385 (B) after reaching binding equilibrium at 
adenosine A2A receptors. In A [
3H]ZM-241,385 was allowed to first reach equilibrium binding at the 
receptor before the dissociation was induced by addition of an excess of antagonist, in absence and 
presence of increasing concentrations of amiloride (analogue). The results are expressed as a ratio 
between the binding of [
3H]ZM-241,385 after 120 min in presence (‘B’) and in absence (Bcontrol) of 
amiloride (analogue). Reproduced with permission from Gao and IJzerman.20 
 
A B 
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In a study by Gao et al. in 2003 it appeared that agonists and antagonists are 
differently affected by amilorides on adenosine receptors.21 Amilorides increased the 
dissociation rates of antagonists [3H]DPCPX at the rat adenosine A1 and [
3H]PSB-11 at the 
human A3 receptors, just as with [
3H]ZM-241,385 at the rat A2A receptor. However, they 
did not affect the dissociation rates of agonists [3H]R-PIA from the rat A1 and [
3H]CGS-
21,680 from the rat A2A receptors. At the A2A receptor amilorides still displaced agonist 
[3H]NECA binding in a mutually exclusive manner, which makes them competitive 
inhibitors of agonist binding (Chapter 3). Amilorides even decreased the dissociation rate 
of agonist [125I]-AB-MECA at the rat adenosine A3 receptor, revealing that amilorides can 
also act as positive allosteric modulators depending on the radiolabeled probe used.21 
Furthermore the amilorides exhibited selectivity for the different adenosine receptor 
subtypes. Amiloride and 5-(N,N-dimethyl)amiloride (DMA) were more potent at the A1 
receptor in accelerating antagonist dissociation, while HMA was the most potent at the 
A2A receptor and to a lesser extent at the A3 receptor.  
Solving the crystal structure of the adenosine A2A receptor at a resolution of 1.8 Å 
provided a sufficiently high resolution to detect for the first time a sodium ion bound in its 
allosteric binding site.8 The amino acids interacting with the sodium ion are highly 
conserved amongst GPCRs which confirmed previous studies in which modulation by 
sodium ions was tied to the same amino acids for different GPCRs.7 The most conserved 
amino acid is a negatively charged aspartic acid (Asp522.50) which interacts directly with 
the positively charged sodium ion by means of a salt bridge. The positively charged 
guanidinium moiety of amilorides may also interact in a similar manner with this Asp522.50, 
and this is confirmed in Chapter 3 of this thesis by a docking study based on the A2A crystal 
structure (Figure 4), and in Chapter 4 by a mutational study in which mutation of this 
aspartic acid into an alanine decreased the affinity of amiloride and HMA. In the same 
chapter, the mutation of other amino acids forming the sodium ion site, Trp2466.48, 
Asn2807.45, and Asn2847.49, into Ala influenced the binding of amiloride and HMA as well. 
However, mutation of these residues increased the amilorides’ affinity, especially in case 
of Trp2466.48. At the adenosine A3 receptor the mutation of Trp243
6.48 into Ala increased 
the affinity of HMA as well,22 and it can be concluded that this residue strongly impedes 
the binding of amilorides in the sodium ion site of both receptors. 
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Figure 4. Docking of HMA in the sodium ion site. The guanidinium group of HMA has a salt bridge 
interaction with Asp522.50 whereas the 5’-azepane moiety of HMA clashes with Trp2466.48. Chapter 3 
provides more details about this docking study. 
 
Adrenergic receptors 
One of the first indications that amiloride inhibited the binding of orthosteric ligands at α- 
and β-adrenergic receptors was found in 1987 by Howard et al,23 which was followed by 
many studies with amiloride and its analogues at adrenergic receptors. At the human α1A-
adrenergic receptor amiloride and its analogues benzamil, DMA, 5-(N-ethyl-N-isopropyl)-
amiloride (EIA), MIBA, and HMA increased the dissociation rate of antagonist [3H]prazosin, 
and the analogues with bulky lipophilic 5’-moieties were more potent in doing so.24, 25 
Amiloride itself was characterized as an allosteric modulator acting at one allosteric site, 
but all the amiloride analogues appeared to bind to two different allosteric sites. The 
authors speculated that these allosteric sites could be present on one receptor or were an 
effect of receptor dimerization, but could not further confirm this. The allosteric 
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interaction by amilorides was seemingly in contradiction with previous results at rat and 
mouse α1-adrenergic receptors in which amiloride only showed a competitive interaction 
with antagonist [3H]prazosin binding but did not influence its dissociation rate,23 which 
may be attributed to the not yet discovered subtypes of α1-receptors or the difference in 
species. 
α2-Adrenergic receptors are allosterically modulated by amilorides as well. At rat, 
human, bovine, and porcine α2A-adrenergic receptors amiloride increased the dissociation 
rate of the antagonists [3H]rauwolscine23, 26 and [3H]yohimbine.27 Amiloride analogues also 
increased antagonist dissociation at the α2A-adrenergic receptor, which was found for the 
amilorides (N-2-aminoethyl-N-isopropyl)amiloride-N-(4-azidosalicylamide) (A-EIA-AS) at 
the porcine receptor,28 and DMA, EIA, MIBA, and HMA at the human receptor, in relation 
to [3H]yohimbine, [3H]rauwolscine, and [3H]RX-821,002 dissociation.29  It is noteworthy 
that A-EIA-AS has no affinity for the Na+/H+ exchange protein, making it a GPCR selective 
amiloride.  EIA, HMA, and MIBA were exceptionally strong negative allosteric modulators 
of antagonist binding, being 50- to 80-fold more potent than amiloride in increasing the 
dissociation rate of [3H]yohimbine, showing that bulky lipophilic moieties at the 5’-
position of amiloride increase the allosteric potency at the α2A-adrenergic receptor 
considerably. The apparent affinities of these amilorides were not correlating at all with 
their derived allosteric potencies in this study, cautioning to not confuse these two 
different pharmacological properties with each other. 
In contrast to their effect on antagonists, amiloride, DMA, and HMA decreased the 
dissociation rate of agonist [3H]UK-14,304 at the human α2A-adrenergic receptor, with 
HMA having the largest effect.30 The dissociation slowing effect on agonist binding (2.7-
fold slower dissociation by HMA) was considerably smaller though than the dissociation 
accelerating effect on antagonist binding (140-fold faster dissociation by HMA). Even as 
they slowed agonist dissociation, amilorides acted as negative allosteric modulators of α2A 
receptor agonist activation, since amiloride, DMA, and HMA decreased the potency of 
norepinephrine and UK-41,304. This paradoxical behavior was in line with previous 
indications that in addition to their allosteric effects amilorides could displace the 
orthosteric ligand competitively at the α2A receptor.
29 Moreover, addition of sodium ions 
increased the affinity of amiloride in doing so.23 This led to the conclusion that at α2A-
adrenergic receptors amilorides could bind to two different sites, namely the orthosteric 
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site and an allosteric sodium ion site.  Howard et al. hypothesized that amiloride binding in 
the orthosteric site was enhanced by binding of a sodium ion in the allosteric site, while 
amiloride binding in the allosteric site increased the dissociation rate of other orthosteric 
ligands.23 In a later study by Leppik et al., variations in the affinity of several amiloride 
analogues for the antagonist occupied and non-occupied receptor led to two different 
hypotheses. Either the amilorides could indeed bind to both the allosteric and orthosteric 
sites, or binding of an antagonist to the orthosteric site modified the conformation of the 
allosteric binding site in such a way that amiloride affinity decreased.29 
At the α2B subtype however, amilorides can both increase and decrease the 
dissociation rate of antagonists. The 5’-substituted amilorides EIA and MIBA increased the 
dissociation rate of [3H]rauwolscine binding, while the guanidino-substituted amiloride 
CBDMB decreased it (Figure 5).31  
 
Figure 5. Positive and negative allosteric modulation of [3H]rauwolscine binding at the α2B-
adrenergic receptor, in presence of 100 µM CBDMB and EIA, respectively. CBDMB decreased and EIA 
increased the dissociation rate of the orthosteric antagonist. Reproduced with permission from 
Wilson et al.31 
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The interaction of amiloride with the β-adrenergic receptors has only been studied by 
Howard et al. in 1987.  At both the β1- and β2-adrenergic receptors amiloride displaced the 
antagonist [125I]iodocyanopindolol competitively, since their binding was mutually 
exclusive.23 Addition of sodium ions did not compete with amiloride binding, and it was 
concluded that amiloride did bind to the orthosteric site rather than to an allosteric 
sodium ion site. Even for the lack of modulation of β-adrenergic receptors by sodium ions 
and amiloride, a sodium ion site was found in the crystal structure of the β1-adrenergic 
receptor.9 The amino acids forming the sodium ion sites of the β1-adrenergic and the 
adenosine A2A receptor were the most similar of the solved GPCR crystal structures with 
such a site.7 That makes the difference in modulation by sodium ions and amilorides 
between these receptors remarkable and it is probably due to differences in the overall 
architecture of the two receptors. 
Chemokine receptors 
Amiloride interactions with the chemokine receptor family have only been studied by 
Zweemer et al. on the chemokine CCR2 receptor.32 The sodium ion site was the third 
binding site found on this receptor, next to the more extracellularly located orthosteric 
and an intracellular allosteric site.33, 34 Amiloride analogues MIBA and HMA inhibited 
binding of antagonist [3H]INCB3344 binding to the orthosteric site and antagonist 
[3H]CCR2-RA-[R] binding to the intracellular site.32 Moreover, HMA inhibited binding of the 
orthosteric agonist [125I]CCL2. Amiloride, benzamil, MCGMA, and phenamil did however 
not displace any of these radioligands. 
The increased dissociation rates of the orthosteric antagonist [3H]INCB3344, the 
intracellular antagonist [3H]CCR2-RA-[R], and the orthosteric agonist [125I]CCL2 induced by 
HMA indicated a noncompetitive allosteric interaction. Remarkably, the dissociation rate 
of the agonist [125I]CCL2 increased more (9.7-fold) than of the antagonists (1.25- and 1.36-
fold) by the presence of HMA. Saturation binding assays revealed that HMA had a mixed 
competitive/noncompetitive interaction with the orthosteric antagonist [3H]INCB3344 
(insurmountable binding of HMA indicated by decreased Bmax and competitive interaction 
indicated by increased KD) while it had a purely noncompetitive interaction with the 
intracellular antagonist [3H]CCR2-RA-[R] (decreased Bmax only). 
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Figure 6. Two dimensional interaction map of HMA docking into the sodium ion pocket of a 
homology model of the CCR2 receptor, demonstrating a salt bridge between the guanidinium group 
of HMA and Asp88
2.50, π-stacking between the pyrazine core of HMA and Trp2566.48, and a hydrogen 
bond between the oxygen of HMA and His2977.45. The hydrogen bond between Trp2566.48 and 
HMA’s oxygen was not captured from this angle. Reproduced with permission from Zweemer et al.32 
 
The allosteric effect of HMA was diminished by mutation of sodium ion site residues 
Asp882.50 and His2977.45 into Ala. Mutation of Trp2566.48 even completely abolished HMA’s 
allosteric effect, which is in contrast to the observed increase of HMA’s affinity by the 
same mutation in adenosine receptors as discussed by Gao et al.22 and Chapter 4 of this 
thesis. Indeed, HMA fitted well in the sodium ion site of a homology model of the CCR2 
receptor in a docking study, predicting interactions with these three residues (Figure 6). 
Asp882.50 formed a salt bridge with the guanidinium moiety of HMA, Trp2566.48 formed a 
hydrogen bond with HMA’s oxygen as well as engaging in a π-stacking interaction with its 
pyrazine core, and His2977.45 formed a hydrogen bond with the same oxygen of HMA. 
Amino acid His2977.45 is different from most class A GPCRs which mostly harbor an Asn at 
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the same position, but is conserved amongst chemokine receptors, and the binding of 
HMA in CCR2’s sodium ion site indicates that amiloride binding allows for a certain 
variation in the amino acids that form the sodium ion site. 
Dopamine receptors 
The general trend amongst the dopamine receptor subtypes is an increase of the 
dissociation rate of orthosteric ligands by amiloride and its analogues, as found in a 
comprehensive study of the effect of amiloride, benzamil, and MIBA.35 MIBA had the 
largest effect on the dissociation rates of the antagonists [3H]SCH-23,390 at the human D1 
receptor and [3H]spiperone at the human D2(short), D2(long), D3, and D4 dopamine receptors. 
As with other GPCRs the analogues with lipophilic moieties at the 5’-position were more 
potent than amiloride itself. At the D1, D2(short), D2(long), and D3 dopamine receptors the 
amilorides displaced the orthosteric antagonist [3H]spiperone in both noncompetitive and 
competitive manners. This may indicate affinity of the amilorides to both the orthosteric 
and allosteric sites, and moreover a positive homotropic cooperativity was suggested 
based on a high Hill coefficient, i.e. amilorides binding at the allosteric site modulate the 
binding of amilorides to the orthosteric site positively. 
The results at the D2 receptor complemented results from other studies, in which 
similar dissociation rate increasing effects and mixed competitive/noncompetitive 
behavior were found. Amiloride competed with and increased the dissociation rate of 
antagonists [3H]spiperone and [125I]epidepride binding.36 Amiloride, DMA, benzamil, EIA, 
MIBA, and HMA did so as well to the antagonist [3H]spiperone at both the rat37 and 
human38 D2 dopamine receptors, and of these amilorides HMA was the most potent 
amiloride (Figure 7). Agonists are modulated similarly as antagonists by amilorides at the 
rat D2 and D3 dopamine receptors, since amiloride, DMA, and MIBA decreased the potency 
of the agonist dopamine in inducing receptor activation in functional assays.35, 39 At the D4 
receptor the allosteric effect of amiloride and its analogues was too small to be measured 
accurately, but an increase in antagonist [3H]spiperone dissociation rate was still detected. 
As amilorides still inhibited binding of the orthosteric ligand the displacement was more 
competitive in nature.35 
The amino acids forming the sodium ion site in the dopamine receptors are conserved 
compared to the adenosine and adrenergic receptors. Computational and mutagenesis 
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studies have confirmed the importance of Asp802.50, Ser1213.39, Asn4197.45, and Asn4237.49 
for the allosteric effects by sodium ions.40-42 At the D4 dopamine receptor mutation of 
Asp802.50 into Asn decreased MIBA affinity,43 indicating that amilorides bind in the sodium 
ion site as well. It may be assumed that amilorides also bind in the sodium ion site of the 
other dopamine receptors, but this has not been confirmed yet.  
 
 
Figure 7. Concentration dependent dissociation modulation by amiloride and its analogues of 
[
3H]spiperone at the dopamine D2 receptor after 20 minutes. (Δ-amiloride, ▲-benzamil, ○-DMA, ●-
EIA, □-MIBA, ■-HMA). Amiloride modulates dissociation the least, while HMA and MIBA are the 




Gonadotropin-releasing hormone receptor 
The gonadotropin-releasing hormone (GnRH) receptor, also known as luteinizing 
hormone-releasing hormone receptor, is targeted by various drugs on the market for 
treatment of sex-hormone-dependent diseases such as breast or prostate cancer.44, 45 
These drugs are mostly peptidic agonists and antagonists that need to be administered by 
subcutaneous or intramuscular injections. The development of small molecule ligands that 
may replace these peptidic ligands is therefore desirable.46 Earlier results had indicated 
allosteric modulation of GnRH stimulated luteinizing hormone release by sodium ions and 
amilorides.47 In that light, the allosteric effects of amilorides on the GnRH receptor were 
investigated by Heitman et al.48 Amiloride, benzamil, MCGMA, and phenamil had a 
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negligible effect on displacement of the peptide agonist [125I]triptorelin at the GnRH 
receptor. However, DCB, MIBA, and HMA increased the dissociation rate of 
[125I]triptorelin, with HMA having the strongest effect. In a luciferase assay, HMA acted as 
a purely insurmountable noncompetitive allosteric modulator as it only decreased the 
efficacy (Emax) of GnRH receptor activation by triptorelin and the endogenous ligand GnRH. 
Furthermore, it was demonstrated that the GnRH receptor harbors a second allosteric site 
next to the sodium ion site, since HMA did not compete with FD-1, an allosteric modulator 
with a distinct chemical structure, for the same allosteric site.  
Muscarinic receptors 
Amiloride effects have been found on muscarinic receptors in rat tissue preparations. 
Benzamil and HMA inhibited [3H]pirenzepine binding at the muscarinic M1 and [
3H]N-
methylscopolamine binding at the muscarinic M2 and M3 receptors.
16 In rat trachea 
amiloride inhibited muscarinic M3 receptor mediated smooth muscle contraction
49 by the 
endogenous agonist acetylcholine, by an insurmountable noncompetitive interaction as its 
efficacy (Emax) was reduced.
50 In rat parotic acini, which express the muscarinic M3 
receptor,51 amiloride inhibited binding of the muscarinic receptor antagonist [3H]N-
methylscopolamine in a competitive manner.52 In the recent relatively low resolution 
crystal structures of the muscarinic M2 and M3 receptors sodium ion binding was not 
detected,53-55 but the amino acids making up the sodium ion site are perfectly conserved 
compared to adenosine and adrenergic receptors,7 making amiloride binding to this site 
likely. 
Serotonin receptors 
Amiloride and analogues have been found to inhibit orthosteric ligand binding to 
serotonin receptors. Benzamil inhibited agonist [3H]8-OH-DPAT binding at the rat 5-HT1A 
receptor.16 Amiloride and EIA inhibited agonist [3H]5-carboxamidotryptamine binding at 
the human 5-HT1B receptor.
56  In functional assays at the same receptor, amiloride 
inhibited receptor activation by agonist sumatriptan in a competitive manner, while EIA 
had intrinsic antagonistic activity as it inhibited forskolin-stimulated cAMP formation, 
albeit with a 15-fold higher EC50 value (200 µM) compared to its Ki in inhibiting [
3H]5-
carboxamidotryptamine binding (13 µM).56 Endogenous agonist [3H]serotonin binding was 
inhibited by HMA at the rat 5-HT1C receptor and by benzamil and HMA at the rat 5-HT2 
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receptor.16 Crystal structures of the agonist bound 5-HT1B receptor
57 and the 5-HT2B 
receptor,58 again at relatively low resolution, did not reveal a bound sodium ion, but the 
well conserved amino acids of the sodium ion site compared to the other class A GPCRs7 
makes binding of amiloride in the same location likely. 
Concluding remarks 
This review summarizes the current knowledge of the allosteric effects of amiloride and its 
analogues on GPCRs. Allosteric effects of amilorides have been found on adenosine 
receptors, α-adrenergic receptors, the CCR2 chemokine receptor, dopaminergic receptors, 
the gonadotropin-releasing hormone receptor, the histamine H1 receptor, muscarinic 
receptors, opioid receptors, and serotonin receptors.  
Amiloride and its analogues seem to follow a few general ‘rules’ in their activity on 
these receptors. The propensity of amilorides to bind to the well conserved sodium ion 
site amongst GPCRs may explain these common behaviors. For most receptors, amiloride 
analogues with bulky lipophilic moieties on the 5’-position have greater affinity and 
potency than the unsubstituted parent compound. This has not been explained fully, but it 
is clear that in most GPCRs there is a hydrophobic pocket above the sodium ion site that 
can accommodate these lipophilic moieties. Most receptors allow substitution on the 
guanidinium group as well, with a good affinity in displacing orthosteric ligands, but with 
less or no effect on the dissociation of orthosteric ligands. 
Another general ‘rule’ is the importance of Asp2.50 for amiloride binding, just as for 
sodium ions. In the docking studies performed, the binding mode of amiloride and HMA 
was predicted in the sodium ion site of the adenosine A2A receptor crystal structure and a 
CCR2 chemokine receptor homology model. The positively charged guanidinium group has 
a strong salt bridge interaction with Asp2.50, underlining the great importance of this 
residue for amiloride binding as found before in mutagenesis studies. Trp6.48 interacts with 
amilorides as well, in some cases hampering and in other cases accommodating amiloride 
binding. These interactions of amilorides with the amino acids of the sodium ion site are 
of interest since these have been shown to be important in receptor functionality, with 
Asp2.50 and Trp6.48 as most noticeable examples. Mutation of Asp2.50 silences receptor 
activation in many GPCRs.59 Trp6.48 is noteworthy as a ‘toggle switch’ between the active 
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and inactive states of GPCRs,60, 61 and in docking studies of the adenosine A2A receptor 
amiloride and HMA seem to toggle it into its inactive rotamer (Chapter 3). 
In contrast with these general ‘rules’, differences in the affinities, potencies, and 
modulatory behaviors of amilorides are quite diverse, even between receptors where the 
sodium ion site constitutes of exactly the same amino acids (i.e. adenosine, adrenergic, 
dopamine, and muscarinic receptors). To appreciate these differences it is important to 
discern between the different properties by which the allosteric effect of amilorides on 
orthosteric ligand binding may be described. In Table 1 we collected values for the 
different amilorides, of their affinity in displacing orthosteric ligands (IC50 or Ki), their 
effect on dissociation of orthosteric ligand (koff/koff(control)), and their potency for these 
dissociation effects (EC50). This information also helps to understand whether the 
interaction of a particular amiloride with an orthosteric ligand is competitive or 
noncompetitive. If an amiloride inhibits orthosteric ligand binding, but does not affect its 
dissociation rate, the binding is mutually exclusive and the interaction is defined as 
competitive. If the dissociation rate is changed though, both the orthosteric ligand and 
amiloride can bind to the receptor at the same time and the interaction is deemed 
noncompetitive. Another way to confirm a noncompetitive interaction is by showing 
insurmountability of the inhibiting effect in radioligand saturation (Bmax decrease) or 
functional assays (Emax decrease), as discussed for the chemokine CCR2, muscarinic M3, 
and gonadotropin-releasing hormone receptor. However, these assays have been 
conducted far less than dissociation assays in amiloride research so we did not include 
them in Table 1. 
In some cases, amilorides behave only as purely competitive inhibitors, while in other 
cases they behave as noncompetitive negative modulators, and a mixed behavior has also 
been observed. For some receptors the cause for mixed competitive/noncompetitive 
behavior was explained by a tendency of amilorides to bind both orthosteric and allosteric 
sites, but also in these cases the observed effect may be caused by binding in the sodium 
ion site only, where the competitive ‘fraction’ of the allosteric effect is caused by either an 
overlap of binding with the orthosteric site or a conformational change of the receptor by 
amiloride binding. The latter option is quite likely from the structural evidence provided by 
the recently elucidated crystal structures.  
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At some of the discussed receptors the modulatory effect by amilorides is probe-
dependent, which has been described in other cases of allosteric modulation as well.62, 63 
Amilorides act as positive allosteric modulators for agonist binding and as negative 
modulators for antagonists at the α2A-adrenergic and adenosine A3 receptors. At the α2B-
adrenergic receptor different amilorides even exhibit both positive and negative 
modulatory effects. Some of the differences in affinity and modulatory effect may be 
caused by differences in the sodium ion site itself, but the substantial conservation of the 
sodium ion site residues amongst GPCRs makes it more likely that these differences are 
caused by variations in structural conformations elsewhere in the receptor. 
Clinical application of amilorides targeting GPCRs is unlikely, due to their micromolar 
range affinities and lack of selectivity. However, it may be feasible to synthesize amiloride 
analogues with variations on the 5’-position to improve their affinity and selectivity for 
GPCRs. The possibility to use amilorides as tools to understand GPCR pharmacology is of 
greater interest though. For some of the amiloride-modulated receptors it has been 
confirmed that amilorides bind in the allosteric sodium ion site, and for the other 
receptors this is very likely. Indeed, allosteric modulation by sodium ions and amilorides 
often go together, and the investigation of confirmed sodium ion-modulated GPCRs that 
have not yet been researched for amiloride effects may be worthwhile. The sodium ion 
pocket region is important in the overall receptor activation of GPCRs, since mutation of 
sodium ion site residues has been shown to affect receptor functionality. With the 
ongoing expansion of the crystal structure pool of GPCRs, further study and knowledge of 
the mechanisms of amiloride modulation will help in understanding and appreciating the 
allosteric mechanism in GPCR functioning.  
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Table 1. Modulation of G protein-coupled receptors by amiloride and amiloride analogues. The 
given values reflect i) inhibitory potency or affinity for ligand displacement in radioligand binding 
assays or inhibition of ligand-induced receptor activation in functional assays, ii) modulatory potency 
of their effect on radioligand dissociation, and iii) fold change of dissociation rates of orthosteric 
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[3H]DPCPX Amiloride 2.0 ± 0.2B19 - 1.5Rd21 
197 ± 23R21 
Benzamil 0.65 ± 0.04B19 - - 
CBDMB 1.2 ± 0.1B19 - - 
DCB 1.6 ± 0.1B19 - - 
DMA 8 ± 2R21 - 1.9R21 
HMA 0.41 ± 0.03B19 - 1.7R21 
22 ± 4R21 
MBA 0.070 ± 0.004B19 - - 
MGCMA 22 ± 1B19 - - 
MIBA 0.16 ± 0.01B19 - - 
13 ± 1R21 
Phenamil 1.5 ± 0.1B19 - - 
[3H]PIA Amiloride 2.4 ± 0.1B19 - No effectRd21 
Benzamil 0.85 ± 0.03B19 - - 
CBDMB 4.0 ± 0.4B19 - - 
DCB 2.7 ± 0.2B19 - - 
DMA - - No effectR21 
HMA 0.50 ± 0.03B19 - No effectR21 
MBA 0.09 ± 0.01B19 - - 
MGCMA 16 ± 1B19 - - 
MIBA 0.20 ± 0.01B19 - - 
Phenamil 2.3 ± 0.1B19 - - 
  





Amiloride 9.7 ± 1.1R20 - 1.2Rd20 
Benzamil 2.2 ± 0.3R20 - 2.4Rd20 
HMA 3.3 ± 0.5R20 - 12Rd20 
MGCMA 89 ± 13R20 - 1.2Rd20 
MIBA 3.0 ± 0.2R20 - 5.7Rd20 
Phenamil 2.6 ± 0.4R20 - 1.9Rd20 
[3H]CGS-21,680 Amiloride - - No effectRd21 
DMA - - No effectR21 
HMA - - No effectR21 
Adenosine 
A3 
[3H]PSB-11 Amiloride 82 ± 7H21 - No effectHd21 
DMA 13 ± 2H21 - 1.3H21 
HMA 6 ± 1H21 - 2.3H21 
MIBA 8 ± 1H21 - 1.6H21 
[125I]I-AB-MECA Amiloride >100R21 - No effectHd21 
DMA 20 ± 3R21 - 0.80H21 
HMA 7 ± 1R21 - 0.53H21 
MIBA 7 ± 2R21 - 0.59H21 
α1A-
Adrenergic 
[3H]Prazosin Amiloride 11 ± 2H24 - 1.2H24 
Benzamil 0.8 ± 0.1H24 - 1.7H24 
DMA 0.82 ± 0.03H24 - 1.5H24 
EIA 2.7 ± 0.3H24 - 2.2H24 
HMA 1.1 ± 0.2H24 - 5.5H24 
MIBA 0.49 ± 0.07H24 - 2.4H24 
α2A-
Adrenergic 
[3H]Yohimbine Amiloride 30 ± 2H29 - 2.0He29 
A-EIA-AS - 40P28 > 1P28 
Benzamil 3.5 ± 0.7H29 - No effectHe29 
DMA 3.6 ± 0.1H29 - 5.3He29 
[3H]Rauwolscine - - 6.3He29 
[3H]RX-821,002 DMA - - 7.1He29 
[3H]Yohimbine EIA 1.7 ± 0.2H29 50P28 > 1P28 
155He29 
HMA 0.21 ± 0.00H29 - 138He29 
[3H]Rauwolscine - - 57He29 
[3H]Yohimbine MIBA 0.56 ± 0.01H29 - 101He29 
[3H]UK-14,304 Amiloride 25 ± 0.2H30 - 0.67He30 
DMA 3.2 ± 0.2H30 - 0.77He30 
HMA 0.18 ± 0.02H30 - 0.37He30 
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α2B-
Adrenergic 
[3H]Rauwolscine CBDMB - - < 1R31 
EIA - - > 1R31 










Amiloride 60R23 - - 
CCR2 [
3H]INCB3344 Amiloride No effectHf32 - - 
Benzamil No effectHf32 - - 
HMA 79H32 - 1.25H32 
MCGMA No effectHf32 - - 
MIBA 158H32 - - 
Phenamil No effectHf32 - - 
[3H]CCR2- 
RA-[R]g 
Amiloride No effectHf32 - - 
Benzamil No effectHf32 - - 
HMA 79H32 - 1.36H32 
MCGMA No effectHf32 - - 
MIBA 126H32 - - 
Phenamil No effectHf32 - - 
[125I]CCL2 HMA - - 9.7H32 
Dopamine 
D1 
[3H]SCH-23,390 Amiloride 49 ± 1H35 >1000H35 - 
Benzamil 1.6 ± 0.5H35 74 ± 8H35 - 
MIBA 4.4 ± 0.2H35 13 ± 1H35 26He35 
Dopamine 
D2 
[125I]Epidepride Amiloride - - 2.5Ri36 
[3H]Spiperone 390 ± 4H35 215 ± 35R38 1.5Ri36 
- 100 ± 10H35 2.7Rj38 
Benzamil 25 ± 2H35 46 ± 4R38 4.8Rk38 
29 ± 7H35 
DMA - 76 ± 8R38 8.4Rk38 
EIA - 20 ± 5R38 18Rl38 
HMA - 10 ± 2R38 16Rl38 
MIBA 6.6 ± 0.4H35 14 ± 1R38 14Rl38 
2.1 ± 0.2H35 88He35 
Dopamine Amiloride 29Rm39 - - 
DMA 1.4Rm39 - - 
MIBA 0.9Rm39 - - 
0.6 ± 0.2Hn35 
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Dopamine 
D3 
[3H]Spiperone Amiloride 120 ± 7H35 43 ± 3H35 - 
Benzamil 16 ± 1H35 15 ± 2H35 - 
MIBA 1.7 ± 0.1H35 0.29 ± 0.14H35 18He35 




3H]Spiperone Amiloride 280 ± 30H35 420 ± 4H35 - 
Benzamil 6.1 ± 0.4H35 28 ± 2H35 - 
MIBA 1.3 ± 0.2H35 22 ± 5H35 > 1He35 
GnRH [125I]Triptorelin Amiloride > 100H48 - - 
Benzamil > 100H48 - - 





MIBA 39 ± 7H48 - 2.1H48 
HMA 29 ± 3H48 49 ± 7H48 2.5H48 
MCGMA > 100H48 - - 
Phenamil > 100H48 - - 
Histamine 
H1 
[3H]Mepyramine Amiloride > 10R16 - - 
Benzamil 3.2 ± 0.2R16 - - 
HMA 5.6 ± 1.2R16 - - 
Muscarinic 
M1 
[3H]Pirenzepine Amiloride >10R16 - - 
Benzamil 2.9 ± 0.7R16 - - 





Amiloride > 10R16 - - 
Benzamil 5.8 ± 1.1R16 - - 





Amiloride 50R52 - - 
Benzamil 2.8 ± 0.5R16 - - 
HMA 4.7 ± 0.8R16 - - 
Acetylcholine Amiloride 478Rq50 - - 
δ-Opioid [3H]DADLE Amiloride > 10R16 - - 
Benzamil > 10R16 - - 
HMA 1.0 ± 0.2R16 - - 
κ-Opioid [3H]Ethyl-
ketazocine 
Amiloride > 10R16 - - 
Benzamil > 10R16 - - 
HMA 3.9 ± 0.6R16 - - 
µ-Opioid [3H]Naloxone Amiloride > 10R16 - - 
Benzamil 1.1 ± 0.4R16 - - 
HMA 0.06 ± 0.02R16 - - 
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Serotonin  
5-HT1A 
[3H]8-OH-DPAT Amiloride > 10R16 - - 
Benzamil 1.9 ± 0.3R16 - - 





Amiloride 20H56 - - 
Sumatriptan 35Hs56 - - 
[3H]Serotonin Benzamil > 10R16 - - 
[3H]5-Carboxa-
midotryptamine 
EIA 13H56 - - 





Amiloride >10R16 - - 
Benzamil >10R16 - - 
HMA 6.7 ± 1.2R16 - - 
Serotonin  
5-HT1D 
[3H]Serotonin Amiloride > 10R16 - - 
Benzamil > 10R16 - - 
HMA > 10R16 - - 
Serotonin  
5-HT2 
[3H]Serotonin Amiloride > 10R16 - - 
Benzamil 1.4 ± 0.1R16 - - 
HMA 0.40 ± 0.06R16 - - 
-: Not determined. 
a: IC50 values determined with concentrations of orthosteric radioligands around their KD. 
B: Bovine receptor. 
c: In presence of 100 µM amiloride (analogue) except when stated otherwise. 
d: In presence of 1 mM amiloride (analogue). 
e: Calculated for the amiloride (analogue) occupied receptor. 
f: No displacement of orthosteric ligand by 100 µM amiloride (analogue). 
g: [
3H]CCR2-RA-[R] is an ‘intracellular antagonist’ as it binds to the second intracellular site of the 
chemokine CCR2 receptor. 
H: Human receptor. 
i: In presence of 500 µM amiloride (analogue). 
j: In presence of 3.16 mM amiloride (analogue). 
k: In presence of 1 mM amiloride (analogue). 
l: In presence of 316 µM amiloride (analogue). 
m: Inhibition by amiloride (analogue) of dopamine-stimulated increase in extracellular acidification 
rate  in cells expressing the dopamine D2 receptor. 
n: Inhibition by MIBA of dopamine-stimulated [35S]GTPγS binding to dopamine D2 receptors. 
o: Inhibition by MIBA of dopamine-stimulated increase in extracellular acidification rate  in cells 
expressing the dopamine D3 receptor. 
P: Porcine receptor. 
q: Modulation by amiloride of acetylcholine-induced contractions of rat tracheal smooth muscle, 
which expresses the muscarinic M3 receptor. 
R: Rat receptor. 
s: Inhibition by amiloride of the sumatriptan-induced reduction of cAMP formation stimulated by 
forskolin in cells expressing the Serotonin 5-HT1B receptor. 
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Abstract 
The function of G protein-coupled receptors (GPCRs) can be modulated by a number of 
endogenous allosteric molecules. In this study, we used molecular dynamics, radioligand 
binding and thermostability experiments to elucidate the role of the recently discovered 
sodium ion binding site in the allosteric modulation of the human A2A adenosine receptor, 
conserved among class A GPCRs.  While the binding of antagonists and sodium ions to the 
receptor was noncompetitive in nature, the binding of agonists and sodium ions appears 
to require mutually exclusive conformational states of the receptor. Amiloride analogs can 
also bind to the sodium binding pocket, showing distinct patterns of agonist and 
antagonist modulation. These findings suggest that physiological concentrations of sodium 
ions affect functionally relevant conformational states of GPCRs, and can help to design 
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Introduction 
Cellular responses to a wide variety of extracellular signals are mediated by the 
superfamily of seven transmembrane helical receptors coupled to intracellular G proteins 
(G protein-coupled receptors, GPCRs). It is now well recognized that many GPCRs function 
as “allosteric machines” with the orthosteric binding pocket representing just one of the 
many sites for possible signal modulation and pharmacological intervention. Thus, 
molecules targeting other (allosteric) sites can modulate binding of native orthosteric 
ligands and shift the delicate equilibrium between active and inactive states of GPCRs.1 
Potential therapeutic advantages include a gain in target selectivity, the “ceiling effect”, 
and preservation of the spatiotemporal profile of intercellular signaling.2-5 Some 
endogenous chemical entities, such as ions or lipids, have also been demonstrated to act 
as allosteric modulators of GPCRs,1, 6, 7 but the structural basis and functional importance 
of these interactions are not well understood. 
Recent advances in protein engineering and membrane protein crystallography8-10 
have led to the elucidation of a growing number of experimental GPCR structures,11 
contributing to the alluring perspective of structure-based drug design,12 and the 
deciphering of molecular mechanisms underlying conformational equilibrium.13 Several 
receptors, including one of the best-characterized GPCRs, the A2A adenosine receptor 
(A2AAR), have been crystallized in inactive
14-17 and active-like18, 19 conformations. The 
conformational changes associated with A2AAR activation mirrored similar structural 
changes observed in other receptors, namely the β2-adrenergic receptor (2AR)
20 and 
rhodopsin.21 Recently, the 1.8 Å resolution structure of inactive A2AAR in complex with ZM-
241,385 revealed the presence of a sodium ion bound to the core of the transmembrane 
(TM) bundle,22 coordinated by Asp2.50 and other side chains highly conserved in class A 
GPCRs23 and by a cluster of structural water molecules.24, 25 The allosteric effect of sodium 
ions has been described previously in A2A and A1 adenosine receptors,
6, 26 as well as in 
GPCRs from other subfamilies such as dopamine D2,
7, 27 opioid,28, 29 or -adrenergic 
receptors,30, 31 among others. Similarly, the positively charged, synthetic small molecule 
amiloride and its analogs have been found to be allosteric modulators of agonist and 
antagonist binding of a number of GPCRs (Chapter 2), including A2AAR, and were shown to 
compete with sodium ions for the same binding site.6 Moreover, mutation of Asp2.50 to 
either asparagine or alanine has been shown to reduce or abrogate the allosteric effects of 
50 | Chapter 3 
sodium ions or amiloride in many GPCRs.7, 32-34 While the 1.8 Å structure of A2AAR provides 
a static picture of sodium interactions with the receptor, the dynamic nature of the 
sodium ion-water cluster, its effect on binding of orthosteric agonists and antagonists, and 
its functional role are poorly understood. Molecular dynamics (MD) studies, supported by 
biochemical and biophysical experiments, provide a molecular framework for the 
allosteric effects of sodium and amilorides, which can ultimately aid in the discovery of 
new compounds targeting this site.4  
Material and methods 
Computational simulations 
The standard amino acid sequence numbering for the human A2AAR is used in the text, 
with the Ballesteros and Weinstein residue numbering for GPCRs35 shown in superscript if 
the residue belongs to a transmembrane helix. The inactive structure of the A2AAR in 
complex with ZM-241,385 and a sodium ion (PDB code 4EIY),22 was refined in order to 
model the missing loops and add protons as detailed in the supplemental information, 
prior to MD simulations. When the sodium ion was not considered, manual replacement 
with a water molecule, also maintaining the surrounding water molecules, was followed 
by energy minimization to fully optimize the H-bond network in the allosteric site. In the 
simulations with amiloride, the initial conformation of the A2AAR-amiloride complex was 
used as proposed previously by flexible docking.22 The starting coordinates of the 
antagonist caffeine were obtained by superimposing the A2AAR-caffeine complex (PDB 
code 3RFM)14 with the A2AAR structure described above using PyMOL (The PyMOL 
Molecular Graphics System version 1.4, Schrödinger). The MD simulations of the active-
like conformation were performed starting from the A2AAR in complex with the stabilizing 
agonist UK-432,097 (PDB code 3QAK).19 The starting coordinates of the sodium ion and 
coordinating water molecules were transposed from the inactive structure by structural 
superimposition with 4EIY. Finally, the A2AAR in complex with the agonist NECA was 
obtained by "morphing" the A2AAR-ZM-241,385 structure (PDB code 4EIY) to the active-
state A2AAR-UK-432,097 conformation (PDB code 3QAK), and subsequent reconstruction 
of the intracellular loop 3 as detailed in the supplemental experimental procedures. Note 
that the available crystal structure of NECA in complex with thermostabilized A2AAR (PDB 
code 2YDV),18 was not suitable for this analysis because of a highly distorted conformation 
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of the allosteric site, which includes a deformed helix VII backbone due to a cis-Proline in 
the NPxxY motif. 
 







MDS1a Inactive ZM-241,385 Na+ 3x100 ns 
MDS1-ba Inactive ZM-241,385 Na+ 3x100 ns 
MDS2 Inactive --- Na+ 3x100 ns 
MDS3 Inactive ZM-241,385 --- 3x100 ns 
MDS4 Inactive --- --- 3x100 ns 
MDS5 Active UK-432,097 Na+ 3x40 ns 
MDS6 Active NECA Na+ 3x40 ns 
MDS7 Active --- Na+ 3x40 ns 
MDS8 Inactive ZM-241,385 Amiloride 3x100 ns 
MDS9 Inactive Caffeine Amiloride 3x40 ns 
MDS10 Inactive Caffeine --- 3x40 ns 
MDS11 Inactive ZM-241,385 HMA 3x100 ns 
MDS12 Inactive Caffeine HMA 3x40 ns 
a: MDS1-b corresponds to the same system as MDS1, but considering the physiological saline 
concentration of 150mM.  
 
Membrane insertion and all MD simulations were performed with the GROMACS 
software,36 using our original protocol for the MD simulations of GPCRs37 as adapted in the 
PyMemDyn program.38 The final systems, consisting of approximately 50,000 atoms (~74% 
belong to solvent molecules, ~15% to lipids and ~11% to protein and ligand atoms), were 
energy minimized and equilibrated for a total of 5 ns, with specific details provided in the 
supplemental experimental procedures. The production phase of unrestrained MD 
simulations followed for 100 ns simulation time (shorter production times were 
considered in certain cases, see Table 1 and explanation in main text). MD simulations 
were performed under the OPLSAA force field,39 with ligand parameters obtained with 
Macromodel,40 lipid parameters adapted from Berger41 together with the use of the half- 
double-pairlist method42 and the SPC water model.43 The periodic boundary conditions 
(PBC) were implemented with hexagonal prism-shaped boxes in the isobaric NPT 
ensemble, using a Nose-Hoover thermostat44 with a target temperature of 310 K using. 
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Electrostatic interactions beyond a cutoff of 12 Å were estimated with the particle mesh 
Ewald (PME) method. All MD analyses were conducted with several GROMACS and VMD45 
utilities. Molecular superimpositions, trajectory visualizations and molecular images were 
performed with PyMOL. 
Cell growth and transfection  
HEK293T cells were grown in culture medium consisting of  Dulbecco's modified Eagle's 
medium (DMEM)  supplemented with 10% newborn calf serum (NCS), 50 µg/ml 
streptomycin and 50 IU/ml penicillin at 37 °C and 7% CO2. Cells were subcultured twice a 
week at a ratio of 1:15 on 10 cm ø plates. Cells were transfected with the wild-type A2AAR- 
plasmid (pcDNA3.1, 1 µg) using the calcium phosphate precipitation method.46 
Membrane preparation 
Cells were detached from plates 48 h after transfection by scraping them into 5 ml 
phosphate buffered saline (PBS), collected and centrifuged at 700 ×g (3000 rpm) for 5 min. 
Pellets derived from 50 plates (10 cm ø) were pooled and resuspended in 40 ml of ice-cold 
assay buffer (50 mM Tris-HCl  supplemented with 5 mM MgCl2, pH 7.4). An Ultra-Turrax 
was used to homogenize the cell suspension. Membranes and the cytosolic fraction were 
separated by centrifugation at 100,000 ×g (31,000 rpm) in a Beckman Optima LE-80K 
ultracentrifuge at 4 °C for 20 min. The pellet was resuspended in 20 ml of Tris buffer and 
the homogenization and centrifugation step was repeated. Assay buffer (10 ml) was used 
to resuspend the pellet and adenosine deaminase (ADA) was added (0.8 IU/ml) to break 
down endogenous adenosine. Membranes were stored in 250 µl aliquots at -80 °C. 
Membrane protein concentrations were measured using the BCA (bicinchoninic acid) 
method.47  
Competition and saturation binding assays using HEK293T cell membranes 
For competition binding experiments with [3H]ZM-241,385 (46.6 Ci/mmol, ARC Inc, St. 
Louis, MO, USA), between 6 and 8 µg of  membranes was used to ensure that total binding 
was less than 10% of the total radioactivity added to prevent radioligand depletion. For 
[3H]NECA (16.3 Ci/mmol, Perkin Elmer, Groningen, The Netherlands) competition binding 
experiments between 18 and 25 µg of membranes were used for the experiments. 
Membrane aliquots were incubated in a total volume of 100 μl of assay buffer at 25 °C for 
2 h. Radioligand displacement experiments were performed using five concentrations of 
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competing ligand (NaCl, amiloride or HMA (5-[N,N-hexamethylene]amiloride), all from 
Sigma Aldrich, Zwijndrecht, The Netherlands).  [3H]ZM-241,385 and [3H]NECA were used at 
concentrations of ~ 4.0 nM and 15-20 nM, respectively. Nonspecific binding was 
determined in the presence of 100 μM CGS21680 (Ascent Scientific, Bristol, UK, for 
experiments with [3H]ZM-241,385) or 10 µM ZM-241,385 (Ascent Scientific, Bristol, UK, for 
experiments with [3H]NECA)  and represented less than  15% of the total binding. For 
saturation experiments, total binding was determined at increasing concentrations of 
[3H]ZM-241,385 (0.10-45 nM), in the absence or presence of ZM-241,385 (10 nM), NaCl 
(30 or 100 mM), amiloride (30 µM), or HMA (3 µM). In addition, unlabeled NECA (Ascent 
Scientific, Bristol, UK) was spiked with 25% [3H]NECA resulting in final concentrations of 
8.0 to 400 nM, in the absence or presence of ZM-241,385 (10 nM), NaCl (30 or 100 mM), 
amiloride (30 µM), or HMA (4 µM). Nonspecific binding was determined at three 
concentrations of radioligand and analyzed by linear regression. Incubations were 
terminated by rapid vacuum filtration to separate the bound and free radioligand through 
96-well GF/B filter plates using a Filtermate-harvester (PerkinElmer Life Sciences). Filters 
were subsequently washed three times with ice-cold assay buffer. The filter-bound 
radioactivity was determined by scintillation spectrometry using the PE 1450 Microbeta 
Wallac Trilux scintillation counter (PerkinElmer Life Sciences). 
Thermostability assays 
The A2AAR-BRIL-ΔC receptor construct was purified from Spodoptera frugiperda (Sf9) 
insect cells in the apo form as described previously,22 except that KCl was used throughout 
purification instead of NaCl. N-(4-[7-diethylamino-4-methyl-3-coumarinyl]phenyl)-
maleimide (CPM) dye (Invitrogen) was dissolved in DMSO (Sigma) at 4 mg/ml and stored 
at −80 °C. Before use, the CPM stock solu on was thawed and diluted 1:40 in dye dilu on 
buffer (10 mM HEPES pH 7.50, 10% glycerol, 0.05% dodecyl maltoside (DDM) (Anatrace)). 
The thermal denaturation assay was performed with a total volume of 200 µl per sample 
in a quartz fluorimeter cuvette (Starna Cells, Inc., Atascadero, CA) and an apparent relative 
Tm was obtained.48 Receptor (4 µg) was diluted in assay buffer (10 mM HEPES pH 7.5, 
0.05% DDM, 0.01% cholesterol hemisuccinate (CHS) (Sigma)) with and without different 
concentrations and combinations of NaCl, amiloride, and ZM-241,385 to a final volume of 
200 µl. 5 µl of the diluted dye was added to the protein-containing assay solution and 
incubated for 30 min at 4 °C. The mixed solutions were transferred into cuvettes and 
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fluorescence data were collected by a Cary Eclipse spectrofluorometer (Varian, USA) with 
a temperature ramping rate of 2 °C/min. The excitation wavelength was 387 nm and the 
emission wavelength was 463 nm. All assays were performed over a temperature range 
starting from 20 °C to 90 °C.  
Data analysis 
The radioligand binding and thermostability data were processed with Prism 5 (GraphPad 
Software, San Diego, CA, USA). Statistical significance was assessed with a Student’s t-test. 
Results 
Molecular dynamics studies 
A series of MD simulations were designed to evaluate the functional role of the sodium 
ion in the A2AAR, as summarized in Table 1. Three MD replicates of 40-100 ns length each 
were run for each setup, in order to increase the statistics of the sampling, with a total 
simulation time exceeding 2.8 µs. The effect of the sodium ion on the conformational 
equilibrium of the receptor was examined considering both the inactive and active-like 
conformation of the A2AAR (simulations MDS1-MDS7). The influence of the orthosteric 
ligands in this process was examined by comparing the MD simulations with and without 
the antagonist ZM-241,385 (MDS1 and MDS2) or the agonists UK-432,097 and NECA 
(MDS5 through MDS7). In addition, the allosteric effect of amiloride and its derivative 
HMA in the antagonist-bound conformation was examined in MDS8 through MDS12, with 
two distinct chemotypes of antagonists (i.e., ZM-241,385 and caffeine).  
The sodium binding site in the A2AAR inactive conformation 
In the high resolution crystal structure of inactive A2AAR,
22 the sodium ion is directly 
coordinated by Asp522.50 and Ser913.39 (first shell residues) and three structured water 
molecules (Figure 1A). Water molecules also bridge interactions with residues in the 
second (Trp2466.48 and Asn2807.45), and the third shells (Thr883.36 and Ser2817.46). Overall, 
the sodium ion/water binding pocket is formed by 15 out of the 34 amino acids that are 
conserved in the majority of non-olfactory class A GPCRs23 and their conformation is 
similar in most GPCRs crystallized in the inactive state (Figure 1B-D).  
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Figure 1. Structure and conservation of the central sodium ion-binding allosteric pocket in Class A 
GPCRs. A) The sodium ion distorted octahedral coordination as in the A2AAR crystal structure: The 
first shell is occupied by two conserved polar residues (green) and three water molecules, which 
contact with a second shell of residues (cyan), or with a second layer of water molecules connecting 
with the third shell of residues (magenta).  B) Sequence conservation of the 15 residues lining the 
binding pocket among inactive GPCR crystal structures. C) Structure of the A2AAR complex with ZM-
241,385, showing residues with higher than 50% conservation in all Class A receptors as sticks with 
green carbons. D) A close-up of the central allosteric pocket (transparent blue surface), showing the 
side chains located within 5 Å from the ten waters of the sodium ion-water cluster (green sticks: 
A2AAR; gray thin lines: the corresponding side chains of the overlaid GPCR crystal structures listed in 
B. See also supplemental Figure S1. 
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Figure 2. The two coordination states of the sodium ion as observed in MD simulations  
A) Volumetric density map (isosurface contoured at 0.3 Å-3 value, blue) corresponding to the sodium 
ion occupancy as calculated from simulations MDS1 (see Table 1). The starting crystal structure is 
displayed, together with the electron density (contoured at 1  level, black). B) The time-evolution 
of the distances between the sodium ion and Asp2.50 (blue), Ser3.39 (red) and Asn7.45 (green), shown 
for the 3 independent replicates (R1-R3) of MDS1. The corresponding distances are denoted as 
dashed lines in A with the same color code, and are the source of the data in Table S1. The RMSD of 
the ion with respect to its crystallographic position is indicated with a black line, while the horizontal 
bar at 1.8 Å (the resolution of the parent crystal structure) denotes the limit for the crystallographic 
coordination state (position c1). See also Table S1 and Figure S2. 
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Analysis of the sodium ion’s mobility and its coordination state reveals a high level of 
stability for the ion when bound to the receptor’s inactive conformation. The dominant 
charge-charge interaction with Asp522.50 is clearly maintained along the simulation runs in 
the different MD trajectories, while the side chain oxygen atoms of Ser913.39 and 
Asn2807.45 alternate direct interactions with the ion (Figure 2). More precisely, the ion 
fluctuates between a coordination state as seen in the crystal structure, which we will 
refer to as position c1, and a second state that we will refer to as position c2. This 
fluctuation involves an exchange between the sodium ion and the water molecule W52, 
initially linked to the OD1 of Asn2807.45, as shown in Figure 2A by the overlay of the 
electron density of the crystal structure with the volumetric density map calculated from 
the MD simulations. In position c2, the ion is still coordinated by Asp522.50 (OD1), while it 
is the OD1 of Asn2807.45 (occasionally replaced by a new water molecule) that participates 
in the first coordination shell, which is completed with three other water molecules. The 
radial distribution function indicates the average sodium-oxygen distance is 2.4 Å, with the 
first coordination shell predominantly formed by 4 or 5 oxygen atoms (see supplemental 
Figure S2), in agreement with the geometric analysis of sodium ion binding sites found in 
the Protein Data Bank (PDB).49 The consistent observation of these two dominant 
coordination modes suggests a possibility of fast exchange between the sodium ion and 
the water molecule, supported by the significantly shorter distance (2.2 Å) observed in the 
crystal structure for the Na+-O(W52) pair. Interestingly, this fast exchange occurs 
regardless of the presence of the antagonist ZM-241,385 in the orthosteric binding site 
(Table S1). In the setup MDS1b, we evaluated the effects of a physiological saline 
concentration in the simulations, and observed  no difference in results (see supplemental 
Figure S2 and Table S1). Moreover, none of the sodium ions from the extracellular solvent 
could cross the narrow channel into the allosteric pocket during 100 ns simulations, 
suggesting that exchange of sodium ions in A2AAR may occur on a longer time scale. 
To investigate a possible effect of the sodium ion on the stability of the inactive 
conformation of the receptor, the MD simulations described above (MDS1 and MDS2) 
were compared with the corresponding simulations of the inactive A2AAR in the absence 
of the ion (MDS3 and MDS4). The most pronounced difference in local conformational 
dynamics was located in the region of the sodium ion: the highly conserved residue 
Trp2466.48 in the second sphere of solvation experienced a rotameric transition from  
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theinitial g+ rotamer to the trans (t) conformation, observed in two out of three 
independent simulations of the apo receptor without sodium ion (MDS4, see Figure 3). 
This rotameric change appears connected to a rotation of residue Asn2807.45 from the 
initial g- rotamer to either trans or g+ (Figure 3A and C). In contrast, rotamer changes in 
Tpr2466.48 and to a lesser extent Asn2807.45 were not observed when the sodium ion was 
bound to the allosteric site (MDS2), suggesting that the sodium ion contributes to a 
stabilization of these two residues (Figure 3A and B). Similarly, the furyl moiety of the 
antagonist ZM-241,385 stabilized the g+ rotamer of Trp2466.48 through Van der Waals 
interactions (simulations MDS1 and MDS3). Consequently, no movements in this 
microenvironment occured with ZM-241,385 bound, regardless of the presence of the 
sodium ion.  
The sodium ion binding site in the A2AAR active-like conformation 
Analysis of the agonist-bound structures of A2AAR
18, 19 indicates that the activation–related 
changes in helix VII partially collapse the sodium ion pocket, making it incompatible with 
ion binding.22 In order to further evaluate this effect, the sodium ion-water cluster was 
simulated in the context of the active-like conformation of A2AAR with agonists UK-
432,097 (MDS5) or NECA (MDS6), or without any agonist (MDS7, see Table 1). The 
simulations show that in the active-like state the receptor cannot bind the sodium ion, as 
evidenced by two alternative events that occur in the early stages of production runs. In 
the first event, (observed in 1 out of 3 replicas in MDS5, in 2 out of 3 replicas in MDS6, and 
in all 3 replicas in MDS7) the ion escaped from the proposed binding site. In the 
alternative event, observed in the remaining simulations, the ion remained in the 
allosteric binding site, but a conformational change of helix VII occurred, resembling the 
inactive-like conformation of helix VII observed in all antagonist-bound A2AAR structures. 
In particular, the region between His2787.43 and Asn2847.49 undergoes an outward 
movement driving helix VII apart from helix III and expanding the pocket cavity (Figure 4). 
In the MDS5 and MDS6 simulations, this rearrangement was also accompanied by a loss of 
contact between His2787.43 and the O2' of the ribose moiety of the agonist, suggesting that 
sodium ion binding destabilizes activation-related movements and agonist binding. Note 
that all conformational events described here occurred within the first 5-10 ns of the 
simulation, justifying that a total simulation time of 40 ns was sufficient to properly 
sample the sodium binding site in the active-like system. These findings indicate that the 
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binding of sodium ions and agonists each require a different conformational state of the 
receptor and, therefore, are mutually exclusive.  
 
 
Figure 3. Rotameric transitions of Trp6.48 and Asn7.45 in the apo simulations of the inactive A2AAR. 
A) Populations of the initial conformational states in the simulations with (MDS2) and without 
(MDS4) the sodium ion, and the number of waters in the ion binding site (each data is an average of 
the 3 MD replicas). Note that Trp6.48 only finds the trans conformation when not in the initial g(+) 
conformation, while Asn7.45 is more flexible and can be found in either trans, g(+) or the initial g(-) 
conformations. B) and C) Representative snapshot (magenta) of the conformation of these two 
residues in MDS2 (B) and MDS4 (C), with the reference crystal structure overlaid in light gray. 
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Figure 4. The movement of helix VII in order to accommodate the sodium ion. A) Starting (light grey) 
and ending (rainbow, with helix VII colored orange) conformations of the agonist-bound A2AAR in 
the presence of sodium ion (MDS5), with the inactive crystal structure denoted in anthracite. 
B) The distance between helices III and VII (X axis, Cα of residues Ile
3.40 and Asn7.45 as indicated by a 
dashed line in A) is plotted against the backbone RMSD of the motif His7.43-Asn7.49, (Y axis), using as a 
reference the inactive conformation of A2AAR. Each dot is a snapshot extracted every 0.5 ns, with 
the time evolution depicted by the shading code (light grey -> black). Active and inactive 
conformations are indicated with an asterisk and a triangle, respectively. 
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Amiloride and HMA as A2AAR allosteric modulators 
Amiloride and its derivatives are known to be nonspecific GPCR modulators.50 A binding 
mode of amiloride and its bulkier analog HMA to the A2AAR was determined by flexible 
side chain docking where the charged guanidinium group of amiloride interacted with 
Asp522.50.22 An additional hydrogen bond was also predicted between amiloride and the 
Trp2466.48 side chain (see Figure 5A), which is shifted ~1.5 Å towards the orthosteric 
pocket as a result of induced fit. This tight binding of amilorides is clearly not compatible 
with the collapsed allosteric pocket observed in the active-like conformation of the A2AAR, 
in an even more pronounced way than in the case of sodium ions. Therefore, we explored 
this docking hypothesis with a series of MD simulations of the inactive A2AAR in the 
presence of different orthosteric antagonists, i.e. the ternary complexes A2AAR-ZM-
241,385-amiloride (MDS8) and A2AAR-caffeine-amiloride (MDS9). The effect of amiloride 
on the binding of antagonists turned out to be complex and varied between the different 
antagonist chemotypes tested. Figure 5D shows a comparison of the RMSF (root mean 
square fluctuation) of compound ZM-241,385 with no allosteric modulator present 
(MDS3), and with either sodium ion (MDS1), amiloride (MDS8) or HMA (MDS11) present in 
the proposed allosteric site. A significant increase in the mobility of ZM-241,385 (p<0.05) 
was observed in the presence of both amilorides. This effect is likely due to the influence 
of the side chain of Trp2466.48, which is the only residue that interacts with ZM-241,385 
and amilorides simultaneously (in particular with the 5’-azepane substituent of HMA, see 
Figure 5C), leading to the hypothesis that this highly conserved residue acts as an 
important link between the two sites. Consequently, binding of antagonists that do not 
directly interact with Trp2466.48, for example, caffeine,14 should be less affected by the 
presence of amiloride in the allosteric site (Figure 5B). Indeed, we found no statistically 
significant difference for the mobility of caffeine as a function of the presence of 
amilorides (Figure 5D). Due to the high mobility of caffeine, which is small in size, has few 
receptor contacts, and displays low affinity, the simulation time in this particular system 
was limited to 40 ns time scale. 
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Figure 5. Impact of amiloride and HMA on binding of antagonists. A) Amiloride docking (magenta 
carbons) induces a shifted position of Trp2466.48 side chain, revealing  potential steric clashes with 
the orthosteric ligand ZM-241,385 (yellow carbons, superimposed from the crystal structure with 
PDB code 4EIY). B) Same conformation of the amiloride-bound A2AAR, with the caffeine pose (green 
carbons) superimposed from the crystal structure of A2AAR/caffeine complex (PDB code 3RFM). 
C) Flexible docking of HMA (magenta carbons) is predicted to further shift Trp2466.48 and interfere 
with ZM-241,385 binding. D) Mobility of antagonists in presence or absence of amiloride, HMA and 
the sodium ion in the allosteric pocket, calculated as RMSF from the MD simulations (dark shaded 
bars for ZM-241,385; light shaded bars for caffeine). Error bars indicate the standard deviation 
estimated from three MD replicas (n=3); ami=amiloride; ZM= ZM-241,385. Significantly different 
from the control simulation (absence of any allosteric ligand) in a Student’s t-test with *p < 0.05. 
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Biochemical studies 
Radioligand binding experiments were performed to examine the effects of sodium ions 
and amiloride derivatives on antagonist, [3H]ZM-241,385, and agonist, [3H]NECA, binding 
to the A2AAR. In order to experimentally assess the dependence of ligand binding on the 
presence of a sodium ion in the allosteric site, we performed equilibrium displacement 
studies with increasing concentrations of NaCl (Figure 6A). These experiments show a full 
displacement of [3H]NECA by sodium ions, with an IC50 value of 49 ± 7 mM (Table S2 and 
Figure 6A). In contrast, there is an enhancement of antagonist [3H]ZM-241,385 binding, 
especially at higher sodium ion concentrations. All these results correlate with the MD 
conclusions that the sodium ion selectively stabilizes the antagonist-bound receptor state.  
Saturation binding experiments performed with [3H]NECA also show that  the 
presence of NaCl significantly reduces [3H]NECA binding to the A2AAR (Table 2 and Figure 
S3). Interestingly, this reduction in agonist binding was due to an increase of the KD value 
while the radioligand’s Bmax value remained at a control level, within experimental error. 
This profile of pharmacological parameters usually implies a competitive interaction 
between the two ligands. However, in this case the binding sites of the two ligands are not 
overlapping, therefore the observed “mutually exclusive binding” suggests that the 
sodium ion-bound conformation of A2AAR is not compatible with agonist binding, and vice-
versa. In contrast, no significant effect of sodium ions was observed on the binding of the 
antagonist radioligand [3H]ZM-241,385 to the A2AAR (Table 2). 
We also characterized the influence of amiloride and HMA on radioligand binding to 
the A2AAR. The two compounds inhibited the binding of both agonist and antagonist 
radioligands in displacement assays, albeit with different potencies (Figure 6B and 6C and 
Table S2). HMA proved to be more active than amiloride in both cases, and displayed the 
highest potency (2.4 µM) with the agonist [3H]NECA as the radiolabel. Radioligand 
saturation experiments were performed in the presence of the amiloride analogs, 
revealing distinct differences between the two radioligands (Table 2 and Figure S3). The 
interaction between amiloride and [3H]ZM-241,385 was noncompetitive in nature as the 
radioligand’s Bmax value was significantly reduced with little effect on the KD value, 
whereas unlabeled ZM-241,385, serving as a control orthosteric ligand, showed all traits of 
a competitive ligand. In this experimental setup, HMA behaved somewhat in between ZM-
241,385 and amiloride, showing a small  but significant shift in KD and a nonsignificant 
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change in Bmax value. Similar experiments with the radiolabeled agonist [
3H]NECA 
produced a very different outcome. While unlabeled ZM-241,385 appeared competitive 
with [3H]NECA, as expected for two orthosterically binding compounds, the same was true 
for the interaction between the amilorides and [3H]NECA. Hardly any effect was observed 
on NECA’s Bmax value, whereas all KD values were significantly increased, which we 
attribute to the mechanism of “mutually exclusive binding” discussed above for the case 
of agonist and sodium ion binding.  
 
Table 2. Saturation of [3H]ZM-241,385 and NECA spiked with 25% [3H]NECA binding to human 
A2AARs transiently expressed in HEK293T cell membranes in the absence and presence of ZM-
241,385, NaCl, amiloride, and HMA. See associated experiments in Figure S3. 
 [3H]ZM-241,385 [3H]NECA 
 KD (nM) Bmax
a (%) KD (nM) Bmax
a (%) 
Control 1.3 ± 0.4 100 ± 10 84 ± 11 100 ± 2 
+ 10 nM ZM 8.3 ± 2.2** 85 ± 7 123 ± 9* 95 ± 3 
+ 30 mM NaCl 1.2 ± 0.3 120 ± 11 213 ± 10*** 106 ± 4 
+ 100 mM NaCl 0.8 ± 0.1 87 ± 3 471 ± 53*** 114 ± 9 
+ 30 µM Amiloride 1.9 ± 0.8 61 ± 4* 290 ± 52** 119 ± 13 
+ 3 or 4 µM HMAb 4.1 ± 0.9* 78 ± 9 246 ± 2*** 110 ± 1* 
a: % of Bmax of control ( = 100%) 
b: 3 µM HMA for [3H]ZM-241,385 and 4 µM HMA for [3H]NECA 
Significantly different from control in a Student’s t-test with * p < 0.05, ** p < 0.01, or *** p < 0.001. 
Values are means ± SEM of 2-5 separate assays performed in duplicate. 
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Figure 6. Equilibrium displacement of [3H]ZM-241,385 and [3H]NECA by allosteric modulators.  
NaCl (A), amiloride (B), and HMA (C). Representative graphs from one experiment performed in 
duplicate on hA2AARs transiently expressed in HEK293T cell membranes. Associated IC50 values listed 
in Table S2. 
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Biophysical studies 
The effects of sodium ions, orthosteric ligands and amiloride analogs on A2AAR stability 
were analyzed with a series of thermal stability assays.48 Increasing sodium ion 
concentrations induced a significant increase in the thermostability of the unliganded 
A2AAR-BRIL complex, as shown in Figure 7A. A two-phase response was observed, with a 
modest increase in thermostability from 52 to 57 C at sodium ion concentrations below 
the physiological concentration of 150 mM, and a further more substantial increase to 65 
C upon addition of higher concentrations up to 500 mM NaCl.  
In order to evaluate the effects of allosteric modulators on various receptor-ligand 
complexes, we measured the thermal stability of the A2AAR-BRIL construct in the presence 
or absence of sodium ions and/or amiloride, and their combinations with the orthosteric 
ligands caffeine (antagonist), ZM-241,385 (antagonist), or UK-432,097 (full agonist) (Figure 
7B). Sodium ions and amiloride each increased A2AAR thermostability by 5-6 C, but their 
effect when combined was non-additive, corroborating the suggested competition of 
these two charged molecules for the same binding site. In contrast, the addition of 
caffeine in the presence of saturating concentrations of amiloride or sodium ions caused a 
further 6 C increase in the thermostability of the complex, suggesting an additive 
stabilizing effect of the orthosteric caffeine and allosteric ligands. Also, while we observed 
an additive effect of sodium ions and ZM-241,385, amiloride did not contribute to the 
stability of A2AAR in saturating concentrations of ZM-241,385, in agreement with 
unfavorable indirect interactions between amiloride and ZM-241,385. Finally, neither 
sodium ions nor amiloride had a stabilizing effect on the A2AAR saturated with UK-432,097, 
likely because this agonist precluded binding of these allosteric modulators. 
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Figure 7. Effect of allosteric binders on A2AAR thermostability measured by CPM assays. A) Effect of 
titration of NaCl on A2AAR thermostability, mean ± SEM shown for measurements performed in 
triplicate. B) Effect of NaCl (150 mM), amiloride (100 µM), caffeine (500 µM), ZM-241,385 (50 µM), 
UK-432,097 (50 µM) and combinations thereof on A2AAR thermostability.  
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Discussion 
The 1.8 Å resolution structure of A2AAR in complex with the antagonist ZM-241,385 
revealed a highly conserved sodium ion binding site22 and provided an excellent 
opportunity to examine the molecular mechanism of the allosteric modulation of sodium 
ions in this receptor. Our MD simulations suggest that the electron density assigned to the 
water molecule closest to sodium ion in the crystal structure (W52) could correspond to a 
second resonance position of the ion, which would involve direct interaction with another 
conserved residue, Asn2807.45 (Figure 2). Although we could not find a clear evidence of 
such dynamic rearrangements in the A2AAR crystal structure, this may reflect the “frozen” 
state of the sodium ion-water cluster at the low temperatures (~100K) used in cryo-
crystallography. While further crystallographic studies at room temperature may help to 
validate such subtle effects experimentally,51 the thermal fluctuations explored by the MD 
simulations under physiological conditions are particularly suited to explore this 
phenomenon.52 The potential dynamic nature of the sodium ion and water network in the 
allosteric pocket could partially explain why the ion was not observed previously in lower 
resolution GPCR structures. A closer look at this region in two recently published, 
antagonist-bound GPCR structures, i.e. carvedilol-1-adrenergic receptor
53 and FNA- 
opioid receptor,54 reveals that they are indeed compatible with the presence of a sodium 
ion (Figure S1). More recently, a similar configuration of the sodium ion/water network 
was also identified in other ligand complexes of the 1-adrenergic receptor.
55 
The communication between the highly conserved class A GPCR residues Asp2.50, 
Trp6.48, and to a lesser extent Asn7.45, had been suggested to occur through a cluster of 
water molecules.24 The current MD results strongly support the preference of the sodium 
ion for the inactive conformation of this micro-environment, at least in the A2AAR, 
suggesting that it contributes to its stabilization. The increased dynamic flexibility of 
Trp2466.48 and Asn2807.45 in the absence of the sodium ion (Figure 3) is consistent with 
previous MD simulations of the A2AAR,
37 and agrees well with similar MD simulations in 
the dopamine D2 receptor with explicit consideration of a sodium ion.
27 The 
conformational flexibility of Trp6.48 has been associated with the initial steps of the 
activation mechanism of GPCRs,56, 57 probably by facilitating the higher order 
conformational changes observed in helix VI between inactive and active states. 
Conversely, the presence of the sodium ion and coordinating water molecules in this 
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pocket hampers an activation-related inward movement of helix VII towards helix III,18, 19 
as indicated by MD simulations. Instead, we observed an “inactivation” movement of helix 
VII in the agonist-bound conformation (Figure 4) that led to the loss of key agonist-
receptor interactions, suggesting that the simultaneous binding of the allosteric ion and 
the orthosteric agonist to the same receptor molecule is unlikely. Such a structural 
mechanism explains the negative allosteric effect of sodium ions on agonist binding to the 
A2AAR observed here (Figure 6A and Table 2) and in earlier studies.
6, 22  
In radioligand binding experiments performed with both agonist and antagonist 
radioligands, sodium ions differentially affected radioligand binding to the A2AAR, 
providing further insights into its allosteric effect: they induced an increase in [3H]ZM-
241,385 binding, but abrogated [3H]NECA binding in a concentration-dependent manner 
with an IC50 value of approximately 50 mM (Figure 6A). This potency is in the same range 
of sodium ion concentrations that cause an increase in receptor thermostability (Figure 7), 
indicating that sodium ion binding could mediate both effects. Moreover, this IC50 
corresponds to about one third of the extracellular physiological concentration of sodium 
ions. This suggests that about 75% of the A2AARs that are present in the body are in a 
sodium ion occupied state, provided that there is unrestricted access to the sodium 
binding site from the outside of the cell, as recently proposed for the dopamine D2 
receptor.27 Thus, it is likely that sodium is significantly involved in modulating the 
physiological state of the A2AAR and possibly other class A GPCRs.  
Interestingly, saturation binding experiments (Table 2) demonstrate that the presence 
of sodium ions (30 and 100 mM) reduces [3H]NECA affinity (KD) rather than its Bmax value, 
while no affinity reduction was observed for [3H]ZM-241,385. This fact, together with the 
observed increase of [3H]ZM-241,385 binding at high sodium ion concentrations (Figure 
6A), is in good agreement with an earlier study where the slight affinity increase of this 
radioligand at even higher sodium concentrations (1 M)58 was due to a decrease in its 
dissociation rate.6 The structural information and the computational results provided in 
this study suggest that binding of agonists and sodium ions can be considered as “mutually 
exclusive”.59 This mechanism is further supported by thermal stability assays, showing that 
antagonists ZM-241,385 and caffeine display additive stabilizing effects with sodium ions, 
whereas the agonist UK-432,097 stabilizes the receptor but shows no additive effect when 
any allosteric ligand is added (Figure 7B).  
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Similar to sodium ions, the diuretic drug amiloride is an allosteric modulator of several 
GPCRs (Chapter 2), including such diverse subfamilies as adenosine, aminergic and 
gonadotropin-releasing hormone receptors.6, 60-64 The present study in the human A2AAR 
shows that both amiloride and its derivative HMA negatively modulate agonist binding 
(Table 2), with HMA being more potent than amiloride in radioligand displacement studies 
(Figure 6) as previously suggested by kinetic studies in the rat A2AAR.
6 The saturation 
studies with [3H]ZM-241,385 as the radioligand (Table 2) also point to a noncompetitive 
interaction between amiloride and the antagonist binding site. Moreover, the additive 
increase in A2AAR thermostability in the presence of both amiloride and the orthosteric 
antagonist caffeine (Figure 7B) suggests that both allosteric and orthosteric ligands can 
bind simultaneously. These findings are in concert with docking and MD simulations 
(Figure 5), which suggest that amiloride and HMA bind in the allosteric sodium pocket, 
with the charged guanidinium group anchored by the carboxyl of Asp2.50. Although the 
proposed amiloride binding does not directly overlap with the orthosteric ligand binding 
site, our simulations indicate that amiloride derivatives can impact orthosteric ligand 
binding indirectly, primarily via modulation of Trp2466.48 conformation. This explains a 
more pronounced negative allosteric effect of HMA, which has extensive steric 
interactions with the Trp2466.48 side chain. Overall, the distinct allosteric effects of 
amilorides are probably the result of a delicate balance between an improved stability of 
the inactive conformation and an indirect (noncompetitive) interference with the 
orthosteric site for antagonists.  
In summary, a combination of biochemical and thermal stability data with MD 
simulations, based on both inactive and the active-like crystal structures of the A2AAR, 
provided valuable mechanistic insights into the role of the allosteric sodium ion in the 
conformational equilibrium of the receptor. Our findings suggest that the binding of either 
the sodium ion or amilorides to the allosteric pocket selectively stabilizes the inactive 
conformation of the receptor, and this allosteric effect is responsible for the observed 
reduction in orthosteric agonist binding. Comprehensive experimental and theoretical 
analyses of A2AAR in simultaneous complex with both allosteric modulators and 
orthosteric ligands also explain, on a molecular basis, the distinct interaction profiles 
observed between allosteric amiloride derivatives and different orthosteric antagonists. 
These observations pave the way for better understanding of GPCR allosteric control, 
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which may be used in the design of novel allosteric modulators to more precisely tune 
receptor function. 
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Abstract 
Recently a sodium ion binding pocket in a high resolution structure of the human 
adenosine A2A receptor was identified. In the present study we explored this binding site 
through site-directed mutagenesis and molecular dynamics simulations. Amino acids in 
the pocket were mutated to alanine, and their influence on agonist and antagonist 
affinity, allosterism by sodium ions and amilorides, and receptor functionality was 
explored. Mutation of the polar residues in the sodium ion pocket was shown to either 
abrogate (D52A2.50 and N284A7.49) or reduce (S91A3.39, W246A6.48, and N280A7.45) the 
negative allosteric effect of sodium ions on agonist binding. Mutations D52A2.50 and 
N284A7.49 completely abolished receptor signaling, while mutations S91A3.39 and N280A7.45 
elevated basal activity and mutations S91A3.39, W246A6.48, and N280A7.45 decreased 
agonist-stimulated receptor signaling. In molecular dynamics simulations D52A2.50 directly 
affected the mobility of sodium ions, which readily migrated to another pocket formed by 
Glu131.39 and His2787.43. The D52A2.50 mutation also decreased the potency of amiloride 
with respect to ligand displacement, but did not change orthosteric ligand affinity. In 
contrast, W246A6.48 increased some of the allosteric effects of sodium ions and amiloride, 
while orthosteric ligand binding was decreased. These new findings suggest that the 
sodium ion in the allosteric binding pocket not only impacts ligand affinity, but also plays a 
vital role in receptor signaling. Because the sodium ion binding pocket is highly conserved 
in other class A GPCRs, our findings may have a general relevance for these receptors and 
may guide the design of novel synthetic allosteric modulators or bitopic ligands. 
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Introduction 
G protein-coupled receptors (GPCRs) are seven transmembrane helical proteins, which 
regulate a multitude of physiological processes, and therefore are targeted by 30-40% of 
the drugs currently on the market.1 GPCR crystal structures are becoming increasingly 
available, which considerably contributes to our understanding of both drug-receptor 
interactions and receptor activation mechanisms.2 Still, much remains to be discovered 
and therefore the new crystal structure repertoire of GPCRs is continuously analyzed by 
biochemical, computational and pharmacological studies.  
One of the most widely explored GPCRs is the human adenosine A2A receptor 
(hA2AAR), a drug target related to Parkinson’s disease, cardiovascular diseases, and 
inflammatory disorders.3 Recently, a high resolution crystal structure of the inactive 
hA2AAR in complex with antagonist ZM-241,385 identified the precise location of a sodium 
ion in the region around the conserved Asp522.50,4 as previously hypothesized for other 
GPCRs5, 6 (numbering in superscript according to Ballesteros and Weinstein).7 Residues 
Ser913.39, Trp2466.48, Asn2807.45, and Asn2847.49, together with a network of structural 
water molecules, completed the coordination of the ion in the hA2AAR. The fact that this 
site changes its conformation dramatically between inactive and active-like structures of 
the hA2AAR,
4, 8 inspired us to further explore the nature of this allosteric binding site.  
In Chapter 3 we used a combination of molecular dynamics (MD) simulations, 
biophysical and biochemical experiments to conclude that sodium ions selectively stabilize 
the inactive conformation of the wild-type receptor, and that a physiological 
concentration was sufficient to achieve this effect. This mechanism was further 
corroborated with radioligand binding data, indicative of a competitive interaction 
between the sodium ion in this allosteric pocket and an agonist in the orthosteric pocket. 
Further, we proposed in Chapter 3 that the diuretic drug amiloride and analogs compete 
for the same site, and exert an allosteric control on the hA2AAR quite similar to that of 
sodium ions, albeit with pharmacological differences in modulation of orthosteric ligand 
binding. 
In the present study we mutated residues in the first and second coordination shell 
around the sodium ion, to define the role of individual amino acids in allosteric 
modulation by sodium ions, amiloride and its derivative HMA. This enabled us to analyze 
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the effects of these manipulations on orthosteric ligand binding and receptor activation, 
employing a combination of biochemical and computational techniques.  
Materials and methods 
Cell growth and transfection  
HEK293 cells were grown in culture medium consisting of Dulbecco's modified Eagle's 
medium (DMEM) supplemented with 10% newborn calf serum (NCS), 50 µg/ml 
streptomycin and 50 IU/ml penicillin at 37 °C and 7% CO2. Cells were subcultured twice a 
week at a ratio of 1:20 on 10 cm ø plates. Single point mutations were introduced in the 
wild-type hA2AAR-plasmid DNA (FLAG-tag at N-terminus, in pcDNA3.1) by BaseClear 
(Leiden, The Netherlands). Cells were transfected with the indicated plasmids (1 µg each) 
using the calcium phosphate precipitation method.9 All experiments were performed 48 h 
after transfection. HEK293 cells stably expressing the wild-type A2AAR receptor (A2AAR-WT) 
were grown in the same medium as the other HEK293 cells but with the addition of G-418 
(200 µg/ml). 
Enzyme-linked immunosorbent assay 
Twenty-four hours after transfection, cells were brought into 96-well poly-D-lysine-coated 
plates at a density of 105 cells per well. After an additional 24 h, the monolayers were 
washed with phosphate-buffered saline (PBS) and fixed for 10 minutes with 3.7% 
formaldehyde. Subsequently, cells were washed two times with PBS and cell-surface 
receptors were labeled with mouse anti-FLAG (M2) primary antibody (Sigma, 1:1000) in 
culture medium for 30 min at 37 °C. The cells were then washed once with DMEM 
supplemented with 25 mM HEPES and then incubated for another 30 min at 37 °C in 
culture medium supplemented with horseradish peroxidase-conjugated anti-mouse IgG 
produced in goat (Brunschwig, Amsterdam, The Netherlands; 1:5000) as the secondary 
antibody. The cells were washed twice with PBS. Finally, the cells were incubated with 
3,3’,5,5’-tetramethylbenzidine (TMB) for 5 min in the dark at room temperature. The 
reaction was stopped with 1 M H3PO4 and after 5 min the absorbance was read at 450 nm 
using a VICTOR 2 plate reader (PerkinElmer Life Sciences, Groningen, The Netherlands). 
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Radioligand binding assays  
[3H]ZM-241,385 (50 Ci/mmol)  and [3H]NECA (17 Ci/mmol) were  obtained  from ARC Inc. 
(St. Louis, MO, USA) and PerkinElmer (Groningen, The Netherlands), respectively. ZM-
241,385 was obtained from Ascent Scientific (Bristol, UK). Amiloride and HMA were 
obtained from Sigma Aldrich (Zwijndrecht, The Netherlands). All other materials were 
purchased from commercial sources and were of the highest available purity.  
HEK293 cells were grown and transfected as described above. Membranes were 
prepared as follows. Cells were detached from plates 48 h after transfection by scraping 
them into 5 ml PBS, collected and centrifuged at 700 ×g (3000 rpm) for 5 min. Pellets 
derived from 20 plates (10 cm ø) were pooled and resuspended in 16 ml of ice-cold assay 
buffer (50 mM Tris-HCl, pH 7.4). An Ultra-Turrax was used to homogenize the cell 
suspension. Membranes and the cytosolic fraction were separated by centrifugation at 
100,000 ×g (31,000 rpm) in a Beckman Optima LE-80K ultracentrifuge (Woerden, The 
Netherlands) at 4 °C for 20 min. The pellet was resuspended in 8 ml of Tris buffer and the 
homogenization and centrifugation step was repeated. Assay buffer (4 ml) was used to 
resuspend the pellet and adenosine deaminase (ADA) was added (0.8 IU/ml) to break 
down endogenous adenosine. Membranes were stored in 250 µl aliquots at -80 °C. 
Membrane protein concentrations were measured using the BCA (bicinchoninic acid) 
method.10  
For competition binding experiments with [3H]ZM-241,385 membranes with 
transiently expressed A2AAR-WT (7 μg of total protein), A2AAR-D52A
2.50 (5 μg), A2AAR-
S91A3.39 (1 μg), A2AAR-W246A
6.48 (2 µg), A2AAR-N280A
7.45 (1.5 μg), A2AAR-N284A
7.49 (1 μg) 
were used; we added different protein amounts to ensure that total binding to the 
membrane preparations was less than 10% of the total radioactivity added in order to 
prevent radioligand depletion. For [3H]NECA competition binding experiments 30 μg, 15 
μg, 10 μg, 45 μg, 50 μg, 10 μg of expressed A2AAR-WT, D52A
2.50, S91A3.39, W246A6.48, 
N280A7.45, N284A7.49 receptors were used, respectively. Membrane aliquots were 
incubated in a total volume of 100 μl of assay buffer at 25 °C for 2 h. For homologous 
competition curves, radioligand displacement experiments were performed in the 
presence of nine concentrations of NECA (0.1 nM – 100 µM) and ZM-241,385 (0.01 nM – 
10 µM). For concentration-effect curves, radioligand displacement experiments were 
performed in the presence of six concentrations of NaCl (10 μM – 1 M) and five 
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concentrations of amiloride (100 nM – 1 mM) and HMA (10 nM – 1 mM). [3H]ZM-241,385 
and [3H]NECA were used at concentrations of 2.5 nM and 20 nM, respectively. Nonspecific 
binding was determined in the presence of 10 µM ZM-241,385 ([3H]NECA) or 100 µM 
NECA ([3H]ZM-241,385) and represented less than 10% of the total binding. Incubations 
were terminated by rapid vacuum filtration to separate the bound from free radioligand 
through 96-well GF/B filter plates using a Filtermate-harvester (PerkinElmer Life Sciences). 
Filters were subsequently washed three times with ice-cold assay buffer. The filter-bound 
radioactivity was determined by scintillation spectrometry using a PE 1450 Microbeta 
Wallac Trilux scintillation counter (PerkinElmer Life Sciences). 
Functional cAMP assays 
HEK293 cells were grown and transfected as described above. Experiments were 
performed 48 h after transfection. The amount of cAMP produced was determined with 
the LANCE cAMP 384 kit (PerkinElmer). In short, 5000 cells per well were pre-incubated 
for 30 min at 37°C and subsequently incubated for one hour at room temperature with a 
range of CGS-21680 concentrations (0.1 nM – 10 µM), one concentration of ZM-241,385 
(10 µM), or without addition of ligand. cAMP generation was performed in the medium 
containing cilostamide (50 µM), rolipram (50 µM) and ADA (0.8 IU·ml-1). The incubation 
was stopped by adding detection mix and antibody solution, according to the instructions 
of the manufacturer. The generated fluorescence intensity was quantified on an EnVision® 
Multilabel Reader (PerkinElmer). cAMP production by 10 µM CGS-21680 on the parental 
HEK293 cell line represented less than 5% of cAMP production generated in cells 
expressing the hA2AAR receptor. 
Molecular dynamics simulations 
Molecular dynamics (MD) simulations of wild-type and mutant forms of the A2A receptor 
were performed following the computational protocol in Chapter 3. Briefly, the inactive 
structure of the A2AAR in complex with ZM-241,385 and a sodium ion (PDB code 4EIY)
4 was 
used as a basis for our simulations, after a refinement process that consisted in modeling 
the missing ICL3 segment and proton addition, assessing the protonation state of 
titratable residues (i.e. all charged) and histidine residues, which were protonated on N 
except for His155ECL2 (protonated on N and His264ECL3 (positively charged). The sodium 
ion and coordinating water molecules were explicitly considered except in the simulations 
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with amiloride or HMA, which occupied the allosteric sodium ion site. Further details are 
summarized in Chapter 3. Building the mutant variants of the A2A receptor explored in this 
work was achieved by means of the “protein mutation tool” in Maestro.11 
MD simulations were performed with GROMACS software,12 using our original 
protocol for the MD simulations of GPCRs.13 Our PyMemDyn program was used for 
membrane insertion, soaking with bulk water and inserting the resulting system, 
consisting of approximately 50,000 atoms (~74% belong to solvent molecules, ~15% to 
lipids and ~11% to protein and ligand atoms), into a hexagonal prism-shaped box, which 
was then energy-minimized and carefully equilibrated in the framework of periodic 
boundary conditions (PBC) for 5 ns.14 Three replicate production simulations (i.e., 
changing the initial velocities of the system) were followed for 100 ns simulation time 
each, thus accounting for a total of 300 ns MD sampling of each system. The OPLSAA force 
field was adopted throughout the simulations,15 with ligand parameters obtained from 
Macromodel,16 and lipid parameters adapted from Berger17 together with the use of the 
half- double-pairlist method18 and the SPC water model.19 A Nose-Hoover thermostat20 
with a target temperature of 310 K was used. Electrostatic interactions beyond a cutoff of 
12 Å were estimated with the particle mesh Ewald (PME) method. All MD analyses were 
conducted with several GROMACS and VMD21 utilities. Molecular superimpositions, 
trajectory visualizations and molecular images were performed with PyMOL.22  
82 | Chapter 4 
Results 
Design of mutations in the sodium ion binding pocket 
We mutated the residues important for the sodium ion coordination (Figure 1) to alanine, 
i.e. D52A2.50, S91A3.39, W246A6.48, N280A7.45, and N284A7.49. This approach thus yielded a 
total of five mutant receptors, which were studied further and compared to the wild-type 
receptor with respect to their expression levels and pharmacology. 
 
Figure 1. Residues in or close to the sodium ion binding site that we subjected to an alanine scan in 
the hA2AAR, mapped on the crystal structure of the hA2AAR in the inactive ZM-241,385 and sodium 
ion bound conformation (PDB 4EIY)4. Residues Asp522.50, Ser913.39, Trp2466.48, Asn2807.45, and 
Asn2847.49 (represented by sticks, of which red and blue sticks are oxygen and nitrogen atoms, 
respectively) coordinate the sodium ion (purple sphere). Numbering of the residues follows the 
Ballesteros-Weinstein system for comparison of positions between GPCRs.
7 Water molecules 
interacting with the sodium ion are represented by red spheres; hydrogen bonds are represented by 
black dotted lines; receptor backbone is represented by ribbons. Purple stick structure on top 
represents (part of) co-crystallized ZM-241,385. 
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Cell surface receptor expression of mutated receptors 
ELISA was performed on HEK293 cells transiently expressing FLAG-tagged wild-type and 
mutant hA2AAR (Figure 2). Wild-type and mutant receptors were expressed efficiently at 
similar levels. 
 
Figure 2. Receptor expression levels on the cell surface of HEK293 cells transiently transfected with 
wild-type hA2AAR or D52A
2.50, S91A3.39, W246A6.48, N280A7.45, or N284A7.49 single point mutated 
hA2AAR, represented as fold-over-mock transfected HEK293T cells. The figure represents data 
combined from at least two separate experiments performed in quadruplicate. 
 
Homologous competition assays 
First we analyzed the effect of mutation of these residues on the affinity of radioligands 
[3H]NECA (agonist) and [3H]ZM-241,385 (antagonist) in the absence of NaCl (Table 1). The 
affinity of [3H]NECA and [3H]ZM-241,385 for the wild-type hA2AAR was 81 nM and 4.6 nM, 
respectively. D52A2.50 showed the same affinity as the wild-type receptor for both 
radioligands (77 nM and 3.5 nM, respectively). The other mutations caused some decrease 
in affinity for both radioligands, with a more pronounced effect on the agonist. An 
approximately 3-fold decrease of [3H]NECA affinity was observed for receptors with 
mutations S91A3.39 and N284A7.49, while [3H]ZM-241,385’s affinity did not change 
significantly by these mutations. Radioligand agonist affinity decreased approximately 9-
fold on N280A7.45, while a 1.8-fold decrease was observed for the antagonist. The 
W246A6.48 mutation affected affinities most, i.e. a 24-fold decrease in [3H]NECA affinity 
and a 5-fold decrease in [3H]ZM-241,385 affinity.  
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Table 1. Homologous competition displacement studies yielding KD values (nM) for [
3H]NECA and 
[
3H]ZM-241,385 binding to wild-type human A2AAR and single point mutants D52A
2.50, S91A3.39, 
W246A6.48, N280A7.45, and N284A7.49, transiently expressed on HEK293 cell membranes. 
 [3H]NECA [3H]ZM-241,385 







Wild-type 81 ± 5 1.0 4.6 ± 0.5 1.0 
D52A2.50 77 ± 8 1.0 3.5 ± 0.5 0.75 
S91A3.39 258 ± 24*** 3.2 7.0 ± 0.2 1.5 
W246A6.48 1942 ± 124*** 24 23.2 ± 4.3*** 5.0 
N280A7.45 752 ± 147*** 9.3 8.4 ± 1.3* 1.8 
N284A7.49 237 ± 27*** 2.9 7.0 ± 0.7 1.5 
a: Change in fold over wild-type. 
Significantly different from wild-type with * p < 0.05 or *** p < 0.001 (one-way ANOVA with 
Dunnett’s post test performed on corresponding pKD values). 
Values are means ± SEM of at least three separate assays performed in duplicate. 
 
Concentration-effect curves in radioligand displacement studies 
Displacement curves of [3H]ZM-241,385 and [3H]NECA binding were recorded with 
different concentrations of NaCl, amiloride, and its more lipophilic derivative HMA for the 
wild-type and mutant receptors (Figure 3). Whenever possible, IC50 values were derived 
for the inhibitory modulation of agonist [3H]NECA and antagonist [3H]ZM-241,385 binding 
by NaCl, amiloride, and HMA (Tables 2 and 3). NaCl inhibited [3H]NECA binding to the wild-
type receptor with an IC50 value of 44 ± 6 mM. At the highest concentration tested (1 M) 
NaCl had modest effects with 59 ± 3 %, 89 ± 2 %, and 52 ± 11 % of [3H]NECA binding 
remaining on mutants S91A3.39, N2807.45, and W246A6.48, respectively (Figure 3A). 
[3H]NECA binding was not inhibited by NaCl on mutant N284A7.49 (Figure 3A). Increasing 
concentrations of NaCl showed a tendency to enhance [3H]ZM-241,385 binding to the 
wild-type receptor as well as to the mutants tested, with W246A6.48 showing the biggest 
enhancement (Figure 3B). At the highest concentration of NaCl (1 M), [3H]NECA agonist 
binding was also enhanced in the mutant receptor D52A2.50 (172 ± 9 %), which suggests 
that at such extreme concentrations NaCl can exert allosteric effects that are different 
from the specific effect of sodium ion binding at Asp522.50. 
Sodium ion binding pocket mutations and adenosine A2A receptor function | 85 
 
Figure 3. Displacement/enhancement of specific [3H]NECA (A, C, E) and [3H]ZM-241,385 (B, D, F) 
binding by NaCl (A, B), amiloride (C, D), and HMA (E, F) on wild-type human A2AAR and point 
mutants D52A2.50, S91A3.39, W246A6.48, N280A7.45, and N284A7.49 transiently expressed on HEK293T 
cell membranes. Representative graphs from one experiment performed in duplicate are shown. 
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Table 2. Displacement of specific [3H]NECA binding by amiloride and HMA from wild-type human 
A2AAR and point mutants D52A
2.50, S91A3.39, W246A6.48, N280A7.45, N284A7.49 transiently expressed 
















Wild-type 16 ± 3 1.0 2.5 ± 0.4 1.0 
D52A2.50 175 ± 75*** 11 35 ± 9*** 14 
S91A3.39 13 ± 1.8 0.81 2.3 ± 0.6 0.92 
W246A6.48 2.7 ± 0.9*** 0.17 0.43 ± 0.05*** 0.17 
N280A7.45 10 ± 2 0.63 2.4 ± 0.6 1.0 
N284A7.49 5.9 ± 1.4 0.37 1.0 ± 0.3* 0.40 
a: Change in fold over wild-type. 
Significantly different from wild-type with * p < 0.05 or *** p < 0.001 (one-way ANOVA with 
Dunnett’s post test performed on corresponding pIC50 values). 
Values are means ± SEM of at least three separate assays performed in duplicate.  
 
Amiloride and HMA were capable of displacing [3H]NECA and [3H]ZM-241,385 binding 
on the point mutant receptors (Figures 3C-F), although with different IC50 values with 
respect to the wild-type receptor (Tables 2 and 3). D52A2.50 was particularly insensitive to 
amilorides: the inhibitory potency of amiloride and HMA on [3H]NECA binding was 
decreased by 11- and 14-fold and on [3H]ZM-241,385 binding by 17- and 18-fold, 
respectively. Conversely, W246A6.48 showed an increased inhibitory potency of amiloride 
and HMA, both on [3H]NECA (6-fold for both amilorides) and on [3H]ZM-241,385 (24- and 
25-fold, respectively) binding. For N280A7.45 we observed a smaller but also significant 
increase (3.6-fold) of the negative modulation of [3H]ZM-241,385 binding by HMA, and for 
N284A7.49 a similar increase (2.6-fold) of the modulation of both [3H]NECA and [3H]ZM-
241,385 binding by HMA. For N284A7.49 the potency of amiloride increased significantly 
only in case of [3H]ZM-241,385 displacement. Mutant S91A3.39 exhibited similar potencies 
as the wild-type receptor for displacement of both radioligands by amiloride and HMA 
(Tables 2 and 3). These observations suggest that while polar interactions with W246A6.48, 
N280A7.45 and N284A7.49 are important for binding of the sodium ion and coordinating 
water molecules, the interactions of amilorides with these three side chains are somewhat 
suboptimal.  
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Table 3. Displacement of specific [3H]ZM-241,385 binding by amiloride and HMA from wild-type 
human A2AAR and point mutants D52A
2.50, S91A3.39, W246A6.48, N280A7.45, N284A7.49 transiently 
















Wild-type 63 ± 16 1.0 8.9 ± 1.5 1.0 
D52A2.50 1065 ± 274*** 17 164 ± 47*** 18 
S91A3.39 82 ± 8 1.3 8.2 ± 0.5 0.92 
W246A6.48 2.6 ± 0.4*** 0.04 0.36 ± 0.06*** 0.04 
N280A7.45 20 ± 4 0.32 2.5 ± 0.6** 0.28 
N284A7.49 16 ± 4* 0.25 3.3 ± 0.8* 0.37 
a: Change in fold over wild-type. 
Significantly different from wild-type with * p < 0.05, ** p < 0.01, or *** p < 0.001 (one-way ANOVA 
with Dunnett’s post test performed on corresponding pIC50 values). 
Values are means ± SEM of at least three separate assays performed in duplicate. 
 
Concentration-effect curves for cAMP production 
Functional assays were performed to further characterize the effect of the single point 
mutations on hA2AAR signaling. As an agonist CGS-21680 was used to activate the 
receptor, yielding an increase in cAMP production through Gs protein activation (Figure 4 
and Table 4). The use of the selective agonist CGS-21680 for the hA2AAR rather than the 
nonselective NECA ensured that no endogenously expressed hA2BAR was activated in the 
HEK293 cells. The absence of activation by 10 µM CGS-21680 in the untransfected 
parental cell line confirmed that indeed no endogenously expressed receptor was 
activated in this experimental setup. Mutations of the residues involved in the sodium ion 
binding site affected basal activity and efficacy of cAMP signaling by the hA2AAR. D52A
2.50 
and N284A7.49 mutants showed neither basal activity nor any activation by CGS-21680. In 
all other cases, the mutant receptor showed a dramatically decreased receptor signaling 
response to CGS-21680 binding (Emax-Ebasal), ranging from only 27 % to 46 % of the wild-
type response. The basal activity significantly increased over wild-type in mutation 
S91A3.39. The N280A7.45 mutant also showed a tendency to increased basal activity but this 
was not significantly different from wild-type. This constitutive activity was inhibited by 
addition of 10 µM ZM-241,385, confirming that the elevated basal cAMP production in the 
transiently transfected cells was caused by these mutant receptors (supplemental Figure 
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S1). CGS-21680 activated both the wild-type and mutant N280A7.45 hA2AAR with an EC50 
value of 17 nM. The potency of CGS-21680 was somewhat decreased on mutant 
W246A6.48 (~5-fold). In the case of S91A3.39 the difference between basal and maximum 
activity was judged too small to derive an accurate EC50 value. 
 
Figure 4. Full concentration-effect curves of hA2AAR selective agonist CGS-21680 induced stimulation 
of cAMP production by HEK293T cells stably expressing wild-type, transiently expressing D52A2.50, 
S91A3.39, W246A6.48, N280A7.45, or N284A7.49 hA2AAR, or by untransfected parental HEK293T cells. 
Graphs represent mean ± SEM from at least three separate experiments performed in triplicate. 
 
Molecular dynamics simulations 
The dynamic behaviors of the wild-type receptor and the receptors with mutated residues 
important for sodium ion coordination D52A2.50, S91A3.39, W246A6.48, N280A7.45, and 
N284A7.49, were simulated with either only antagonist ZM-241,385 present or with both 
ZM-241,385 in the orthosteric pocket and the sodium ion in its allosteric binding site 
(Supplemental Table S1). In addition, the wild-type receptor and mutated receptors 
D52A2.50 and W246A6.48 were simulated with ZM-241,385 in the orthosteric pocket and 
amiloride or HMA in the sodium ion binding site. Analysis of the root mean squared 
deviation (RMSD) revealed equilibrated trajectories typically after 20-30 ns with an 
average value of 1.8 Å in all simulations, and analysis of the root mean squared fluctuation 
(RMSF) confirmed no major conformational changes in the receptor due to any of the 
mutations.  
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Table 4. Agonist activation of wild-type and mutant adenosine A2A receptor. cAMP production by 
HEK293T cells stably expressing wild-type or transiently transfected with D52A
2.50, S91A3.39, 









Wild-type 7.8 ± 0.0 (17) 1.0 100 ± 14 
D52A2.50 N.D.d N.D.d -2 ± 1*** 
S91A3.39 N.D.e N.D.e 27 ± 11*** 
W246A6.48 7.1 ± 0.0*** (86) 5.1 46 ± 13** 
N280A7.45 7.8 ± 0.1 (17) 1.0 29 ± 12*** 
N284A7.49 N.D.d N.D.d 2 ± 2*** 
a: EC50 (nM) in parentheses. 
b: Change in fold over wild-type. 
c: % Signaling response of receptor to CGS-21680 (Emax - Ebasal) in % of wild-type response. 
d: No stimulation of cAMP was observed with 10 µM CGS-21680. 
e: Basal activity was too high to determine an accurate EC50 value. 
Significantly different from wild-type with ** p < 0.01 or *** p < 0.001 (one-way ANOVA with 
Dunnett’s post test). 
pEC50 and % response values are means ± SEM of at least three separate assays performed in 
triplicate. 
 
The effect of each single point mutation on the sodium ion mobility and coordination 
was assessed (Table 5). During the simulation in the wild-type model conducted in Chapter 
3 the sodium ion alternated between two resonance positions, in which the sodium ion 
had a direct interaction with either Ser913.39 (22% occurrence of direct interaction during 
the simulations) or Asn2807.45 (29%), while maintaining a continuous direct interaction 
with Asp522.50 (90%). In mutation D52A2.50 however, sodium ion mobility increased by 5-
fold and almost no direct interactions with residues Ser913.39 (1%) and Asn2807.49 (0%) 
occurred. In the first 10 ns of the simulation with the D52A2.50 mutant receptor, the 
sodium ion migrated from its starting position in the sodium ion binding site near Ala522.50 
to a vestibular pocket formed by residues Glu131.39 and His2787.43, where the sodium ion 
remained stable for the remaining 90 ns of the simulation (Figure 5). In contrast, mutants 
S91A3.39, W246A6.48, N280A7.45 or N284A7.49 did not show major deviations as compared to 
the wild-type situation with regards to either the ion mobility or the average number of 
oxygen atoms coordinating it (Supplemental Table S2),23 due to the replacement of the 
mutated side chain by an additional water molecule. However, the occurrence of direct 
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interactions with the three coordinating residues appeared lowered to some extent, 
indicative of a non-optimal ion coordination by these mutants. This was true in particular 
for the interaction with Asp522.50 (51-76%, see Table 5).  
Mobility and interactions with the receptor of amiloride and HMA, as docked in the 
sodium ion binding site, were assessed in simulations of the wild-type receptor and 
mutant receptors D52A2.50 and W246A6.48 (Figure 6). In these relatively short MD runs 
amiloride was equally stable in the proposed binding site upon both mutations, with an 
RMSF value of approx. 2 Å. The mobility of the amiloride derivative HMA was increased 3-
fold by mutation D52A2.50, and in one out of three simulations it left the putative binding 
pocket following the same pathway as depicted in Figure 5B. Mutation W246A6.48, on the 
contrary, did not affect HMA stability in the same way. However, it is worth noting that 
specific contacts changed for the two ligands with both mutants. In the wild-type 
receptor, both ligands achieved an average number of 4 simultaneous hydrogen bonds, 
mainly with residues Asp522.50 and Trp2466.48 (Supplemental Figure S2 and Chapter 3). For 
amiloride, the number of hydrogen bonds dropped to approx. 2 in the two mutants 
examined, as well as for HMA with mutant W246A6.48, while mutation D52A2.50 had a more 
dramatic effect on HMA with only one hydrogen bond left on average (Supplemental 
Figure S2). Note that in this analysis, interactions between amino (amilorides) and 
carbonyl (Asp522.50) groups were approximated as hydrogen bonds, instead of the 
stronger salt bridge interactions that occur in reality, the loss of which is expected to have 
a large effect on the affinities of amilorides. This analysis did not reveal stable hydrogen 
bonds of amilorides with either of the asparagines close by (Asn2807.45 and Asn2847.49). 
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Figure 5. A) Average distance in Å of sodium ion from Glu131.39 (Oε), Ala522.50 (Cα), and His2787.43 
(Nδ) as a function of the simulation time for the D52A2.50 mutant. Graphs represent means from 
three independent simulations. B) 3D representation of the migration pathway of the sodium ion 
(cyan sphere, with labels indicating the occupancy at averaged MD simulation windows) from its 
putative binding site towards the vestibular pocket formed by Glu13
1.39 and His2787.43. The residues 
and water molecules interacting with the sodium ion are represented in sticks, and hydrogen bonds 
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Table 5. Mobility of the sodium ion in root mean squared fluctuation (RMSF) in wild-type and 
mutant receptor, and the occurrence in % of direct interactions with the different residues 
coordinating the ion in the crystal structure along the simulation time. 
 
Na+ mobility 
RMSF in Å 
Na+ interactions 
% occurrence with indicated residues 
Asp522.50 Ser913.39 Asn2807.45 
Wild-type 2.5 ± 0.3 89.6 ± 7.8 22.3 ± 10.3 28.7 ± 5.4 
D52A2.50 11.2 ± 0.3* - 1.1 ± 0.2* 0.0 ± 0.0* 
S91A3.39 1.8 ± 0.2 75.6 ± 5.9 - 25.5 ± 2.9 
W246A6.48 2.5 ± 0.3 51.1 ± 7.9* 17.1 ± 6.2 10.0 ± 4.3* 
N280A7.45 2.6 ± 0.2 67.1 ± 0.7* 12.4 ± 3.1 - 
N284A7.49 2.6 ± 0.1 75.5 ± 7.3 3.8 ± 1.5* 25.6 ± 17.9 
RMSF values are means ± SEM of three separate 100 ns simulations. 
% interaction occurrence values are means ± SEM of three separate 100 ns simulations. 




Figure 6. Root mean squared fluctuation (RMSF, Y axis, in Ångstrom) of amiloride (AMI, dotted bars) 
or HMA (gray bars) indicating their mobility in the wild-type (WT) or mutant forms D52A2.50 and 
W246A6.48. The figures represent data (± SD) combined from three independent simulations of 100 
ns. 
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Discussion 
The sodium ion binding site appears conserved amongst class A GPCRs.24 Subsequent to 
the hA2AAR the crystal structures of the human protease-activated receptor 1,
25 the β1-
adrenergic receptor,26, 27 and the human δ-opioid receptor28 further confirmed the 
common role of this site in the inactive conformation of GPCRs. A sequence comparison of 
the sodium ion binding site between more distant class A GPCRs shows that individual 
amino acids may differ, but collectively they apparently maintain the properties to 
coordinate a sodium ion.  
These observations made us examine the residues involved in the hA2AAR sodium ion 
binding site in more detail, through a combined approach of mutational and 
computational studies. Most importantly, we learned that all mutations in the sodium ion 
binding pocket impact A2A receptor signaling significantly, including both constitutive and 
agonist-stimulated activity. Although all mutant data in the present study is novel, we 
have shown a number of similar findings on the wild-type receptor before (Chapter 3 and 
Lane et al.),29 indicative of the robustness of the assay system. We will discuss our findings 
in the light of available mutation data in literature, by examining the mutated amino acids 
individually. For the search we made use of data available in the GPCRDB.30 
Asp2.50. The pronounced effects of mutation of the conserved Asp2.50 are in agreement 
with previous studies. Mutation of Asp2.50 abolished the effect of NaCl on agonist binding 





34 and δ-opioid receptors.28 In MD simulations of the 
wild-type hA2AAR Asp52
2.50 dominated coordination of the sodium ion (Chapter 3). 
Mutation of Asp2.50 is known to silence signaling in many GPCRs.5 The migration of the 
sodium ion to Glu131.39 and His2787.43 agrees with the involvement of these amino acids in 
sodium ion allosterism observed previously by Gao et al.35 From a reversed perspective, 
this simulation could envisage a pathway for the entrance of the sodium ion, which should 
occur from the extracellular side according to the physiological gradient,6, 36 and where 
residue Glu131.39, conserved in all adenosine receptors, could stabilize such a pathway. 
The enhancement of agonist binding to the D52A2.50 mutant at high (1 M) concentrations 
of NaCl suggests that binding of the ion to alternative sites may produce further allosteric 
effects, different from the effects on wild-type Asp522.50.  
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The affinities of amiloride and HMA were 10 – 20-fold decreased on the Asp522.50 
mutant receptor (Tables 2 and 3), strongly suggesting that the positively charged 
guanidinium moiety of the compounds interacts with the negatively charged aspartic acid. 
A more modest, 4-fold, decrease in affinity for an amiloride derivative has been reported 
for the D4 dopamine receptor by mutation D
2.50N.37 In adenosine A3 and α2-adrenergic 
receptors affinities of amiloride and its derivatives were largely undisturbed by mutation 
D2.50N,31, 34 suggesting that the more drastic mutation to Ala in the current study more 
precisely revealed the importance of this residue for amiloride binding.  
Trp6.48. It appeared that sodium ions and agonist NECA can bind simultaneously to the 
W246A6.48 receptor (Figure 3A), in contrast with the wild-type receptor where NECA and 
sodium ion binding are mutually exclusive (Chapter 3). Conversely, mutant W246A6.48 
augmented the positive effect of sodium ions on antagonist ZM-241,385 binding (Figure 
3B). It seems that Trp2466.48 may clash with both agonists and antagonists in the 
orthosteric pocket, as the absence of this residue has a positive effect on binding of both 
agonists and antagonists in presence of the sodium ion. Trp6.48, conserved in many GPCRs, 
has long been suggested to act as a “toggle switch” in receptor activation,38 but has never 
been studied in the context of allosteric modulation by sodium ions. It has been mutated 
to both Phe and Ala in the human adenosine A3 receptor, being the closest homolog to the 
A2A receptor.
34, 39 Interestingly, agonist binding was hardly affected by these mutations, 
whereas antagonists showed a modest decrease in affinity. Receptor activation, however, 
was largely impeded, seemingly more than our current findings on the A2A receptor (see 
e.g. Figure 4).  
Remarkably, the affinities for amiloride and HMA were strongly increased on this 
mutant (Tables 2 and 3), suggesting that the wild-type tryptophan creates a substantial 
steric strain for the binding of amilorides. In the adenosine A3 receptor the W
6.48A 
mutation increased HMA potency on agonist binding as well.34 The mobility of amiloride 
and HMA was unaffected by the W246A6.48 mutation (Figure 6), which indicates that the 
weakened polar interactions (Supplemental Figure S2) are compensated by the absence of 
steric strain with Trp2466.48 in this mutant. The collision of the bulkier azepane group of 
HMA with Trp2466.48 in the wild-type receptor may result in a loosened interaction with 
the receptor, which explains HMA’s increased mobility by mutation D52A2.50 compared to 
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amiloride. In Chapter 3, the more substantial steric clash of HMA with Trp2466.48 
compared to amiloride had been observed as well.  
Ser3.39, Asn7.45, and Asn7.49. In the wild-type receptor the sodium ion alternates direct 
interactions with Ser913.39 and Asn2807.45 in two distinct resonance positions, as predicted 
in MD simulations (Table 5 and Chapter 3), while maintaining contact with Asp522.50. This 
is in agreement with the observation that sodium ion modulation of agonist binding is not 
completely abolished in mutant receptors S91A3.39 and N280A7.45 (Figure 3A), and that the 
two remaining residues in mutants S91A3.39 and N280A7.45 (Asp522.50, and Asn2807.45 or 
Ser913.39, respectively) still interact directly with the sodium ion, although less than in the 
wild-type receptor (Table 5). Jiang et al. had found that the same S91A mutation did not 
affect orthosteric ligand binding very much,40  even less so than the slight decrease in 
affinity in our experiments (Table 1). In the adenosine A1 receptor however, orthosteric 
ligand binding could not be detected for this mutation, maybe due to lack of expression.33 
In mutant N284A7.49 sodium ion modulation of agonist binding was completely 
abolished (Figure 3A). In the antagonist-bound inactive conformation of the receptor, 
Asn2847.49 might improve sodium ion coordination through stabilization of the side chain 
of Asp522.50, explaining the disruption of sodium ion binding by mutation N284A7.49. The 
same role of Asn7.49 in stabilization of Asp2.50 was proposed previously in e.g., the 
histamine H1 and thyrotropin receptors.
41, 42 At the same time, in the agonist-bound 
structure of the A2AAR residues Asn280
7.45 and Asn2847.49 form a hydrogen bond, possibly 
stabilizing the collapsed state of the pocket that excludes sodium ion binding.8, 43 
Consequently, mutations N280A7.45 and N284A7.49 might facilitate the formation of the 
uncollapsed state of the sodium ion pocket and shift the receptor away from the active 
state, even when the sodium ion is not present in its binding site.  Our results support this 
hypothesis, as mutation of either residue decreases agonist affinity drastically, while 
antagonist affinity is only slightly decreased (Table 1), sodium ions inhibit agonist binding 
only weakly (N280A7.45) or not at all (N284A7.49, Figure 3A). In the adenosine A1 receptor 
mutation N7.49C increased antagonist binding slightly, which could point to a similar 
mechanism.44 Moreover, mutation N284A7.49 abolished agonist activation completely 
(Table 4). Correspondingly, Asn2847.49 is part of the highly conserved NPXXY motif, 
involved in GPCR activation.38, 45  
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Mutants N280A7.45 and N284A7.49 generally affected the potencies of amilorides in a 
positive way, in particular for HMA Figures 3E, F and Tables 2, 3). According to the binding 
mode proposed in Chapter 3, the nitrogen atoms in the amide moiety of both asparagines 
lie close to the guanidinium group of both amilorides coordinated by Asp522.50, yet they 
only make sporadic H-bond contacts (Supplemental Figure S2). Thus alanine substitutions 
might indeed facilitate binding of amilorides by avoiding unfavorable polar interactions 
(Asn2807.45) or by allowing more conformational freedom to Asp522.50 (Asn2847.49), 
accommodating in particular the bulky HMA and enhancing its binding.  
The MD simulations showed only minor effects on the capacity of mutants S91A3.39, 
W246A6.48, N280A7.45, and N284A7.49 to bind the sodium ion in the inactive conformation 
of the receptor. This seems in contrast to the greatly reduced sensitivity of these mutants 
to physiological concentrations of NaCl (Figure 3A).  In addition to the explanations 
discussed above, an alternative explanation arises from the observation that each of these 
four side chain annihilations creates additional room for an extra water molecule, thus 
fulfilling the coordination number of the ion (Supplemental Table S2). This might allow 
that, in contrast to the wild-type receptor, the mutants also bind the sodium ion in an 
active receptor conformation, resulting in the observed loss of modulatory effect on 
agonist binding.  
In conclusion, our results show the importance of the sodium ion binding site in 
orthosteric ligand binding and receptor activity. Mutation D52A2.50 caused an immediate 
displacement of the sodium ion to a distant pocket in MD simulations, in agreement with 
the loss of the modulatory effect in our molecular pharmacology experiments. The effects 
of the other mutations were varied, but they significantly affected sodium ion modulation 
of agonist binding and modulation by amilorides of both agonist and antagonist binding. In 
addition, all mutations influenced receptor activation, particularly by affecting the levels 
of constitutive and agonist-stimulated activity, emphasizing the importance of the sodium 
ion binding pocket for the receptor’s active conformation(s). These findings imply that 
because of allosterism by sodium ions and amilorides, the sodium ion binding pocket is a 
prominent player in receptor functionality and ligand affinity. Our study also opens the 
door to the design of novel synthetic allosteric modulators or bitopic ligands connecting 
the sodium ion binding site and the orthosteric binding pocket. 
Sodium ion binding pocket mutations and adenosine A2A receptor function | 97 
Supplemental information 
Supplemental information includes Figures S1 and S2, and Tables S1 and S2, and can be 
found with this article online at dx.doi.org/10.1124/mol.114.095737 
Acknowledgments 
This work was supported by the Netherlands Organization for Scientific Research - 
Chemical Sciences (Grant 714.011.001), the Swedish Research Council (Grant 521-2014-
2118), the Swedish strategic research program eSSENCE, and the Swedish 
National Infrastructure for Computing. 
References 
1. Rask-Andersen M, Almén MS, and Schiöth HB, Trends in the exploitation of novel drug 
targets. Nat Rev Drug Discovery, 2011. 10(8): p. 579-90. 
2. Katritch V, Cherezov V, and Stevens RC, Structure-function of the G protein-coupled 
receptor superfamily. Annu Rev Pharmacol Toxicol, 2013. 53: p. 531-56. 
3. Chen JF, Eltzschig HK, and Fredholm BB, Adenosine receptors as drug targets — what are 
the challenges? Nat Rev Drug Discovery, 2013. 12(4): p. 265-86. 
4. Liu W, Chun E, Thompson AA, et al., Structural basis for allosteric regulation of GPCRs by 
sodium ions. Science, 2012. 337(6091): p. 232-36. 
5. Parker MS, Wong YY, and Parker SL, An ion-responsive motif in the second transmembrane 
segment of rhodopsin-like receptors. Amino Acids, 2008. 35(1): p. 1-15. 
6. Selent J, Sanz F, Pastor M, et al., Induced effects of sodium ions on dopaminergic G-protein 
coupled receptors. PLoS Comput Biol, 2010. 6(8): p. e1000884. 
7. Ballesteros JA and Weinstein H, Integrated methods for the construction of three-
dimensional models and computational probing of structure-function relations in G 
protein-coupled receptors, in Methods Neurosci. 1995, Academic Press: San Diego. p. 366-
428. 
8. Xu F, Wu H, Katritch V, et al., Structure of an agonist-bound human A2A adenosine receptor. 
Science, 2011. 332(6027): p. 322-7. 
9. Sambrook J, Fritsch EF, and Maniatis T, Molecular Cloning: A Laboratory Manual. 2nd ed. 
1989, New York: Cold Spring Harbor Laboratory Press. 
10. Smith PK, Krohn RI, Hermanson GT, et al., Measurement of protein using bicinchoninic 
acid. Anal Biochem, 1985. 150(1): p. 76-85. 
11. Schrödinger LLC, Maestro, version 9.3. 2012: New York. 
12. Hess B, Kutzner C, van der Spoel D, et al., GROMACS 4: algorithms for highly efficient, load-
balanced, and scalable molecular simulation. J Chem Theory Comput, 2008. 4(3): p. 435-
47. 
13. Rodríguez D, Piñeiro A, and Gutiérrez-de-Terán H, Molecular dynamics simulations reveal 
insights into key structural elements of adenosine receptors. Biochemistry, 2011. 50(19): p. 
4194-208. 
14. Gutiérrez-de-Terán H, Bello X, and Rodriguez D, Characterization of the dynamic events of 
GPCRs by automated computational simulations. Biochem Soc Trans, 2013. 41(1): p. 205-
12. 
98 | Chapter 4 
15. Kaminski GA, Friesner RA, Tirado-Rives J, et al., Evaluation and reparametrization of the 
OPLS-AA force field for proteins via comparison with accurate quantum chemical 
calculations on peptides. J Phys Chem B, 2001. 105(28): p. 6474-87. 
16. Schrödinger LLC, Macromodel, version 9.7. 2009: New York. 
17. Berger O, Edholm O, and Jähnig F, Molecular dynamics simulations of a fluid bilayer of 
dipalmitoylphosphatidylcholine at full hydration, constant pressure, and constant 
temperature. Biophys J, 1997. 72(5): p. 2002-13. 
18. Chakrabarti N, Neale C, Payandeh J, et al., An iris-like mechanism of pore dilation in the 
CorA magnesium transport system. Biophys J, 2010. 98(5): p. 784-92. 
19. Berendsen HJC, Postma JPM, Van Gunsteren WF, et al., Interaction models for water in 
relation to protein hydration, in Intermolecular Forces, B. Pullman, Editor. 1981, D. Reidel 
Publishing Company: Dordrecht. p. 331-42. 
20. Nose S and Klein ML, Constant pressure molecular dynamics for molecular systems. Mol 
Phys, 1983. 50(5): p. 1055-76. 
21. Humphrey W, Dalke A, and Schulten K, VMD - visual molecular dynamics. J Mol Graph, 
1996. 14(1): p. 33-8. 
22. Schrödinger LLC, The PyMOL Molecular Graphics System, version 1.5.0.4. New York. 
23. Harding MM, Small revisions to predicted distances around metal sites in proteins. Acta 
Crystallogr D Biol Crystallogr, 2006. 62(Pt 6): p. 678-82. 
24. Katritch V, Fenalti G, Abola EE, et al., Allosteric sodium in class A GPCR signaling. Trends 
Biochem Sci, 2014. 39(5): p. 233-44. 
25. Zhang C, Srinivasan Y, Arlow DH, et al., High-resolution crystal structure of human 
protease-activated receptor 1. Nature, 2012. 492(7429): p. 387-92. 
26. Christopher JA, Brown J, Doré AS, et al., Biophysical fragment screening of the β1-
adrenergic receptor: identification of high affinity arylpiperazine leads using structure-
based drug design. J Med Chem, 2013. 56(9): p. 3446-55. 
27. Miller-Gallacher JL, Nehmé R, Warne T, et al., The 2.1 Å resolution structure of 
cyanopindolol-bound β1-adrenoceptor identifies an intramembrane Na
+ ion that stabilises 
the ligand-free receptor. PLoS ONE, 2014. 9(3): p. e92727. 
28. Fenalti G, Giguere PM, Katritch V, et al., Molecular control of δ-opioid receptor signalling. 
Nature, 2014. 506(7487): p. 191-6. 
29. Lane JR, Klein Herenbrink C, Van Westen GJP, et al., A novel nonribose agonist, LUF5834, 
engages residues that are distinct from those of adenosine-like ligands to activate the 
adenosine A2A receptor. Mol Pharmacol, 2012. 81(3): p. 475-87. 
30. Isberg V, Vroling B, Van der Kant R, et al., GPCRDB: an information system for G protein-
coupled receptors. Nucleic Acids Res, 2014. 42(Database issue): p. D422-5. 
31. Horstman DA, Brandon S, Wilson AL, et al., An aspartate conserved among G-protein 
receptors confers allosteric regulation of 2-adrenergic receptors by sodium. J Biol Chem, 
1990. 265(35): p. 21590-5. 
32. Neve KA, Cox BA, Henningsen RA, et al., Pivotal role for aspartate-80 in the regulation of 
dopamine D2 receptor affinity for drugs and inhibition of adenylyl cyclase. Mol Pharmacol, 
1991. 39(6): p. 733-9. 
33. Barbhaiya H, McClain R, IJzerman AP, et al., Site-directed mutagenesis of the human A1 
adenosine receptor: influences of acidic and hydroxy residues in the first four 
transmembrane domains on ligand binding. Mol Pharmacol, 1996. 50(6): p. 1635-42. 
34. Gao ZG, Kim SK, Gross AS, et al., Identification of essential residues involved in the 
allosteric modulation of the human A3 adenosine receptor. Mol Pharmacol, 2003. 63(5): p. 
1021-31. 
Sodium ion binding pocket mutations and adenosine A2A receptor function | 99 
35. Gao ZG, Jiang Q, Jacobson KA, et al., Site-directed mutagenesis studies of human A2A 
adenosine receptors: involvement of Glu
13 and His278 in ligand binding and sodium 
modulation. Biochem Pharmacol, 2000. 60(5): p. 661-8. 
36. Shang Y, LeRouzic V, Schneider S, et al., Mechanistic insights into the allosteric modulation 
of opioid receptors by sodium ions. Biochemistry, 2014. 53(31): p. 5140-49. 
37. Schetz JA and Sibley DR, The binding-site crevice of the D4 dopamine receptor is coupled to 
three distinct sites of allosteric modulation. J Pharmacol Exp Ther, 2001. 296(2): p. 359-63. 
38. Nygaard R, Frimurer TM, Holst B, et al., Ligand binding and micro-switches in 7TM receptor 
structures. Trends Pharmacol Sci, 2009. 30(5): p. 249-59. 
39. Gao ZG, Chen A, Barak D, et al., Identification by site-directed mutagenesis of residues 
involved in ligand recognition and activation of the human A3 adenosine receptor. J Biol 
Chem, 2002. 277(21): p. 19056-63. 
40. Jiang Q, Van Rhee AM, Kim J, et al., Hydrophilic side chains in the third and seventh 
transmembrane helical domains of human A2A adenosine receptors are required for ligand 
recognition. Mol Pharmacol, 1996. 50(3): p. 512-21. 
41. Urizar E, Claeysen S, Deupí X, et al., An activation switch in the rhodopsin family of G 
protein-coupled receptors: the thyrotropin receptor. J Biol Chem, 2005. 280(17): p. 17135-
41. 
42. Bakker RA, Jongejan A, Sansuk K, et al., Constitutively active mutants of the histamine H1 
receptor suggest a conserved hydrophobic asparagine-cage that constrains the activation 
of class A G protein-coupled receptors. Mol Pharmacol, 2008. 73(1): p. 94-103. 
43. Lebon G, Warne T, Edwards PC, et al., Agonist-bound adenosine A2A receptor structures 
reveal common features of GPCR activation. Nature, 2011. 474(7352): p. 521-25. 
44. Dawson ES and Wells JN, Determination of amino acid residues that are accessible from 
the ligand binding crevice in the seventh transmembrane-spanning region of the human A1 
adenosine receptor. Mol Pharmacol, 2001. 59(5): p. 1187-95. 
45. Rosenbaum DM, Rasmussen SGF, and Kobilka BK, The structure and function of G-protein-







5’-Substituted amiloride derivatives as allosteric 
modulators binding in the sodium ion pocket of 




Corine van Veen 
Berend J. H. Huisman 
Gabrielle S. Dijksteel 
Dong Guo 
Eelke B. Lenselink 




Adriaan P. IJzerman 
 
Journal of Medicinal Chemistry, 2016, 59(10): 4769-77 
  
102 | Chapter 5 
Abstract 
The sodium ion site is an allosteric site conserved among many G protein-coupled 
receptors (GPCRs). Amiloride 1 and 5-(N,N-hexamethylene)amiloride 2 (HMA) supposedly 
bind in this sodium ion site and can influence orthosteric ligand binding. The availability of 
a high resolution X-ray crystal structure of the human adenosine A2A receptor (hA2AAR), in 
which the allosteric sodium ion site was elucidated, makes it an appropriate model 
receptor for investigating the allosteric site. In this study, we report the synthesis and 
evaluation of novel 5’-substituted amiloride derivatives as hA2AAR allosteric antagonists. 
The potency of the amiloride derivatives was assessed by their ability to displace 
orthosteric radioligand [3H]4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-[1,3,5]tria-
zin-5-yl)amino)ethyl)phenol ([3H]ZM-241,385) from both the wild-type and sodium ion site 
W246A mutant hA2AAR. 4-Ethoxyphenethyl-substituted amiloride 12l  was found to be 
more potent than both amiloride and HMA, and the shift in potency between the wild-
type and mutated receptor confirmed its likely binding to the sodium ion site.  
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Introduction 
G protein-coupled receptors (GPCRs) are proteins that consist of seven transmembrane 
helices and reside in cell membranes. They are able to transfer a multitude of signals, 
conducted by carriers such as light, hormones, and small molecules, from the extracellular 
environment to the interior of the cell. The superfamily is predicted to contain 
approximately 800 different receptors, of which a considerable number are yet to be 
characterized.1 Approximately 30% to 40% of drugs currently on the market target GPCRs, 
underlining their importance in physiology and medicine.2 Most of these drugs are 
orthosteric ligands that target endogenous ligand-binding sites of GPCRs. However, GPCRs 
also contain allosteric binding sites, and ligands that bind to these can influence 
endogenous GPCR signaling. The use of allosteric ligands as drugs has several potential 
advantages, such as a more specific drug effect in time and location, due to their ability to 
modulate orthosteric ligand responses.3, 4  
The sodium ion binding site is an allosteric site that is well-conserved among GPCRs. 
The first X-ray crystal structure of a GPCR containing an allosterically bound sodium ion 
was of the human adenosine A2A receptor (hA2AAR),
5 which was followed by several other 
GPCR structures with a sodium ion.6-9 At physiological concentrations of sodium ions, 
approximately 80% of hA2AARs are occupied by the cation, which reduces orthosteric 
agonist binding (Chapter 3). Mutation of amino acids that make up the sodium ion site 
changes the activation characteristics of the hA2AAR, highlighting the importance of the 
site for receptor function (Chapter 4). 
Amiloride 1 and its derivative 5-(N,N-hexamethylene)amiloride 2 (HMA) are known to 
bind to the sodium ion site of several GPCRs,10-13 including adenosine receptors.14, 15 
Amiloride and HMA act on other targets as well, such as the enzyme urokinase-type 
plasminogen activator (uPA).16, 17 Furthermore, amiloride is used clinically as a potassium-
sparing diuretic drug, where its action arises predominantly through blockade of renal 
epithelial sodium channels (ENaCs).18 The positively charged guanidinium moiety of 
amiloride and HMA may explain their propensity to bind to negatively charged target sites 
and their pharmacological promiscuity more generally. Nevertheless, their affinity for the 
sodium ion site of GPCRs makes amiloride and its derivatives potentially useful 
pharmacological tools for probing molecular mechanisms of GPCR activation and 
regulation, as demonstrated in Chapter 4. The increased affinity of HMA compared to that 
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of amiloride for the sodium ion site of the hA2AAR
14 suggests that there is potential to 
further elaborate the amiloride core at its 5’ position, possibly yielding derivatives with 
higher potency.  
In a study by Matthews et al., several new amiloride derivatives with substituents at 
the 5’ position were found to be active against uPA.16 In our current study, we tested a 
selection of these for their activity at the hA2AAR by measuring their ability to displace 
orthosteric radioligand [3H]4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-[1,3,5]tria-
zin-5-yl)amino)ethyl)phenol ([3H]ZM-241,385).19 After identifying the most potent 
derivatives, we designed and synthesized novel 5’-substituted amiloride analogues and 
evaluated their hA2AAR activity. From these analogues, compounds were identified that 
were equipotent or more potent than reference compound HMA.  
Compounds were also evaluated using an hA2AAR mutant, where the Trp246
6.48 ‘toggle 
switch’20 (numbering in superscript according to Ballesteros and Weinstein)21 was replaced 
by Ala. This tryptophan forms part of the sodium ion pocket, and mutation to alanine has 
been shown to significantly increase the potency of amiloride and HMA (Chapter 4), 
making the W246A6.48 mutant receptor a useful tool for assessing the binding of ligands in 
the sodium ion pocket. Finally, the most potent derivative was docked into the sodium ion 
site of the hA2AAR crystal structure (PDB: 4EIY).
5 Comparisons of the binding of 
compounds to the wild-type and W246A6.48 mutant receptors and docking of the most 
potent derivatives into the hA2AAR structure provided insights into the molecular 
interactions occurring between the amiloride derivatives and the sodium ion site. 
Materials and methods 
Materials 
[3H]ZM-241,385 (50 Ci/mmol) was obtained from ARC Inc. (St. Louis, MO, USA). ZM-
241,38522 was obtained from Ascent Scientific (Bristol, UK). NECA, amiloride, HMA, and 
bovine serum albumin (BSA) were obtained from Sigma Aldrich (Zwijndrecht, The 
Netherlands). Adenosine deaminase (ADA) was purchased from Boehringer Mannheim 
(Mannheim, Germany). Bicinchoninic acid (BCA) and BCA protein assay reagent were 
obtained from Pierce Chemical Company (Rockford, IL, USA). HEK293 cells stably 
expressing the hA2AAR (HEK293-hA2AAR) were a gift from Dr. J. Wang (Biogen/IDEC, 
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Cambridge, MA, USA).  All other chemicals were of analytical grade and obtained from 
standard commercial sources. 
Chemistry 
2-(4-(Allyloxy)phenyl)ethan-1-amine Hydrochloride (20). To a suspension of LiAlH4 (41 
mmol) in dry THF (20 mL) at 0 °C was added nitro-styrene 19 (2.54 g, 12.4 mmol) slowly. 
The mixture was stirred at 0 °C for 1 h and then heated at reflux for 2 h. The reaction was 
cooled to 0 °C and water (6 mL) was added. The mixture was diluted with THF (10 mL) and 
filtered. The filtrate was extracted with EtOAc/H2O, and the organic layer was washed with 
water and dried using MgSO4. The volatiles were removed in vacuo to afford the free 
amine; HCl (1 M in EtOAc, 5 mL) was added and then evaporated, yielding 20 (1.65 g, 78%) 
as its HCl salt. 1H NMR (400 MHz, CD3OD) 7.19 (d, J = 8.3 Hz, 2H), 6.92 (d, J = 8.3 Hz, 2H), 
6.115.99 (m, 1H), 5.39 (δ, J = 17.3 Hz, 1H), 5.24 (d, J = 10.6 Hz, 1H), 4.53 (d, J = 4.7 Hz, 
2H), 3.13 (t, J = 7.6 Hz, 2H), 2.89 (t, J = 7.6 Hz, 2H). 
General Procedure for the Synthesis of Compounds 12a-12p. To a solution of 21 (0.3 
mmol) and corresponding amine or amine hydrochloride (0.3 mmol) in dry N,N-
dimethylformamide (DMF) (5 mL) was added DiPEA (0.75 mmol in the case of the free 
amine or 1.05 mmol in the case of the amine hydrochloride) at room temperature. The 
resulting reaction mixture was stirred at 100 °C for 1-2 h. Upon reaction completion (TLC), 
the reaction mixture was cooled to room temperature, poured into ice-water and 
extracted with AcOEt/H2O. The organic layer was dried over MgSO4 and, after 
concentration in vacuum, yielded the desired free base of the final compound with a 
purity of at least 95%. The free base was dissolved in 6 mL of 1 N HCl/AcOEt solution, 
stirred at room temperature for 2 h, and evaporated to dryness to give the hydrochloride 
salt of the desired product as a powder (compounds 12a-f, h-k, n, and p).  
The other compounds were further purified by preparative HPLC (using the free base), 
which was performed on a Shimadzu HPLC−ultraviolet (UV) system with a diode array 
detector using a Gemini 5 μm C18 110A column (100 × 10 mm, 5 μm) and a linear gradient 
from 1 to 99% mobile phase B. Mobile phase A consisted of H2O, and mobile phase B 
consisted of CH3CN/1% TFA in H2O. The flow rate was 5 mL/min. The TFA salt of the 
desired product was obtained as a yellow powder (compounds 12g, l-m, and o). 
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3-Amino-N-carbamimidoyl-6-chloro-5-((2,3-dihydro-1H-inden-2-yl)amino)pyrazine-2-
carboxamide Hydrochloride (12a). Yield = 67%. 1H NMR (400 MHz, DMSO-d6): δ 10.64 (s, 
1H), 8.61 (br s, 2H), 8.44 (br s, 2H), 8.02 (d, J = 7.2 Hz, 1H), 7.58 (br s, 2H), 7.237.14 (m, 
4H), 4.874.77 (X part of ABX system, sextet, J = 8.0 Hz, 1H), 3.62 (A part of ABX system, 
dd, J = 16.0, 7.6 Hz, 2H), 3.06 (B part of ABX system, dd, J = 15.6, 8.0 Hz, 2H). ESI-MS m/z: 
346.13 [M+H]+; tR = 7.38 min. 
Biology 
HEK293 cells were grown in culture medium consisting of  Dulbecco's modified Eagle's 
medium (DMEM)  supplemented with 10% newborn calf serum (NCS), 50 µg/ml 
streptomycin and 50 IU/ml penicillin at 37 °C and 7% CO2. Cells were subcultured twice a 
week at a ratio of 1:20 on 10 cm ø plates. A point mutation corresponding to W246A6.48 
was introduced into the wild-type hA2AAR-plasmid DNA (FLAG-tag at the N-terminus, in 
pcDNA3.1) by BaseClear (Leiden, The Netherlands). Cells were transfected with 1 µg per 
plate of the resulting plasmid using the calcium phosphate precipitation method.23 
HEK293 cells stably expressing the wild-type receptor were grown in the same medium 
but with the addition of G-418 (200 µg/ml). 
Membranes were prepared as follows. HEK293 cells were detached from plates 48 h 
after transfection (cells transiently expressing hA2AAR-W246A
6.48) or from confluent plates 
(cells stably expressing hA2AAR-WT) by scraping them into 5 ml PBS, collected and 
centrifuged at 700 g (3000 rpm) for 5 min. Pellets derived from 20 plates were pooled and 
resuspended in 16 ml of ice-cold assay buffer (50 mM Tris-HCl, pH 7.4). An Ultra-Turrax 
was used to homogenize the cell suspension. Membranes and the cytosolic fraction were 
separated by centrifugation at 100000 g (31000 rpm) in a Beckman Optima LE-80K 
ultracentrifuge at 4 °C for 20 min. The pellet was resuspended in 8 ml of Tris buffer, and 
the homogenization and centrifugation steps were repeated. Assay buffer (4 ml) was used 
to resuspend the pellet, and adenosine deaminase (ADA) was added (0.8 IU/ml) to break 
down endogenous adenosine. Membranes were stored in 250 µL aliquots at -80 °C. 
Membrane protein concentrations were measured using the BCA method.24  
For [3H]ZM-241,385 displacement binding experiments membranes with stably 
expressed hA2AAR-WT (15 μg of total protein) or with transiently expressed hA2AAR-
W246A6.48 (4 µg) were used. These protein amounts ensured that total binding to the 
membrane preparations was less than 10% of the total radioactivity added in order to 
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prevent radioligand depletion. Membrane aliquots were incubated in a total volume of 
100 μl of assay buffer at 25 °C for 2 h. [3H]ZM-241,385 was used at a concentration of 2.5 
nM. Total binding was determined in the presence of [3H]ZM-241,385 without addition of 
other compounds. Nonspecific binding was determined in the presence of 100 µM NECA 
(hA2AAR-WT) or 10 µM ZM-241,385 (hA2AAR-W246A
6.48) and represented less than 10% of 
the total binding. For single-point assays, radioligand displacement experiments were 
performed in the presence or absence of 10 µM amiloride 1, HMA 2, or compounds 3-18. 
For concentration-effect curves, radioligand displacement experiments were performed in 
the absence or presence of increasing concentrations of HMA 2 or 12h, i, k, or l. For 
radioligand dissociation experiments, membrane preparations were first allowed to reach 
binding equilibrium with [3H]ZM-241,385 for 1 h at 4 °C. Dissociation was started by 
addition of 100 µM NECA with or without 100 µM HMA 2 or 12h, i, k, or l (hA2AAR-WT), or 
addition of 10 µM ZM-241,385 with or without 10 µM HMA 2 or 12h, i, k, or l (hA2AAR-
W246A6.48) at each time point. The time points were distributed over 180 min (hA2AAR-
WT) or 30 min (hA2AAR-W246A
6.48). Incubations were terminated by rapid vacuum 
filtration to separate the bound radioligand from free radioligand through 96-well GF/B 
filter plates using a Filtermate-harvester (PerkinElmer Life Sciences). Filters were 
subsequently washed three times with ice-cold assay buffer. The filter-bound radioactivity 
was determined by scintillation spectrometry using a PE 1450 Microbeta Wallac Trilux 
scintillation counter (PerkinElmer Life Sciences). 
The radioligand binding data was analyzed with GraphPad Prism 5.0 (GraphPad 
Software Inc., San Diego, CA, USA). The displacement curves were fitted to a one-state site 
binding model, and the dissociation curves were fitted to a one-phase dissociation model. 
A one-way ANOVA with Dunnett’s post hoc test was performed to test for significant 
differences. 
Computational receptor modeling 
All structure-based studies were performed in the Schrödinger suite.25 The inactive 
structure of the A2AAR in complex with ZM-241,385 and a sodium ion (PDB: 4EIY)
5 was 
used as the basis for docking. Docking of 12h, i, k, and l was based on the docking pose of 
HMA described in Chapter 3. To allow for side chain rearrangements, we used core-
constrained docking (with the guanidinium moiety as the core) with a decreased van der 
Waals (vdW) sphere (0.5 instead of 0.8). The vdW sphere was decreased to allow for an 
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induced fit in the sodium pocket. Subsequently, we optimized this pose using an 
exhaustive hierarchical optimization procedure available in Prime,26 which has been used 
previously to model induced fit effects.27 Figures were rendered using PyMol.28 
Results 
Chemistry 
The synthesis of compounds 3–18 has been described previously.16 New compounds 12a-p 
were synthesized in a similar manner, through addition of the appropriate 
phenethylamine onto the amiloride core 21 in the presence of base (Scheme 1). The 
compounds were obtained as hydrochloride or trifluoroacetate salts depending on the 
purification method employed. Amine hydrochloride salt 20, which has not been 
previously described, was synthesized by reducing nitrostyrene 1929 with LiAlH4 followed 
by treatment with HCl.30 
 
 
Scheme 1. Synthesis of phenethyl amiloride derivatives 12a-p. Reagents and conditions: a) i. LiAlH4, 
THF, 0 °C to 76 °C, 2 h, ii. HCl, 78%; b) i. DiPEA, DMF, 100 °C, ii. HCl (X = Cl) or prep HPLC 
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Biology and structure-activity relationships 
Single point displacement assays were performed in which [3H]ZM-241,385 binding to the 
hA2AAR was displaced by 10 µM of compounds 1–18 (Table 1) and 12a-p (Table 2).  
Reference compounds amiloride 1 and HMA 2 displaced [3H]ZM-241,385 binding from the 
wild-type receptor by 29 % and 70 %, respectively, and from the W246A6.48 mutant 
receptor by 89 % and 98 %. Of amiloride derivatives 3–18, compounds 3-5, 7, 8, 10, 11, 
and 14−18 displaced less [3H]ZM-241,385 than amiloride at both the wild-type and 
W246A6.48 receptors. Carboxylate derivatives 3 and 5, and tetrazole 7 showed no or 
marginal displacement of [3H]ZM-241,385 from both receptors. Carboxylate ester 4 and 
diethylamino-ethyl derivative 14 showed negligible displacement of [3H]ZM-241,385 
binding from the wild-type receptor, but they displaced approximately one-half of [3H]ZM-
241,385 binding from the W246A6.48 mutant. Nitrile derivative 6 displaced slightly more 
[3H]ZM-241,385 binding from the wild-type receptor (35%) than amiloride, but it displaced 
less than amiloride at the W246A6.48 receptor (83%). Benzylic derivatives 8-11 did not or 
marginally displaced [3H]ZM-241,385 binding from the wild-type receptor, except for 3-
pyridyl derivative 9, which performed similarly to amiloride. However, compounds 8, 9, 
and 11 were able to displace [3H]ZM-241,385 binding from the mutant receptor by 
approximately 80% (benzyl 8) and 50% (3-pyridyl 9 and 4-fluorobenzyl 11). 4-Pyridyl 
derivative 10 showed minor radioligand displacement at the mutated receptor.  
Extension of the carbon chain to phenylethyl derivative 12 yielded the largest 
decrease in orthosteric [3H]ZM-241,385 binding to both the wild-type (46%) and 
W246A6.48 mutant (99%) receptors. Further extension of the carbon chain to phenylpropyl 
derivative 13 produced slightly lower reductions in [3H]ZM-241,385 binding to the wild-
type (40%) and mutant (91%) receptors relative to that with 12. Increased linker sizes and 
inclusion of heteroatoms (compounds 15-18) marginally displaced [3H]ZM-241,385 binding 
from the wild-type receptor. However, these compounds were able to displace [3H]ZM-
241,385 binding from the W246A6.48 mutant receptor by approximately 80% (sulfone 17), 
65% (sulfide 16 and sulfonamide 18), and 35% (amine 15). 
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Table 1. hA2AAR binding of amiloride derivatives. % [
3H]ZM-241,385 binding to the hA2AAR-WT and 
-W246A
6.48 in the presence of 10 µM amiloride 1, HMA 2, or amiloride derivatives 3-18. The 
concentration of [3H]ZM-241,385 was 2.5 nM. 100 % [3H]ZM-241,385 binding was determined in the 
absence of any amiloride, while 0 % binding was determined as nonspecific binding of [3H]ZM-
241,385 assessed in the presence of 100 µM NECA (WT) or 10 µM ZM-241,385 (W246A
6.48). Values 




% [3H]ZM-241,385 binding ± SEM  
to hA2AAR  







71 ± 2 11 ± 1 
HMA 2 30 ± 2 1.8 ± 0.3 
3 
 
88 ± 1 111 ± 9 
4 
 
87 ± 7 48 ± 10 
5 
 
96 ± 3 70 ± 9 
6 
 
65 ± 3 17 ± 3 
7 
 
99 ± 4 101 ± 2 
8 
 
77 ± 4 21 ± 4 
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9 
 
71 ± 3 46 ± 3 
10 
 
87 ± 4 73 ± 4 
11 
 
96 ± 6 48 ± 5 
12 
 
54 ± 3 1.1 ± 0.4 
13 
 
60 ± 2 9.0 ± 1.9 
14 
 
85 ± 3 53 ± 7 
15 
 
90 ± 3 65 ± 8 
16 
 
84 ± 3 35 ± 2 
17 
 
82 ± 4 18 ± 2 
18 
 
85 ± 3 32 ± 5 
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After observing increased potency with phenylethyl derivative 12, we synthesized and 
tested compounds 12a-p carrying different substituents on the phenyl moiety (Table 2). 
Compounds 12a, 12c-g, and 12n-p displaced less [3H]ZM-241,385 binding than 12 from 
both the wild-type and W246A6.48 mutant hA2AAR. These derivatives performed similarly 
to amiloride at the wild-type receptor, whereas they performed better at the mutated 
receptor, with close to 100% radioligand displacement, with the exception of 4-
chlorophenethyl derivative 12c and 3,4-dichlorophenethyl derivative 12d, which caused 
minor displacement of [3H]ZM-241,385 binding from the wild-type receptor (8% and 18%, 
respectively) and the lowest, although significant, displacement from the mutated 
receptor (68% and 89%, respectively) of the phenethyl derivatives. Compared to parent 
12, 2-(p-tolyl)ethyl derivative 12b displaced similar amounts of radioligand from the wild-
type and W246A6.48 receptors. 4-Bromo 12e, 4-nitro 12f, and 4-hydroxy 12g substituted 
phenethyl derivatives showed lower activity than 12 at both the wild-type and mutant 
receptors. Ether substituted phenethyl derivatives 12h-m displaced more radioligand than 
12 from the wild-type receptor, and reached close to 100% radioligand displacement at 
the W246A6.48 receptor. 4-Methoxyphenethyl derivative 12h displaced 69% of radioligand 
binding from the wild-type receptor, thus performing similarly to HMA, whereas changing 
the methoxy position to give 3-methoxyphenethyl derivative 12i resulted in less 
radioligand displacement (59%). Addition of a second methoxy group, as in 3,4-
dimethoxyphenethyl derivative 12j, decreased radioligand displacement from the wild-
type receptor even more (49%). Dioxolyl derivative 12k increased radioligand 
displacement from the wild-type receptor (65%), bringing its effect close to that of HMA. 
Elongation of 12h by a methyl group resulting in 4-ethoxyphenethyl derivative 12l yielded 
the most effective amiloride derivative of this series, reducing [3H]ZM-241,385 binding 
from the wild-type receptor by 73%. Further elongation of the ethoxy substituent to give 
4-(allyloxy)phenethyl derivative 12m decreased radioligand displacement again, whereas 
the even bulkier ether substituted phenethyl derivatives 12n-p displaced less radioligand 
than 12. 
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Table 2. hA2AAR binding of amiloride phenethyl substituted derivatives. % [
3H]ZM-241,385 binding 
to the hA2AAR-WT and -W246A
6.48 in the presence of 10 µM amiloride derivatives 12a-p. The 
concentration of [3H]ZM-241,385 was 2.5 nM. 100 % [3H]ZM-241,385 binding was determined in the 
absence of any amiloride, while 0 % binding was determined as nonspecific binding of [3H]ZM-
241,385 assessed in the presence of 100 µM NECA (WT) or 10 µM ZM-241,385 (W246A
6.48). Values 




% [3H]ZM-241,385 binding ± SEM  
to hA2AAR  





68 ± 3 6.6 ± 0.3 
12b 
 
50 ± 3 2.1 ± 0.2 
12c 
 
92 ± 2 32 ± 1 
12d 
 
82 ± 1 11 ± 1 
12e 
 
67 ± 4 4.8 ± 1.0 
12f 
 
68 ± 2 5.8 ± 0.5 
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12g 
 
72 ± 2 9.5 ± 0.8 
12h 
 
31 ± 1 -0.4 ± 0.1 
12i 
 
41 ± 2 5.4 ± 1.0 
12j 
 
51 ± 2 1.8 ± 0.5 
12k 35 ± 2 1.0 ± 0.6 
12l 
 
27 ± 1 3.5 ± 0.2 
12m 
 
43 ± 2 2.2 ± 0.6 
12n 
 
66 ± 2 3.4 ± 0.8 
12o 
 
75 ± 2 4.0 ± 0.3 
12p 
 
63 ± 2 5.2 ± 0.3 
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The binding of the four most potent phenethyl derivatives, 12h, i, k, and l, was 
characterized further by establishing their IC50 values in full curve assays for both 
receptors (Table 3). 4-Ethoxyphenethyl derivative 12l had the highest potency at 
displacing [3H]ZM-241,385 binding from the wild-type hA2AAR, showing an IC50 value of 3.4 
µM, which was lower than HMA (5.1 µM, Table 3). 4-Methoxyphenethyl derivative 12h 
and dioxolyl derivative 12k showed similar potencies compared to that of HMA, whereas 
3-methoxyphenethyl derivative 12i showed  lower potency (8.1 µM) for radioligand 
displacement from the wild-type hA2AAR. For the W246A
6.48 mutant hA2AAR, compounds 
12h, k, and l showed increased potencies compared to that of HMA, whereas 12i showed 
similar potency. The fold change in potency for W246A6.48 compared to the wild-type 
receptor was 19-fold for HMA, approximately 35-fold for methoxyphenethyl derivatives 
12h and i, and approximately 80-fold for the dioxolyl 12k and 4-ethoxyphenethyl 12l 
derivatives. 
 
Table 3. hA2AAR affinities of selected amiloride derivatives. IC50 values for the displacement of 
[3H]ZM-241,385 binding to the hA2AAR-WT and -W246A
6.48 by HMA 2 and phenethyl amiloride 
derivatives 12h, i, k, and l. The concentration used of [
3H]ZM-241,385 was 2.5 nM. Nonspecific 
binding was determined in the presence of 100 µM NECA (WT) or 10 µM ZM-241,385 (W246A6.48). 
Values are means ± SEM of at least three independent assays performed in duplicate. 
 [3H]ZM-241,385 displacement from hA2AAR 
WT W246A6.48 
IC50 ± SEM (µM) IC50 ± SEM (µM) Fold change to WT
a 
HMA 2 5.1 ± 0.2 0.27 ± 0.04 19 
12h 4.4 ± 0.4 0.12 ± 0.01** 37 
12i 8.1 ± 0.9* 0.25 ± 0.05 32 
12k 5.6 ± 0.8 0.07 ± 0.01*** 80 
12l 3.4 ± 0.6* 0.05 ± 0.00*** 76 
a Change in fold IC50 of wild-type over W246A
6.48. 
One-way ANOVA with Dunnett’s post hoc test performed against HMA on log IC50 values, with * p < 
0.05, ** p < 0.01, and *** p < 0.001. 
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The effect of saturating concentrations of HMA and compounds 12h, i, k, and l on the 
dissociation characteristics (residence time) of [3H]ZM-241,385 from the wild-type and 
W246A6.48 hA2AAR was examined next (Table 4 and Figure 1). HMA had the largest effect 
on the dissociation velocity of [3H]ZM-241,385 from the wild-type hA2AAR, producing a 
2.2-fold decrease in its residence time (1/koff). Methoxyphenethyl derivatives 12h and i, 
and 4-ethoxyphenethyl derivative 12l decreased residence time by approximately 1.5-fold. 
In the case of dioxolyl derivative 12k, the effect on the residence time was lost at the wild-
type receptor. At the W246A6.48 hA2AAR, HMA, 12h, and 12l showed similar effects as 
those at the wild-type receptor, producing 1.9-, 1.3-, and 2.1-fold decreases in residence 
time, respectively. In contrast, the effect of 3-methoxyphenethyl derivative 12i and 
dioxolyl derivative 12k increased significantly at the W246A6.48 mutant receptor, where 
3.4- and 2.3-fold decreases in residence time of [3H]ZM-241,385, respectively, were 
observed. 
 
Table 4. Effect of amiloride derivatives on residence time of [3H]ZM-241,385. Residence times of 
[3H]ZM-241,385 dissociating from hA2AAR-WT and -W246A
6.48 in the absence (control) or presence 
of 100 µM (WT) or 10 µM (W246A
6.48), i.e. saturating concentrations, of HMA 2 or amiloride 
derivatives 12h, i, k, or l. The concentration of [3H]ZM-241,385 was 2.5 nM. Nonspecific binding was 
determined in the presence of 100 µM NECA (WT) or 10 µM ZM-241,385 (W246A6.48). Values are 
means ± SEM of at least three independent assays performed in duplicate. 
 [3H]ZM-241,385 dissociation from hA2AAR 
Residence time (min) 
 WT W246A6.48 
Control 61 ± 4 2.8 ± 0.4 
+ HMA 2 28 ± 2*** 1.4 ± 0.2** 
+ 12h 44 ± 3** 2.0 ± 0.5 
+ 12i 42 ± 5* 0.8 ± 0.3** 
+ 12k 61 ± 5 1.2 ± 0.5* 
+ 12l 40 ± 1** 1.3 ± 0.3* 
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Figure 1. [3H]ZM-241,385 dissociation from the hA2AAR-WT in absence (control) or presence of 100 
µM of HMA 2 or amiloride derivatives 12h, i, k, or l. After allowing [
3H]ZM-241,385 to bind to its 
target, the dissociation was induced by addition of 100 µM NECA together with 100 µM of the 
respective compounds. Graph shows mean values of one representative dissociation experiment 
performed in duplicate. 
 
Docking study 
The most potent amiloride derivatives, 12h, i, k, and l were docked into the sodium ion 
binding site of the hA2AAR X-ray cocrystal structure bearing orthosteric ligand ZM-241,385 
(Figures 2 and S1-S3, PDB: 4EIY).5 The cores of these amiloride derivatives were predicted 
to adopt binding poses similar to those of amiloride and HMA observed in Chapter 3 
(Figure S1). The hydrogen bonding and salt bridge interactions with Asp522.50 and Thr883.36 
were predicted similarly for the novel derivatives and HMA. Furthermore, 12h, i, k, and l 
were predicted to occupy Trp2466.48 position, forcing it to adopt a different rotameric 
position, as was observed previously for amiloride and HMA in Chapter 3. 
However, the interactions with Trp2466.48 were predicted to be different for each 
amiloride derivative. Whereas for HMA no π-π stacking was predicted, π-π stacking was 
predicted between Trp2466.48 and the phenyl group of 12h, i, and k, and a second π-π 
stacking interaction was predicted with the pyrazine core of 12i.  Furthermore, the 
phenethyl moieties of the novel derivatives were predicted to intrude a hydrophobic 
pocket not reached by the azepane moiety of HMA. Compared to HMA, the phenethyl 
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substitutions were predicted to be in a 4 Å range of three to four additional hydrophobic 
residues, specifically Phe168EL2, Met1775.38, Leu2496.51 (12h, i, k, and l), and Ile2747.39 (12i 
and l) (Figures S1 and S2). In addition, the dioxolyl and ethoxy substituents of compounds 
12k and l were predicted to be in the vicinity of Asn2536.55 (Figure S2). Residues Phe168EL2, 
Met1775.38, Leu2496.51, Asn2536.55, and Ile2747.39 are part of the orthosteric binding site, 
and their predicted vicinity to these residues indicates that 12h, i, k, and l can intrude the 
orthosteric site and displace orthosteric ligand ZM-241,385 in a direct, competitive 
manner. 
 
Figure 2. Docking of compound 12l into the sodium ion binding site of wild-type hA2AAR (PDB: 4EIY).
5 
Compound 12l is represented by cyan colored sticks, and ZM-241,385 in the orthosteric site is 
represented by grey sticks. Trp246
6.48 is represented by transparent white sticks (crystal structure 
position) and yellow sticks (proposed rotamer with 12l docked in the sodium ion site). Oxygen and 
nitrogen atoms are represented in red and blue, respectively. The local protein backbone is 
represented by yellow ribbons, and relevant binding site confinements are indicated by white-grey 
(hydrophobic), red (electronegative), and blue (electropositive) layers. 
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Discussion 
Amiloride and HMA act as allosteric modulators of several GPCRs,10 including α2 
adrenergic receptors,11 dopamine receptors,12 and the gonadotropin-releasing hormone 
receptor.13 Allosteric effects of both compounds have been extensively explored for 
adenosine receptors. Gao et al. demonstrated that HMA and a few other 5’-substituted 
amiloride derivatives increase the dissociation rate of antagonists from the adenosine A1 
and A3 receptors, whereas amiloride itself was effective only at the adenosine A1 
receptor.15 At the hA2AAR, amiloride and its derivatives exhibited similar effects, where 
dissociation of radiolabeled antagonist [3H]ZM-241,385 increases in their presence.14 
Amilorides supposedly bind in the sodium ion binding site of GPCRs. This has been 
visualized in Chapter 3 by docking amiloride and HMA into the high resolution X-ray crystal 
structure of the hA2AAR.
5 Like sodium ions, the positively charged guanidinium moiety of 
amiloride and HMA made strong interactions with the carboxylate of Asp522.50. 
Furthermore, the presence of amiloride or HMA forced Trp2466.48 to rotate away from its 
most stable position. This proposed binding mode was confirmed in the mutation study in 
Chapter 4, where the effects of amiloride and HMA were largely diminished by mutation 
D52A2.50 but were increased by mutation W246A6.48. The strong increase in potency of 
HMA compared to that of amiloride against the hA2AAR provided the impetus to 
investigate whether different substituents at the 5’ position of amiloride might yield more 
potent amiloride derivatives. In the current study, a selection of 5’-substituted amilorides 
was tested for binding to the wild-type and W246A6.48 mutant hA2AAR (Table 1). 
Carboxylate derivatives 3 and 5 and tetrazole 7 showed minimal or no displacement of 
[3H]ZM-241,385 binding from either receptor. Apparently, amiloride derivatives carrying a 
negative charge on an extended 5’-substituent do not bind in the sodium ion pocket. 
Indeed, 5’ substituents are predicted to enter a hydrophobic pocket, as suggested by the 
proposed binding modes of HMA and 12h, i, k, and l (Figures S1 and S2). Most of the other 
amilorides were more or less active at the W246A6.48 mutant hA2AAR, indicating at least 
some affinity of these compounds for the sodium ion site. The most potent derivative at 
both the wild-type and mutant hA2AARs in the preliminary series was phenethyl derivative 
12. This derivative was the starting point for the synthesis of novel derivatives 12a-p 
carrying substituents on the phenyl moiety (Table 2). The four most potent derivatives to 
emerge for the wild-type receptor were 12h, i, k, and l, of which 4-ethoxyphenethyl 
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derivative 12l proved to be more potent than HMA (Table 3). Differences in potency shifts 
between the wild-type and W246A6.48 mutant hA2AAR ranged from 19-fold for HMA to 80-
fold for 12k. Together with the predicted binding modes, in which Trp2466.48 is forced to 
rotate away from its most stable position, as observed previously for amiloride and HMA 
in Chapter 3 (Figures 2 and S3), these potency shifts support the binding of these ligands 
in the sodium ion site. The bulkiest compounds, dioxolyl derivative 12k and 4-
ethoxyphenethyl derivative 12l, benefited the most from the absence of the bulky 
tryptophan residue, which suggests increased steric clash between Trp2466.48 and bulkier 
5’ substituents. 
Trp2466.48 separates the sodium ion binding pocket from the orthosteric binding 
pocket, which are adjacent.5 The proposed binding modes in the docking study predicted 
that the elongated phenethyl substituents of the amiloride derivatives are in close  
proximity to at least four amino acids that make up the orthosteric pocket (Figures 2 and 
S1-S3), which makes it likely that they protrude into the orthosteric pocket and enter in a 
direct competition with orthosteric ligands. This would change the allosteric mechanism of 
these amiloride derivatives from a noncompetitive to a more competitive nature. To 
investigate whether this was the case, the four most potent phenethyl-amiloride 
derivatives, 12h, i, k, and l, were tested for their influence on the dissociation 
characteristics of the orthosteric ligand [3H]ZM-241,385 from the wild-type hA2AAR (Table 
4). The noncompetitive allosteric effect of HMA was evident as it decreased the residence 
time of [3H]ZM-241,385 significantly at the wild-type receptor, which is in agreement with 
previous studies (Gao et al.14 and Chapter 3). Compounds 12h, i, and l were more 
competitive in nature, as illustrated by their smaller effects on the dissociation 
characteristics of the orthosteric ligand. Interestingly, compound 12k did not influence the 
dissociation of [3H]ZM-241,385 at all, which suggests that the displacement of the 
orthosteric ligand by 12k is entirely due to direct competition between the two ligands. 
The position of Trp2466.48 at the interface of the orthosteric and allosteric sites of the 
hA2AAR suggests that this amino acid  influences the nature of the allosteric mechanism of 
amilorides. Indeed compounds 12i and k showed quite different effects on the 
dissociation of [3H]ZM-241,385 from the W246A6.48 mutant compared to the wild-type 
receptor. These two compounds became noncompetitive allosteric modulators in the 
absence of the bulky tryptophan side chain, as their effect on the dissociation 
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characteristics of [3H]ZM-241,385 increased significantly. For 12k, the effect was 
remarkable, showing no effect at the wild-type receptor while producing a 2.3-fold 
decrease in the residence time of [3H]ZM-241,385 at the mutated receptor. This suggests 
that the presence of Trp2466.48 ‘guides’ the methoxy and dioxolyl substituents on the 
phenethyl moieties of 12i and k toward the orthosteric site, inducing their competitive 
effect. 
Conclusions 
We demonstrated that it is possible to extend amiloride with substituents at the 5’ 
position to produce amiloride derivatives with similar or even higher potencies than HMA 
at the wild-type hA2AAR. Similar to amiloride and HMA, all novel amiloride derivatives 
showed significantly higher potencies at the W246A6.48 mutant hA2AAR, implying that 
Trp2466.48 hinders the binding of these amiloride derivatives. HMA showed the largest 
allosteric effect on [3H]ZM-241,385 dissociation, whereas the most potent novel 
amilorides showed reduced or no effects on this dissociation process. This indicates that 
these novel amilorides engage in a more direct competition with the orthosteric ligand, 
and it can be hypothesized that they do so by intrusion into the orthosteric pocket. The 
striking differences in effect on the dissociation of [3H]ZM-241,385 between the wild-type 
and W246A6.48 hA2AARs imply that Trp246
6.48 influences the nature of the allosteric 
interaction by amilorides. The well-conserved sodium ion pocket and the effects of 
amilorides and HMA shared among a multitude of GPCRs suggest a general mechanism of 
their interaction with the superfamily of GPCRs. 
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Supplemental information 
Supplemental information includes full experimental procedures for synthesis of 
compounds 12a-p, including NMR and HPLC data, 2D interaction maps of docking of HMA 
2 and 12h, i, k, and l (Figures S1 and S2), 3D representation of docking of 12h, i, k, and l 
(Figure S3), and SMILES strings and binding and inhibition data for 1-18 and 12a-p in (CSV). 
It can be found with this article online at dx.doi.org/10.1021/ acs.jmedchem.6b00142 
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Abstract 
Conventional methods to measure ligand-receptor binding parameters typically require 
radiolabeled ligands as probes. Despite the robustness of radioligand binding assays, they 
carry inherent disadvantages in terms of safety precautions, expensive synthesis, special 
lab requirements, and waste disposal. Mass spectrometry (MS) is a method that can 
selectively detect ligands without the need of a label. The sensitivity of MS equipment 
increases progressively, and currently it is possible to detect the low ligand quantities that 
are usually found in ligand binding assays. We developed a label-free MS ligand binding 
(MS binding) assay on the adenosine A1 and A2A receptors (A1AR and A2AAR), which are 
well-characterized members of the class A G protein-coupled receptor (GPCR) family. 
Radioligand binding assays for both receptors are well established, and ample data is 
available to compare and evaluate the performance of an MS binding assay. 1,3-Dipropyl-
8-cyclopentyl-xanthine (DPCPX) and 4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]-
[1,3,5]triazin-5-yl)amino)ethyl)phenol (ZM-241,385) are high-affinity ligands selective for 
the A1AR and A2AAR, respectively. To proof the feasibility of MS binding on the A1AR and 
A2AAR we first developed an MS detection method for unlabeled DPCPX and ZM-241,385. 
To serve as internal standards, both compounds were also deuterium-labeled. 
Subsequently, we investigated whether the two unlabeled compounds could substitute 
for their radiolabeled counterparts as marker ligands in binding experiments, including 
saturation, displacement, dissociation, and competition association assays. Furthermore, 
we investigated the accuracy of these assays if the use of internal standards was excluded. 
The results demonstrate the feasibility of the MS binding assay, even in the absence of a 
deuterium-labeled internal standard, and provide great promise for the further 
development of label-free assays based on MS for other GPCRs. 
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Introduction 
Conventional methods to measure ligand-receptor binding parameters typically require 
labeled probes such as radiolabeled1 or fluorescently labeled ligands.2 Despite the 
robustness of radioligand binding assays, they carry inherent disadvantages in terms of 
safety precautions, expensive synthesis, special lab requirements, and waste disposal. 
Alternatively, the addition of fluorescent moieties holds a substantial risk of affecting the 
pharmacological properties of a ligand; moreover, in many instances it is also required to 
engineer the receptor protein, in particular for fluorescence resonance energy transfer 
assays.3 
The development of the mass spectrometry (MS) binding assay by the group of 
Wanner permits to measure binding of an unlabeled ligand to its target.4 Instead of the 
radiolabeled ligand in radioligand binding assays, an unlabeled marker ligand is employed 
in MS binding assays. The amount of marker ligand bound to the target receptor is 
detected by mass spectrometry. As the mass of the molecule itself is detected, a label is 
not necessary. However, the marker ligand still has to fulfill the same requirements as 
radioligands: high affinity and selectivity for the target, and low nonspecific binding.5   
Therefore, it is practical to choose a ligand for MS binding applications that has already 
been validated as a good radioligand. This also ensures a straightforward validation of an 
MS binding assay by comparing it to existing radioligand binding assays. 
In this study, we developed an MS binding assay for the adenosine A1 (hA1AR) and 
adenosine A2A receptors (hA2AAR). The particular robustness and abundance of published 
results of radioligand binding assays on the hA1AR and hA2AAR make these receptors good 
candidates for development of an MS binding assay.6 The adenosine receptors are 
members of the class A of G protein-coupled receptors (GPCRs). Both receptors are 
important in physiology. The hA1AR has been related to sleep regulation, epilepsy, and 
asthma. The hA2AAR is implicated in neurodegeneration, inflammatory diseases, and 
cancer pathogenesis. Both receptors are involved in cardiovascular physiology.6, 7 As 
marker ligands for the MS binding assay, we chose 1,3-dipropyl-8-cyclopentyl-xanthine 
(DPCPX) for the hA1AR and 4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a]- 
[1,3,5]triazin-5-yl)amino)ethyl)phenol  (ZM-241,385) for the hA2AAR. These ligands are 
well-established radioligands for their respective targets and hence a logical choice to 
serve as marker ligands in MS binding assays.8, 9 
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The development of liquid chromatography-MS (LC-MS) detection methods for 
nonlabeled DPCPX and ZM-241,385 as marker ligands involved the following steps. Firstly, 
deuterated isotopologues of the marker ligands were synthesized to serve as internal 
standards for increased accuracy of the MS detection. In MS detection methods, it is 
common to add a fixed amount of an internal standard to each sample to compensate for 
ion suppression, sample evaporation, and instrumental drift.10 Technically, the use of 
deuterium-labeled internal standards makes the MS binding assay a labeled assay, even if 
the marker ligand that binds to the target is unlabeled itself. Therefore, we also 
investigated whether the results of the MS binding assays were accurate in the absence of 
an internal standard. Secondly, a fast LC method was developed to separate the marker 
ligands from cell membrane contents in the sample. The duration of the LC separation is 
the limiting step for the throughput of the method so this is preferably fast, i.e., within 
one minute. Thirdly, for MS detection, a triple quadrupole MS (TQMS) was employed, 
which has the required sensitivity to measure typical bound ligand quantities of ligand 
binding assays, in the pM range. In a TQMS, the parent ions with the mass of the molecule 
of interest are filtered by the first quadrupole, which are then fragmented in the second 
quadrupole. The fragmentation results in daughter ions that are analyzed by the third 
quadrupole. This setup ensures a high selectivity and sensitivity for the detection of a 
molecule of interest.11 
After establishing the LC-MS methods for detection of the marker ligands, the MS 
binding assays were performed with and without deuterium-labeled internal standard, 
and analogous to radioligand binding assays. Saturation, association, and dissociation 
assays were performed to determine the affinity and kinetic rates of the marker ligands 
DPCPX for the hA1AR and ZM-241,385 for the hA2AAR. Then displacement and competition 
association assays were performed to determine the affinity and kinetic rates of ligands 
competing with the marker ligands. The ensuing results were compared to and validated 
with reference radioligand binding data. 
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Materials and methods 
Materials 
Adenosine deaminase (ADA) was purchased from Boehringer Mannheim (Mannheim, 
Germany). DPCPX, 5’-N- ethylcarboxamidoadenosine (NECA), and bovine serum albumin 
(BSA) were purchased from Sigma (St. Louis, MO, USA). ZM-241,385 was purchased from 
Ascent Scientific (Bristol, UK). N6-Cyclopentyladenosine (CPA) was purchased from Abcam 
Biochemicals (Cambridge, UK). 6-(2,2-Diphenylethylamino)-9-((2R,3R,4S,5S)-5-
(ethylcarbamoyl)-3,4-dihydroxytetrahydrofuran-2-yl)-N-(2-(3-(1-(pyridin-2-yl)piperidin-4-
yl)ureido)ethyl)-9H-purine-2-carboxamide (UK-432,097) was obtained as a gift through  
Pfizer’s Compound Transfer Program. 3-(3-Hydroxypropyl)-7-methyl-1-propargyl-8-(m-
methoxystryryl)xanthine (MSX-2)12 was a gift from Prof. C. E. Müller (Bonn University, 
Germany). 8-Cyclopentyltheophylline (8-CPT) was purchased from Research Biochemicals 
Inc. (Natick, MA, USA). 8-Cyclopentyl-3-(3-((4-(fluorosulfonylbenzoyl)oxy)propyl)-1-
propylxanthine (FSCPX)13 and N5-(2-(4-(2,4-difluorophenyl)piperazin-1-yl)ethyl)-2-(furan-2-
yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine (LUF6632)14  were synthesized in-
house. Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained from Pierce 
Chemical Company (Rockford, IL, USA). CHO cells stably expressing the hA1AR (CHO-
hA1AR) were a gift from Prof. S. Hill (University of Nottingham, UK). HEK293 cells stably 
expressing the hA2AAR (HEK293-hA2AAR) were a gift from Dr. J. Wang (Biogen/IDEC, 
Cambridge, MA, USA).  All other chemicals were of analytical grade and obtained from 
standard commercial sources. 
General synthesis procedures 
Demineralised water is simply referred to as H2O, as was used in all cases unless stated 
otherwise. 1H and 13C NMR spectra were recorded on a Bruker AV 400 liquid spectrometer 
(1H NMR, 400 MHz; 13C NMR, 100 MHz) at ambient temperature. Chemical shifts are 
reported in parts per million (ppm), are designated by δ and are downfield to the internal 
standard tetramethylsilane (TMS) in CDCl3. Coupling constants are reported in Hertz and 
are designated as J. Analytical purity of the final compounds was determined by high 
pressure liquid chromatography (HPLC) with a Phenomenex Gemini 3-m 
C18 110A column (50 x 4.6 mm, 3 μm), measuring UV absorbance at 254 nm. Sample 
preparation and HPLC method were - unless stated otherwise - as follows:  0.3-0.8 mg of 
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compound was dissolved in 1 ml of a 1:1:1 mixture of CH3CN/H2O/tBuOH and eluted from 
the column within 15 min, with a three-component system of H2O/CH3CN/1% TFA in H2O, 
decreasing polarity of the solvent mixture in time from 80:10:10 to 0:90:10. All 
compounds showed a single peak at the designated retention time and were at least 95% 
pure. The synthesized compounds were identified by LC-MS analysis using a Thermo 
Finnigan Surveyor-LCQ Advantage Max LC-MS system and a Gemini C18 Phenomenex 
column (50 × 4.6 mm, 3 µm). The sample preparation was the same as for HPLC analysis. 
The elution method was set up as follows: 1–4 min isocratic system of H2O/CH3CN/1% TFA 
in H2O, 80:10:10, from the 4
th min, a gradient was applied from 80:10:10 to 0:90:10 within 
9 min, followed by 1 min of equilibration at 0:90:10 and 1 min at 80:10:10. Thin-layer 
chromatography (TLC) was routinely performed to monitor the progress of reactions, 
using aluminum-coated Merck silica gel F254 plates. Purification by column 
chromatography was achieved by use of Grace Davison Davisil silica column material 
(LC60A 30-200 μm). Solutions were concentrated using a Heidolph laborota W8 2000 
efficient rotary evaporation apparatus and by a high vacuum on a Binder APT line Vacuum 
Drying Oven. 
Preparation of 8-cyclopentyl-1,3-bis(propyl-2,3-d2)-3,9-dihydro-1H-purine-2,6-dione 2 
([2H4] DPCPX) 
Synthesis steps to arrive to compound 1 (SI Scheme 3) were performed as previously 
described.15-17 1,3-Diallyl-8-cyclopentyl-3,9-dihydro-1H-purine-2,6-dione 1 (1 mmol, 300 
mg) and NaBD4 (4 mmol, 167 mg) were placed in a flask. The flask was flame-dried under 
vacuum to remove traces of water and then purged with N2 gas. Dry THF (10 ml) was 
added. RhCl(PPh3)3 was placed in another flame-dried flask under N2-atmosphere and 
suspended in dry THF (1 ml). The flask containing 1 was heated to 60 °C and the reaction 
was started upon addition of the catalyst suspension, followed by D2O (2 mmol, 0.04 ml). 
The mixture was stirred at 60 °C for 19 h. The reaction mixture was then poured into 
EtOAc and washed with brine (3x). The organic layer was dried over MgSO4 and 
concentrated. The crude product was purified by column chromatography (PET/EtOAc 5/1 
 4/1  3/2). The product 2 was obtained as white solid (46%, 0.46 mmol, 141 mg). 1H 
NMR (400 MHz, CDCl3): δ 11.92 (br s, 1H), 4.11 – 4.06 (m, 2H), 4.03 – 3.97 (m, 2H), 3.30 – 
3.21 (m, 1H), 2.18 – 2.11 (m, 2H), 1.98 – 1.68 (m, 8H), 0.99 – 0.94 (m, 4H) ppm. MS: 
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[M+H]+ calculated 309.22, found 309.20. HPLC purity 97% (tR 9.587 min, mobile phase 15-




Synthesis steps to arrive to compounds 3 and 4 (SI Scheme 4) were performed as 
previously described.18-20 [2H4]Tyramine 4 (0.37 mmol, 53 mg) was suspended in 4 ml 
MeCN, and Et3N (0.14 ml) and 2-(furan-2-yl)-5-(methylsulfonyl)-1,3a-dihydro-
[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 3 (0.34 mmol, 95 mg) were added. The mixture 
was stirred for 3 h at 70 °C under microwave irradiation. The solvent was evaporated, and 
the crude material was adsorbed onto Silica and purified by column chromatography 
(EtOAc/MeOH 99/1) and subsequent PTLC (EtOAc/MeOH 99.5/0.5) to give the product 5 
as an off-white solid (45%, 0.15 mmol, 52 mg). 1H NMR (400 MHz, DMSO-d6): δ 9.17 (s, 
1H), 8.13 (br s, 2H), 7.86 (s, 1H), 7.53 – 7.52 and 7.50 – 7.42 (m, 1H, rotamers), 7.05 (d, J = 
3.2, 1H), 6.67 (m, 1H), 3.43 – 3.40 (m, 2H), 2.74 – 2.71 (m, 2H) ppm. MS: [M+H]+ calculated 
342.16, found 342.7. HPLC purity 95% (tR 6.408 min, mobile phase 10-90 % MeCN/H2O + 
TFA). 
Cell culture 
CHO-hA1AR cells were grown in Ham’s F12 medium containing 10% normal adult bovine 
serum, 100 µg/ml streptomycin, 100 IU/ml penicillin, and 400 µg/ml G418, at 37 °C in 5% 
CO2. HEK293-hA2AAR cells were grown in Dulbecco's modified Eagle’s medium (DMEM)  
supplemented with 10% newborn calf serum, 50 µg/ml streptomycin, 50 IU/ml penicillin, 
and 200 µg/ml G418, at 37 °C and 7% CO2. Cells were subcultured twice a week on 10 cm 
ø plates at a ratio of 1:20 for CHO hA1R cells and 1:8 for HEK293 hA2AAR cells.  
Membrane preparation 
CHO-hA1AR and HEK293-hA2AAR cells were grown as described above. Membranes were 
prepared as follows. Cells were detached from plates grown to confluency by scraping 
them into 5 ml PBS, collected and centrifuged at 700 g (3000 rpm) for 5 min. Pellets 
derived from 20 plates (10 cm ø) were pooled and resuspended in 16 ml of ice-cold assay 
buffer (50 mM Tris-HCl, 5 mM MgCl2, pH 7.4). An Ultra-Turrax was used to homogenize 
the cell suspension. Membranes and the cytosolic fraction were separated by 
centrifugation at 100000 g (31000 rpm) in a Beckman Optima LE-80K ultracentrifuge at 4 
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°C for 20 min. The pellet was resuspended in 8 ml of Tris buffer and the homogenization 
and centrifugation step was repeated. Assay buffer (4 ml) was used to resuspend the 
pellet, and adenosine deaminase (ADA) was added (0.8 IU/ml) to break down endogenous 
adenosine. Membranes were stored in 250 µl aliquots at -80 °C. Membrane protein 
concentrations were measured using the BCA (bicinchoninic acid) method.21 
Radioligand binding assays 
The reference radioligand binding data were published before by our lab or were acquired 
as described before.22, 23 
Membrane harvesting procedure MS binding assays 
100 μl membrane aliquots containing 5 µg (CHO-hA1AR) or 22 µg (HEK293-hA2AAR) of 
protein in assay buffer were harvested by rapid vacuum filtration through 1 µm glass fiber 
AcroPrep Advance 96 filter plates (Pall Corporation, Ann Arbor, MI, USA)  using an 
extraction plate manifold (Waters, Milford, MA, USA) and a 12-channel electronic pipette 
(Gilson, Middleton, WI, USA). Filters were subsequently washed three times with ice-cold 
assay buffer and dried for 1 h at 55 °C. It was essential that the filter plates were 
completely dry before continuing with ligand elution as described below in ‘Sample 
elution’. 
MS binding saturation assays 
Membrane aliquots containing 5 µg (CHO-hA1AR) or 22 µg (HEK293-hA2AAR) of protein 
were incubated in a total volume of 100 μl of assay buffer at 25 °C for 1 h (hA1AR) or at 4 
°C for 3 h (hA2AAR). Total binding was determined at increasing concentrations of marker 
ligand DPCPX (0.08 - 40 nM on hA1AR) or marker ligand ZM-241,385 (0.05 - 15 nM on 
hA2AAR). Dilutions were prepared with a HP D300 Digital Dispenser (Tecan Group, 
Männerdorf, Swiss) from DMSO stocks. Nonspecific binding in presence of 100 μM CPA 
(hA1AR) or 100 μM NECA (hA2AAR) was determined at three concentrations of marker 
ligand and analyzed by linear regression. Incubations were terminated and samples were 
harvested as described under ‘Membrane harvesting procedure MS binding assays’. 
MS binding displacement assays 
Ligand displacement experiments were performed using nine concentrations of competing 
ligand. For the hA1AR the competing ligands used were CPA, 8-CPT, ZM-241,385, and 
NECA, while for the hA2AAR they were UK-432,097, MSX-2, DPCPX, and NECA. As marker 
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ligand DPCPX was used for the hA1AR at a concentration of 6 nM, and ZM-241,385 for the 
hA2AAR at a concentration of 3 nM. Nonspecific binding was determined in the presence of 
100 μM CPA for the hA1AR and 100 μM NECA for the hA2AAR. Incubations were terminated 
as described under ‘Membrane harvesting procedure MS binding assays’. 
MS binding association assays 
Membrane aliquots containing 5 µg / 100 µl (CHO-hA1AR) or 22 µg / 100 µl (HEK293-
hA2AAR) of protein were incubated in a total volume of 2400 μl of assay buffer at 25 °C 
with 6 nM DPCPX for hA1AR or at 4 °C with 3 nM ZM-241,385 for hA2AAR. At each time 
point, 100 µl from the reaction mix was harvested as described under ‘Membrane 
harvesting procedure MS binding assays’ to determine the amount of marker ligand 
bound to the receptor. Nonspecific binding was determined as described under ‘MS 
binding displacement assays’. 
MS binding dissociation assays 
Membrane aliquots containing 5 µg / 100 µl (CHO-hA1AR) or 22 µg / 100 µl (HEK293-
hA2AAR) of protein were incubated in a total volume of 2400 μl of assay buffer at 25 °C 
with 6 nM DPCPX (hA1AR) or at 4 °C with 3 nM ZM-241,385 (hA2AAR). The reaction mixes 
were allowed to reach equilibrium for 1 h before starting the dissociation by adding 100 
µM CPA (hA1AR) or NECA (hA2AAR). At each time point, 100 µl from the reaction mix was 
harvested as described under ‘Membrane harvesting procedure MS binding assays’ to 
determine the amount of marker ligand still bound to the receptor. Nonspecific binding 
was determined as described under ‘MS binding displacement assays’. 
MS binding competition association assays  
Membrane aliquots containing 5 µg / 100 µl (CHO-hA1AR) or 22 µg / 100 µl (HEK293-
hA2AAR) of protein were incubated in a total volume of 2400 μl of assay buffer at 25 °C 
with 6 nM DPCPX in the absence or presence of 250 nM 8-CPT or 250 nM FSCPX (hA1AR) 
or at 4 °C with 3 nM ZM-241,385 in the absence or presence of 90 nM MSX-2 or 15 nM 
LUF6632 (hA2AAR). At each time point, 100 µl from the reaction mix was harvested as 
described under ‘Membrane harvesting procedure MS binding assays’ to determine the 
amount of marker ligand bound to the receptor. Nonspecific binding was determined as 
described under ‘MS binding displacement assays’. 
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Sample elution 
The ligand was eluted from the ligand-receptor complex on the dried filter plates over 
which MS binding samples were harvested. 100 µl eluent (50 % methanol, 50 % 
ammonium formate buffer [final concentration 5 mM] at pH 7, spiked with 2 nM 
[2H]DPCPX or [2H]ZM-241,385 as internal standard, all HPLC grade) was applied to the 
filter plates which were then centrifuged 1 min at 800 g (2000 rpm) in a 5810 plate 
centrifuge (Eppendorf, Hamburg, Germany), while filter eluates were collected in 1.1 ml 
polystyrene deep 96-wells plates (BrandTech Scientific, Essex, CT, USA). This procedure 
was performed twice resulting in a total of 200 µl eluate for each sample. For standard 
curve samples, the same procedure was followed but for the presence of increasing 
concentrations (1 – 100 pM) of DPCPX or ZM-241,385 in the eluent. After elution, 96-
deep-well plates were sealed with rapid easy pierce film (Nacalai, San Diego, CA, USA) and 
stored at -20 °C before LC-MS-MS quantification. 
LC-MS-MS quantification 
All solvents used were of LC-MS grade or better. The LC-ESI-MS-MS setup consisted of a 
Nexera X2 UHPLC (Shimadzu, Kyoto, Japan; degassing unit: 20A3R, autosampler: 30AC, 
column oven: 30AD) and a LCM-8050 triple quadrupole mass spectrometer (Shimadzu, 
Kyoto, Japan) with an electrospray ionization source (ESI) in positive mode. 
Chromatographic separation was performed on an Acquity UPLC BEH C18 column (1 x 50 
mm, 1.7 µm; Waters, Milford, MA, USA) with a VanGuard precolumn of the same type (2.1 
x 5 mm). The column oven was set at 40 °C. Mobile phases consisted of acetonitrile, 
methanol, ammonium formate buffer (final concentration 5 mM) at pH 7, all of LC-MS 
grade or better, in respective volume fractions of 5:5:90 (solvent A) and 45:45:10 (solvent 
B). An isocratic mobile phase flow of 0.2 ml/min was applied consisting of solvents A:B 
(10:90 for the DPCPX and 35:65 for the ZM-241,385 quantification methods), which 
resulted in column pressures of 400 bar and 500 bar, respectively. The sample eluate 
injection volume was 20 µl and run time was 1 min. Source and fragmentation parameters 
were acquired by the Shimadzu optimization for method function (Table 1). For each 
ligand, the parent and four daughter ions were detected by multiple reaction monitoring 
(MRM) in positive mode. Additional MS settings were as follows: ESI interface 
temperature 300 °C; DL temperature 250 °C; heat block temperature 400 °C; ion spray 
voltage 4 kV; heating and drying gas flows 10 L/min; nebulizing gas flow 3 L/min. 
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Table 1. Mass of detected parent and daughter ions. Parent ions were fragmented to daughter ions 
with different optimal collision energies for each daughter ion. 
 Parent ion Daughter ion Collision energy (V) 


















Shimadzu LabSolutions software (Shimadzu, Kyoto, Japan) was used to analyze resulting 
chromatogram peaks. The peak area of the total ion count (TIC) of the daughter ions was 
calculated at the expected retention times, resulting in marker and internal standard peak 
area. To compensate for eluent evaporation and signal suppression by matrix effects from 
the membrane sample, marker peak area was divided by internal standard peak area 
(M/IS). Lower limit of quantitation (LLOQ) values of each marker ligand were defined as 
the lowest concentration in membrane matrix where signal to noise ratio was higher than 
5, the standard deviation within and between runs in hexaplicate was lower than 20% 
(and for all higher concentrations lower than 15%), and calculation of concentration by a 
function derived from 1/x2 linear regression deviated from nominal values less than 20%. 
M/IS values were converted to concentration of marker ligand in pM using the function 
established by 1/x2 linear regression on the 10 – 100 pM standard curve results.  The 
resulting MS binding data was then analyzed with GraphPad Prism 5.0 (GraphPad 
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Software Inc., San Diego, CA, USA). Marker ligand displacement curves were fitted to one- 
and two-state site binding models. kon and koff values of the marker ligands DPCPX and ZM-
241,385 were derived by fitting one-phase association and dissociation models. 
Association and dissociation rates for the competing ligands were calculated by fitting the 
data to the competition association model using ‘kinetics of competitive binding’.24 Log-
transformed Ki, KD, kon, and koff values from MS binding and radioligand binding assays 
were plotted, and a linear regression analysis was applied. A similar correlation plot was 
prepared with values from MS binding assays based on solely marker peak area values 
instead of M/IS. 
Results 
Synthesis of [2H4]DPCPX 2 
 [2H4]DPCPX 2 was prepared according to the synthetic route shown in Scheme 1 and SI 
Scheme 3 and was adopted from previously described syntheses of nondeuterated 
DPCPX.15-17 After the synthesis steps to arrive at compound 1 (SI Scheme 3), the allylic 
double bonds of the DPCPX precursor 1 were reductively deuterated in the presence of 
Wilkinson’s catalyst with NaBD4 as a deuterium source generating deuterium gas in situ 
upon addition of D2O.
25 The mass spectrum showed a mass range for the (M+H+) species 
from 305.20 ([2H0] isotopologue) to 313.27 ([
2H8] isotopologue) in a Gaussian distribution 
with the desired [2H4]DPCPX 2 as most abundant isotopologue generating the main mass 
peak at 309.33. 
 
 
Scheme 1. Synthesis of [2H4]DPCPX 2. Reagents and conditions:  Rh(PPh3)3Cl, NaBD4, D2O, dry THF, 
60 °C, 3.5 h. 
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Synthesis of [2H4]ZM-241,385 5 
[2H4]ZM-241,385 5 was prepared according to the synthetic route shown in Scheme 2 and 
SI Scheme 4 and was adopted from previously described syntheses of nondeuterated ZM-
241,385.18-20 After the synthesis steps to arrive at compounds 3 and 4 (SI Scheme 4), 
reaction of the [2H4]tyramine 4 with methylsulfone compound 3 yielded the final product 
[2H4]ZM-241,385 5.
18 MS analysis showed a mass of 342.7 (M+H+) and confirmed the 
incorporation of four deuterium atoms in the final product.  
 
 
Scheme 2. Synthesis of [2H4]ZM-241,385 5. Reagents and conditions: Et3N, MeCN, MW, 70 °C, 3 h. 
 
LC-MS results of DPCPX, [2H]DPCPX, ZM-241,385, and [2H]ZM-241,385 
Standard curves were made for the quantitation of DPCPX and ZM-241,385 concentrations 
in biological membrane matrix by LC-MS (Figure 1). Membrane samples without addition 
of ligand were filtered, and the applied eluent contained increasing concentrations of 
DPCPX and ZM-241,385, in addition to 2 nM of their deuterated counterparts. This 
method ensured standard curves in presence of the same biological matrix as for the 
quantitated MS binding samples. The LLOQ values derived from the standard curves were 
20 pM for DPCPX and 40 pM for ZM-241,385 and were below nonspecific binding 
concentrations found in MS binding assays for DPCPX (31 pM) and ZM-241,385 (42 pM). 
The linear regression equations to calculate marker ligand concentrations from the M/IS 
values derived from the standard curves were y = 0.00341x + 0.117 with R2 = 0.988 for 
DPCPX and y = 0.00130x + 0.0225 with R2 = 0.987 for ZM-241,385. 
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Figure 1. Standard curve of increasing concentrations of marker ligands A) DPCPX with 2 nM 
[2H]DPCPX and B) ZM-241,385 with 2 nM [2H]ZM-241,385 in matrix membrane samples. On the X-
axis is plotted the concentration of marker ligand. On the Y-axis is plotted the marker area TIC 




DPCPX and ZM-241,385 were used as marker ligands for the MS binding assays. These 
marker ligands are also available as well-established tritium-labeled radioligands with high 
affinity for respectively the hA1AR and hA2AAR, which made it possible to validate the MS 
binding assays. For the displacement assays, the competing ligands on the hA1AR were 
CPA (selective agonist), 8-CPT (selective antagonist), ZM-241,385 (hA2AAR-selective 
antagonist), and NECA (nonselective agonist), and on the hA2AAR they were UK-432,097 
(selective agonist), MSX-2 (selective antagonist), DPCPX (hA1AR-selective antagonist), and 
NECA. For the competition association assays, the competing ligands on the hA1AR were 8-
CPT (fast dissociation) and FSCPX (irreversibly binding to hA1AR resulting in an apparent 
slow dissociation), and on the hA2AAR they were MSX-2 (fast dissociation) and LUF6632 
(slow dissociation). Marker ligand concentrations that were found in the eluates of the MS 
binding assays ranged from 31 pM to 242 pM for DPCPX and 42 pM to 289 pM for ZM-
241,385 (Figure 2). The MS binding data in Figures 3-6 and Tables 2-6 is based on data 
with deuterium-labeled internal standard compensation of the marker ligand peak area 
(M/IS), except when stated otherwise in Tables 5 and 6. In Figure 7 both M/IS-based and 
marker peak area-based (without internal standard compensation and thus completely 
unlabeled) data are compared with radioligand binding data. 
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Figure 2. Typical chromatograms of A) nonspecific binding of DPCPX (31 pM), B) total binding of 
DPCPX (242 pM), and C) [2H]DPCPX (2 nM) in eluate containing hA1AR membrane matrix, and of D) 
nonspecific binding of ZM-241,385 (42 pM), E) total binding of ZM-241,385 (289 pM), and F) [2H]ZM-
241,385 (2 nM) in eluate containing hA2AAR membrane matrix. The straight lines below the peaks 
delineate area of peak integration. 
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For the validation of MS binding assays, radioligand binding data that was published 
previously by our group was used. In the case that no in-house radioligand binding data 
was available, the concerning assays were performed following previously established 
protocols.22, 23 Radioligand binding data for the marker ligands DPCPX and ZM-241,385 on 
their respective targets from saturation, association, and dissociation assays was 
published previously (Table 2). Displacement and competition association radioligand 
binding data of the competing ligands NECA (displacement on hA1AR and hA2AAR), UK-
432,097 (displacement on hA2AAR), FSCPX (competition association on hA1AR), and 
LUF6632 (competition association on hA2AAR) was available as well from previous 
publications (Tables 3 - 6). Newly acquired radioligand binding data was from radioligand 
displacement assays with CPA, 8-CPT, and ZM-241,385 on the hA1AR; radioligand 
displacement assays with MSX-2 and DPCPX on the hA2AAR; and radioligand competition 
association assays with 8-CPT on the hA1AR and with MSX-2 on the hA2AAR.  
 
 
Figure 3. Saturation of DPCPX binding to hA1AR (A, B) and ZM-241,385 binding to hA2AAR (C, D). 
Increasing concentrations of marker ligands were incubated with the respective membranes. Data 
shown without (A, C) and with (B, D) nonspecific binding values subtracted. Graphs show mean 
values of one representative MS binding saturation experiment performed in duplicate. 
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Table 2. Affinity and Bmax values of DPCPX for the hA1AR and ZM-241,385 for the hA2AAR as 
determined in MS binding and radioligand binding saturation assays. Values are mean KD in nM ± 
SEM and mean Bmax in pmol/mg protein ± SEM of at least three independent experiments performed 
in duplicate. 
 KD ± SEM (nM) Bmax (pmol/mg protein) 
MS binding Radioligand 
binding 




3.43 ± 0.02 2.5 ± 0.1a 17.3 ± 0.3 14 ± 1a 
ZM-241,385 on 
hA2AAR 
1.03 ± 0.07 0.60 ± 0.07b 2.3 ± 0.3 1.9 ± 0.4b 
a: D. Guo, J Biomol Screen, 2013.26 
b: D. Guo, Br J Pharmacol, 2012.23 
 
MS binding saturation of the marker ligands DPCPX and ZM-241,385 to the hA1AR and 
hA2AAR, respectively, fitted a one-site saturation binding model (Figure 3). DPCPX had an 
affinity of 3.43 ± 0.02 nM and a Bmax of 17.3 ± 0.3 pmol/mg protein for the hA1AR which 
was well in accordance with the previously found data from radioligand binding assays of 
2.5 ± 0.1 nM and 14 ± 1 pmol/mg protein, respectively (Table 2). The same was true for 
ZM-241,385 with an MS binding affinity of 1.03 ± 0.07 nM and Bmax of 2.3 ± 0.3 pmol/mg 
protein for the hA2AAR, compared to a radioligand binding affinity of 0.60 ± 0.07 nM and 
Bmax of 1.9 ± 0.4 pmol/mg protein.  
 
 
Figure 4. Displacement of DPCPX binding to hA1AR by CPA, 8-CPT, ZM-241,385, or NECA (A), and of 
ZM-241,385 binding to hA2AAR by UK-432,097, MSX-2, DPCPX, or NECA (B). Nonspecific binding is 
plotted at -3 on the x-axis. Graphs show mean values of one representative MS binding 
displacement experiment performed in duplicate. 
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Table 3. Affinity (Ki values) of CPA, 8-CPT, ZM-241,385, and NECA as determined in MS binding and 
radioligand binding displacement assays on hA1AR. The displacement curves of CPA and NECA fitted 
to a two-state site binding model, which yielded high and low binding affinities for the receptor. 
Values are mean Ki in nM ± SEM of at least three independent experiments performed in duplicate. 
 Ki ± SEM (nM) 
MS binding Radioligand 
binding 
CPA 139 ± 32 175 ± 13 
  CPA-High 1.2 ± 0.4 1.0 ± 0.5 
  CPA-Low 256 ± 81 304 ± 23 
8-CPT 43 ± 11 31 ± 1 
ZM-241,385 619 ± 78 523 ± 13 
NECA 616 ± 76 731 ± 94a 
  NECA-High 4.1 ± 1.4 4 ± 1a 
  NECA-Low 1273 ± 56 731 ± 94a 
a: D. Guo, Br J Pharmacol, 2014.22 
 
The displacement of marker ligands DPCPX and ZM-241,385 binding from the hA1AR 
and hA2AAR by their competing ligands fitted well to either one-state or two-state ligand 
binding displacement models (Figure 4).  The affinities found in MS binding displacement 
assays for the competing ligands CPA, 8-CPT, ZM-241,385, and NECA for the hA1AR (Table 
3) and UK-432,097, MSX-2, DPCPX, and NECA for the hA2AAR (Table 4) were in good 
agreement to the radioligand binding assays. The two-state binding model fits observed 
for the agonists CPA and NECA on the hA1AR were observed in radioligand binding assays 
as well, and the resulting high and low affinity values were in good agreement (Table 3).  
 
Table 4. Affinity (Ki values) of UK-432,097, MSX-2, DPCPX, and NECA as determined in MS binding 
and radioligand binding displacement assays on hA2AAR. Values are mean Ki in nM ± SEM of at least 
three independent experiments performed in duplicate. 
 Ki ± SEM (nM) 
MS binding Radioligand 
binding 
UK-432,097 52 ± 1 22 ± 5a 
MSX-2 9.0 ± 0.3 5.7 ± 0.1 
DPCPX 550 ± 141 667 ± 77 
NECA 100 ± 12 64 ± 1a 
a: D. Guo, Br J Pharmacol, 2012.23 
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Figure 5. Association (A, C) and dissociation (B, D) of DPCPX on hA1AR (A, B) and ZM-241,385 on 
hA2AAR (C, D). Graphs show mean values of one representative MS binding association or 
dissociation experiment performed in duplicate. 
 
The association and dissociation of marker ligands DPCPX and ZM-241,385 to the 
hA1AR and hA2AAR fitted well to one-phase association and dissociation models (Figure 5), 
and the resulting association and dissociation rates were in good agreement between MS 
binding and radioligand binding assays (Tables 5 and 6).  
 
Figure 6. Competition association of DPCPX on hA1AR in the presence or absence of 250 nM 8-CPT 
and 250 nM FSCPX (A), and of ZM-241,385 on hA2AAR in the presence or absence of 90 nM MSX-2 
and 15 nM LUF6632 (B). Graphs show mean values of one representative MS binding competition 
association experiment performed in duplicate. 
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Table 5. Association and dissociation rates of DPCPX, 8-CPT, and FSCPX determined in MS binding 
and radioligand binding assays on the hA1AR. MS binding (M/IS) values were obtained by analysis 
with compensation by internal standard, just as the MS binding values in Tables 2-4. MS binding 
(marker) values were obtained by analysis of marker chromatograms solely, without compensation 
by internal standard, and thus label-free. The kinetic values of DPCPX were determined by 
association and dissociation assays, while the kinetic values of 8-CPT and FSCPX were determined by 
competition association assays with 6 nM DPCPX as marker ligand. Values are mean kon in M
-1 min-1 
± SEM and mean koff in min
-1 of at least three independent experiments performed in duplicate. 
 kon




















DPCPX 2.0 ± 0.3 
x108 
1.4 ± 0.2 
x108(a) 








8-CPT 5 ± 2  
x107 
6 ± 2  
x107 








FSCPX(b) 0.7 ± 0.2 
x106 
3.7 ± 1.0 
x106(a) 








a: D. Guo, J Biomol Screen, 2013.26 
b: Apparent kinetic values were calculated for covalently binding FSCPX 
 
With the association and dissociation rates validated for the marker ligands, MS 
binding competition association assays were performed. The competition association 
curves in the presence of FSCPX (hA1AR) and LUF6632 (hA2AAR) yielded an “overshoot” 
shape typical for slowly dissociating ligands, while in the presence of 8-CPT (hA1AR) and 
MSX-2 (hA2AAR), the curves were typical for fast-dissociating ligands (Figure 6). FSCPX 
displaced the marker ligand DPCPX completely after 120 min. The association rates of 8-
CPT and MSX-2 agreed well between MS binding and radioligand binding assays, but less 
so in case of FSCPX and LUF6632 (Tables 5 and 6). The dissociation rates of 8-CPT, MSX-2, 
and LUF6632 were in good agreement as well, but not the apparent dissociation rate of 
FSCPX. 
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Table 6. Association and dissociation rates of ZM-241,385, MSX-2, and LUF6632 determined in MS 
binding and radioligand binding assays on the hA2AAR. MS binding (M/IS) values were obtained by 
analysis with compensation by internal standard, just as the MS binding values in Tables 2-4. MS 
binding (marker) values were obtained by analysis of marker chromatograms solely, without 
compensation by internal standard, and thus label-free. The kinetic values of ZM-241,385 were 
determined by association and dissociation assays, while the kinetic values of MSX-2 and LUF6632 
were determined by competition association assays with 3 nM ZM-241,385 as marker ligand. Values 
are mean kon in M
-1 min-1 ± SEM and mean koff in min
-1 of at least three independent experiments 
performed in duplicate. 
 kon






















9.5 ± 0.7 
x107 
13 ± 6 
x107(a) 








MSX-2 5.4 ± 0.6 
x106 
2.4 ± 0.2 
x106 








LUF6632 0.7 ± 0.1 
x107 
3.4 ± 0.4 
x107(a) 








a: D. Guo, ChemMedChem, 2014.14 
 
Linear regression performed on the correlation plots of MS binding data (based on 
M/IS detection) against radioligand binding data yielded the following coefficients of 
determination and equations: R2 = 0.985 and y = 1.04x – 0.199 (Ki and KD, Figure 7A), R
2 = 
0.775 and y = 0.738x + 2.09  (kon, Figure 7C), and R
2 = 0.968 and y = 1.06x – 0.0550 (koff, 
Figure 7E). Similar correlation plots of MS binding data without IS compensation, solely 
based on marker peak area, against radioligand binding data yielded R2 = 0.988 and y = 
1.05x – 0.299 (Ki and KD, Figure 7B), R
2 = 0.735 and y = 0.767x + 1.82 (kon, Figure 7D), and 
R2 = 0.940 and y = 1.33x – 0.0168 (koff, Figure 7F). 
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Figure 7. (Previous page). Correlation plots of results obtained by MS binding and radioligand 
binding assays on hA1AR and hA2AAR. Values of marker ligands DPCPX and ZM-241,385 were 
measured directly on their respective binding targets hA1AR and hA2AAR by saturation (A, B), 
association (C, D), and dissociation (E, F) assays, while values of the competing ligands were 
measured indirectly by displacement (A, B) and competition association assays (C-F). Affinity values 
in pKD and pKi (A, B), association rates in kon (C, D), and dissociation rates in log koff (E, F) were 
compared. Correlation plots A, C, and E show MS binding results standardized with deuterium-
labeled internal standard, while B, D, and F show truly label-free MS binding results without internal 
standard. Data points represent mean values of at least three separate experiments performed in 
duplicate. R
2 values were calculated by linear regression performed on log-transformed values. 
 
Discussion 
Preparation of internal standards 
Including an internal or external standard is good practice in mass spectrometry, to 
compensate for ion suppression by matrix effects from cell contents, sample evaporation, 
and instrumental drift.10 We used the internal standard method as this is the most 
accurate manner to compensate for these sources of signal distortion and to increase the 
accuracy of MS methods. Preferably, the internal standard is a molecule with the same 
chemical properties as the molecule of interest but with a distinct mass. Hence, 
deuterated DPCPX (d4) and ZM-241,385 (d4) were synthesized to serve as internal 
standard for the MS binding assays on hA1AR and hA2AAR, respectively.  The resulting mass 
difference between the parent compounds and their internal standards ensured minimal 
signal overlap by their isotope patterns. For the synthesis of [2H4]ZM-241,385 5, the pure 
isotopologue [2H4]tyrosine (SI 14) was commercially available as precursor for the 
[2H4]tyramine 4 building block. For the synthesis of [
2H4]DPCPX 2, the building block 1 was 
deuterated in-house by a rhodium-catalyzed reduction of two allylic double bonds in the 
presence of deuterium gas generated in situ. During this process, deuterium-hydrogen 
scrambling occurred which resulted in a mixture of isotopologues [2H0]DPCPX to 
[2H8]DPCPX in a Gaussian distribution as final product. This had no negative influence on 
the results of the MS Binding assays, since the masses of parent ions and fragments of the 
most abundant isotopologue [2H4]DPCPX 5 were selected for quantification.  
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MS binding assays 
Affinity, association, and dissociation rates measured directly for the marker ligands 
DPCPX on the hA1AR and ZM-241,385 on the hA2AAR were in good agreement to the 
values found in radioligand binding assays (Figures 3 and 5, Tables 2, 5, and 6). The good 
performance of the MS binding saturation, association, and dissociation assays in which 
solely the marker ligand and no competing ligand was present was a prerequisite to 
continue with the MS binding displacement and competition association assays.  
To demonstrate the MS binding displacement assays, a combination of selective and 
nonselective agonists and antagonists were chosen as competing ligands. For the hA1AR 
these ligands were CPA, 8-CPT, ZM-241,385, and NECA, and for the hA2AAR they were UK-
432,097, MSX-2, DPCPX, and NECA. The determined affinity values were in good 
agreement between MS binding and radioligand binding assays for all these competing 
ligands (Figure 4, Tables 3 and 4). Furthermore, the binding of agonists CPA and NECA to 
the hA1AR fitted to a pronounced two-phase displacement curve as was found before in 
radioligand binding assays. 
Kinetic properties of ligands are of emerging interest and are thought to be important 
predictors of clinical performance.3, 27 Therefore, we developed and validated MS binding 
competition association assays by which kinetic properties of competing ligands can be 
analyzed by measuring the amount of bound marker ligand at different time points in the 
presence of one concentration of these competing ligands. A fast and a slowly dissociating 
competing ligand were chosen for each target. Fast- and slow-dissociating ligands yield 
distinct characteristic competition association graphs, without and with overshoot, 
respectively. For the hA1AR the ligands 8-CPT and FSCPX, and for hA2AR MSX-2 and 
LUF6632 were tested. 8-CPT and MSX-2 dissociate fast from their targets. FSCPX is an 
irreversibly binding antagonist selective for the hA1R
13, 28, 29 and thus yields the 
characteristic overshoot graph for slowly dissociating ligands,26 with the exception that it 
eventually displaces the marker ligand DPCPX completely (Figure 6A). LUF6632 was 
characterized earlier as a slowly dissociating ligand selective for the hA2AAR.
14 
Dissociation rates were in good agreement between the MS binding and radioligand 
binding competition association assays (Figure 7E, Tables 5 and 6), with the exception of 
the apparent dissociation rate of the irreversibly binding FSCPX (Table 5). Association rates 
found for the competing ligands in competition association assays varied more, especially 
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for the slowly or not at all dissociating ligands FSCPX and LUF6632 (Figure 7C, Tables 5 and 
6). It has to be noted that as it binds irreversibly to the hA1AR, FSCPX does not actually 
dissociate from the target. However, fitting the FSCPX data into the competition 
association model still enables the calculation of apparent association and dissociation 
rates. Being apparent values, they may vary between studies which could be an 
explanation for the diverging kinetic rates of FSCPX found in MS binding and radioligand 
binding assays (Table 5).  
Altogether, these results validate the use of MS binding assays to determine affinity 
values and dissociation rates by saturation, association, dissociation, and competition 
association assays. However, association rate determination was only accurate by direct 
measurement on the marker ligands. 
Necessity of deuterium-labeled internal standard  
As mentioned above, including an internal or external standard is good practice in mass 
spectrometry. We used the internal standard method as this is the most accurate manner 
to compensate for sources of signal distortion. However, the use of a deuterium-labeled 
internal standard makes the MS binding assay a labeled assay, even if the marker ligand 
that binds to the target is itself unlabeled. For fast screening of new marker ligands, the 
use of an external standard or even no standard at all would be vastly advantageous, as 
the whole assay becomes an unlabeled assay. Moreover, to directly determine association 
and dissociation rates of nonlabeled ligands would be an improvement over the use of 
competition association assays. Therefore, we compared the performance of the MS 
binding assay with and without compensation by deuterium-labeled internal standard. 
Although in the latter case the resulting graphs of each separate experiment were 
somewhat less accurate, Ki and KD values could still be determined without loss of 
accuracy (Figure 7B). The koff values indirectly determined by the competition association 
assay correlated less well with radioligand binding assays, although retaining a good 
coefficient of determination (Figure 7F). The determination of kon values correlated less 
well with radioligand binding assays irrespective of the use of an internal standard (Figures 
7C and D). In contrast to this, the directly measured association and dissociation rates of 
marker ligands DPCPX and ZM-241,385 were still in good agreement with radioligand 
binding experiments (Tables 5 and 6). 
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Conclusions 
We developed and validated MS binding assays for the adenosine A1 and A2A receptors. 
The results from ligand saturation, association, dissociation, and displacement assays were 
in good agreement with radioligand binding data. The results from competition 
association assays were in good agreement with radioligand binding data for dissociation 
rates but less so for association rates. Furthermore, we investigated the necessity to 
include deuterium-labeled internal standards in MS binding assays. Saturation, 
association, dissociation, and displacement assay results were still in good agreement with 
radioligand binding assays when the internal standard was not included. In competition 
association assays, the inclusion of an internal standard was beneficial for good 
correlation of dissociation rates with radioligand binding data. However, by excluding the 
use of internal standards in MS binding assays, it would be relatively simple to measure 
association and dissociation rates of a number of unlabeled ligands directly, without the 
need for competition association assays. We conclude that the use of deuterium-labeled 
internal standards is in this case unnecessary which makes the MS binding assay a truly 
unlabeled ligand binding assay. As this internal standard-free approach may be applied to 
other targets than the currently investigated adenosine A1 and A2A receptors, we foresee 
the promising future application of MS binding to directly measure binding properties by 
saturation, association, and dissociation assays, without the use of any labeled internal 
standards.  
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Supplemental information 
Supplemental information includes full experimental procedures for synthesis of 
[2H4]DPCPX 2 and [
2H4]ZM-241,385 5, including Schemes 3 and 4, and can be found with 
this article online at dx.doi.org/10.1007/s11302-015-9477-0 
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The main theme of this thesis, allosteric modulation effectuated through the sodium ion 
site of GPCRs, is inspired by the important role that this site appears to play in GPCR 
signaling. As sodium ions are abundant under physiological conditions they may affect 
GPCR signaling considerably. Receptor activation causes a substantial rearrangement of 
the sodium ion site, suggesting that it has an important role in this process.1  
Chapter 2 reviews the current knowledge on allosteric modulation of amiloride and its 
derivatives binding to the sodium ion site of Class A GPCRs. Chapters 3 to 5 follow-up on 
the recent crystal structure of the adenosine A2A receptor with a sodium ion bound.
2 
Chapters 3 and 4 complement the crystal structure with additional results from combined 
biochemistry, biophysical, molecular dynamics, and mutational studies. Chapter 5 
describes the synthesis of novel amiloride derivatives that bind in the sodium ion site but 
also protrude into the orthosteric binding site. In Chapters 3 to 5, radio-labeled ligands 
were used to quantify ligand binding to the receptor, and Chapter 6 describes an 
alternative approach towards ligand binding assays. Instead of using a radio-label, mass 
spectrometry was used to quantify the binding of an unlabeled ligand to the adenosine A1 
and A2A receptors. 
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Conclusions 
A versatile allosteric site and tool compounds to probe its properties  
Even though the sodium ion site is a well conserved allosteric site among Class A GPCRs, it 
is versatile in the ligands that it can bind and the resulting allosteric effects. Not only does 
it bind the sodium ion, but also the small molecule amiloride and its derivatives. Chapter 2 
of this thesis reviews the variety of amiloride derivatives and the different allosteric 
effects that they can exert on Class A GPCRs. A general trend is the higher affinity for 
GPCRs of amilorides with lipophilic substituents over the parent amiloride. Amilorides 
have been found to allosterically modulate adenosine, adrenergic, dopamine, chemokine, 
muscarinic, serotonin and gonadotropin-releasing hormone receptors. Of these, the 
adenosine, α-adrenergic, and dopamine receptors experience the highest degree of 
modulation by amiloride and analogues. Due to the fact that the sodium ion site is well 
conserved it is to be expected that amilorides can also bind and modulate other GPCRs 
not yet investigated for their sensitivity. 
The allosteric effects triggered by amilorides binding to GPCRs can be divided in 
positive and negative allosteric modulation, and competitive and noncompetitive 
displacement of the orthosteric ligand. The type of allosteric effect depends on whether 
the orthosteric ligand is an agonist or an antagonist and on the specific GPCR type. Even 
for closely related sub-types of GPCRs the effects can be quite different. For most 
receptors amilorides act as negative allosteric modulators of both agonist and antagonist 
binding. However, for some receptors amilorides display probe dependency as they act as 
positive allosteric modulators of agonist binding but not of antagonist binding. Examples 
of this amiloride probe dependency have been found for the adenosine A3 and the α2A-
adrenergic receptors. In the case of the α2B-adrenergic receptor differently substituted 
amiloride derivatives can even have either negative or positive allosteric effects on 
antagonist binding. The flexibility of such a conserved site to exert different allosteric 
effects by the binding of very similar molecules is intriguing and suggests a role for amino 
acids not directly involved in sodium ion binding.  
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A physiological role for allosteric modulation 
Allosteric modulation as a general concept has been found on many different targets, also 
beyond the GPCR superfamily. As a definition, allosteric sites are distinct from orthosteric 
sites where endogenous ligands bind. This implies that no (known) endogenous ligands 
bind to allosteric sites, and hence allosteric ligands are usually found in high-throughput 
screens of large collections of non-endogenous ligands.3 This does not exclude that 
allosteric sites have no endogenous ligands binding to them, but in general these have not 
been found.4 Without the need to accommodate the binding of endogenous ligands, 
allosteric sites have supposedly less evolutionary pressure to stay the same. This is an 
advantage for drug design for sub-types of GPCRs. The orthosteric site of receptor sub-
types (for instance the adenosine A1, A2A, A2B, and A3 receptors) endure evolutionary 
pressure to keep similar features, as they bind the same endogenous ligands, and this is a 
challenge when designing ligands selective for one sub-type. Allosteric sites which do not 
feel this evolutionary pressure can have more diverse features, making it easier to develop 
ligands that are sub-type selective.4, 5  
The allosteric sodium ion binding site is an exception to this rule. First of all, the 
sodium ion binds in this site, which may be defined as an endogenous ligand, for its 
abundant presence in the body. The sodium ion site is remarkably well conserved amongst 
Class A GPCRs, suggesting major evolutionary pressure to maintain its features.1 Indeed, 
one of the conclusions of Chapter 3 of this thesis is that the physiological concentration of 
sodium ions is high enough to occupy the sodium ion site of 75 % of adenosine A2A 
receptors present in the body, substantially reducing their sensitivity to activation by 
endogenous adenosine. This points to a role of sodium ions as suppressors of in-vivo 
adenosine A2A receptor activation. Again, the high conservation of the sodium ion site 
amongst Class A GPCRs suggests that this is an important general mechanism for 
organisms to control GPCR activity. Indeed, the inhibitory effect of sodium ions at 
physiologically relevant concentrations has been found for many GPCRs. This also implies 
the importance to control sodium ion concentrations for in vitro ligand binding assays.  
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Sodium ions stabilize the adenosine A2A receptor in the inactive state 
Even without access to structural information, a few decades of studying the effects of 
sodium ions and amiloride on GPCRs established that they bind to an allosteric site, 
instead of the orthosteric site. The recent elucidation of GPCR crystal structures with a 
bound sodium ion revealed the molecular details of its binding in the allosteric sodium ion 
site. Previous crystal structures of GPCRs in the antagonist-bound state likely had a sodium 
ion bound in the sodium ion site, as usually a large concentration of sodium ions is added 
to stabilize the inactive state of the receptor, but the relatively small ion could not be 
detected due to the limited resolution of these structures.1 The first crystal structure with 
sufficiently high resolution to reveal a bound sodium ion was of the adenosine A2A 
receptor.2 The sodium ion was held by a ionic interaction with Asp522.50, confirming 
previous results tying this residue to sodium ion effects,6 and a hydrogen-bonding network 
of waters and amino acids forming the sodium ion site. One of the most eye-catching 
differences between the inactive sodium ion bound structure and the active structure was 
the occlusion of the sodium ion site in the active structure, which suggested that binding 
of a sodium ion to an agonist-bound receptor is impossible.  
Chapter 3 follows up on this crystal structure studying in more detail the differences in 
allosteric effects exerted by sodium ions and amilorides binding in the sodium ion site. The 
allosteric effects of sodium ions, amiloride, and its analogue HMA on orthosteric ligand 
binding to the adenosine A2A receptor were evaluated by a combination of molecular 
dynamics, radioligand binding, and thermostability studies.  It was concluded that an 
antagonist ([3H]ZM-241,385) and a sodium ion can bind to the receptor simultaneously, 
while the binding of an agonist ([3H]NECA) and a sodium ion excludes each other. The 
results indicated that binding of a sodium ion to the sodium ion site stabilizes the receptor 
in its inactive conformation, thereby prohibiting agonist binding, but facilitating antagonist 
binding. The stabilization of Trp2466.48 by the sodium ion appeared to play an important 
role in maintaining the inactive conformation. This fits well with the previous identification 
of Trp2466.48 as a “toggle switch” for receptor activation.7  
In contrast to sodium ions, amiloride and HMA displaced both the agonist and 
antagonist, but they still displayed distinct allosteric effects between the two. Similar to 
sodium ions, the amilorides displaced agonist [3H]NECA competitively, while the 
amilorides and antagonist [3H]ZM-241,385 could bind simultaneously. Unlike sodium ions 
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however, the amilorides displaced the antagonist in a noncompetitive manner, likely by 
pushing Trp2466.48 into a different rotameric position. This suggests that amiloride binding 
results in a delicate balance between improved stability of the inactive receptor 
conformation and an indirect, noncompetitive, interference with antagonist binding.  
Mutations to further investigate the sodium ion site 
The presence or absence of a sodium ion in its binding site seems to dictate the 
conformation of the receptor in either its inactive or active states, respectively. Hence, 
Chapter 4 of this thesis focuses on the amino acids forming the sodium ion site and their 
purpose in receptor activation. Site-directed single point mutations into alanine of 
Asp522.50, Ser913.39, Trp2466.48, Asn2807.45, and Asn2847.49 were evaluated for their effect 
on orthosteric ligand binding, allosteric modulation by sodium ions and amilorides, and 
receptor activation. Except for Asp522.50, the mutation of these sodium ion site amino 
acids lowered the affinity of agonist [3H]NECA binding substantially, but did not affect 
antagonist [3H]ZM-241,385 binding as much. As Trp2466.48 is the only residue interacting 
directly with an agonist binding in the orthosteric site, the residues Ser913.39, Asn2807.45, 
and Asn2847.49 must be important for maintaining a conformation of the receptor that is 
indirectly suitable for agonist binding.    
All these sodium ion site mutations either abrogated or reduced the negative 
allosteric effect of sodium ions on agonist binding, but had mixed effects on amiloride and 
its derivative HMA. D52A2.50 reduced their potency, confirming the docking pose of the 
amilorides in which their positively charged guanidinium moiety engages in an ionic bond 
with the negatively charged Asp522.50, similar to the sodium ion. In contrast, W246A6.48, 
N280A7.45, and N284A7.49 increased the potency of the amilorides, with a remarkably large 
effect of the Trp2466.48 mutation. This indicates that these residues hinder the binding of 
amiloride and HMA into the sodium ion site.  
Finally, mutation of the amino acids forming the sodium ion site substantially affected 
receptor activation. Mutations D52A2.50 and N284A7.49 completely abolished the receptor’s 
ability to be activated, while mutations S91A3.39 and N280A7.45 induced constitutive activity 
of the receptor, and mutations S91A3.39, W246A6.48, and N280A7.45 decreased the agonist 
activation response of the receptor. From this it can be concluded that besides their effect 
on sodium ion, amiloride, and orthosteric ligand binding, the amino acids forming the 
sodium ion site are involved in the activation mechanism of the adenosine A2A receptor. 
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In molecular dynamics simulations, D52A2.50 caused the sodium ion to dissociate 
promptly towards a vestibule pocket, formed by Glu131.39 and His2787.43, suggesting a 
pathway for sodium ion entering the sodium ion site. Indeed these residues had been 
found to be important for allosteric modulation by sodium ions in a previous mutation 
study.8 His2787.43 is also important for agonist binding, as shown in the same study and in 
the agonist-bound crystal structure of the adenosine A2A receptor, suggesting a second 
site next to the sodium ion site where sodium ions can antagonize agonist binding.  
Larger amiloride derivatives reach into the orthosteric binding site 
The abundance of different 5’-substituted amiloride analogues that can allosterically 
modulate the adenosine A2A receptor but also GPCRs in general, encourages further 
investigation of the possibilities for different moieties on this position. In Chapter 5, 
different phenethyl substitutions on the 5’ position of amiloride were evaluated for their 
allosteric effect on binding of the antagonist [3H]ZM-241,385 to the wild-type and 
W246A6.48 mutated adenosine A2A receptor. On the wild-type receptor, the 4-
ethoxyphenethyl substituted amiloride yielded a higher potency than reference amiloride 
HMA, while methoxy and dioxolylphenethyl derivatives had potencies similar to HMA. 
Docking of these derivatives of amiloride in the sodium ion site suggested that their 
phenethyl moieties entered a hydrophobic pocket close to the sodium ion site, explaining 
the preference for lipophilic moieties on this position. 
Just as for HMA, the novel phenethyl amiloride derivatives had a higher potency for 
the W246A6.48 mutated receptor, confirming their binding in the sodium ion site. Indeed, 
docking of these amiloride phenethyl-derivatives revealed a steric clash with residue 
Trp2466.48, pushing it towards another rotameric position, just as observed for amiloride 
and HMA in Chapter 3. The bulkiest dioxolyl and ethoxyphenethyl derivatives benefited 
the most in their potency from the absence of the tryptophan, suggesting that bulkier 5’ 
substituents increase the steric clash with Trp2466.48. 
The docking modes of the amiloride derivatives predicted that their elongated 
phenethyl substituents protrude into the orthosteric site pocket and can engage in a 
direct competition with orthosteric ligands. This was supported by the observed effects of 
the amilorides on the dissociation kinetics of antagonist [3H]ZM-241,385 on the wild-type 
receptor. Whereas HMA accelerated antagonist dissociation the most, signifying a 
noncompetitive interaction, the phenethyl derivatives had less effect on antagonist 
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dissociation. The dioxolylphenethyl derivative did not affect the dissociation of the 
antagonist at all, signifying a completely competitive displacement of the antagonist. 
An unlabeled ligand binding assay 
In Chapters 3 to 5 of this thesis radioligand binding assays were applied to quantify ligand 
binding to the adenosine A2A receptor. Although radioligands are recognized as robust and 
reliable tools in the measurement of ligand binding, they have their drawbacks in terms of 
safety, production costs, and waste disposal. Alternative ligand binding assays are 
therefore of interest. Such an alternative approach was sought in the quantification of the 
binding of unlabeled ligands to their targets by mass spectrometry, or MS binding. The 
ongoing development of mass spectrometers increases their sensitivity and has opened 
the possibility to accurately quantify the small amounts of ligands that are found in ligand 
binding assays, usually in the pM range. The group of Wanner has pioneered the MS 
binding assay for several targets, among which GPCRs.9 In Chapter 6 of this thesis, we 
developed and validated the MS binding assays for additional GPCR targets, the adenosine 
A1 and A2A receptors. 
As unlabeled marker ligands for the MS binding assay DPCPX and ZM-241,385 were 
chosen, ligands with a high selectivity and affinity for the adenosine A1 and A2A receptors, 
respectively. The application of marker ligands in MS binding is analogous to radioligands 
in radioligand binding, and the availability of radio-labeled versions of these ligands makes 
for a straightforward validation of the MS binding assay by radioligand binding assays. 
Although the ligand that is binding to the receptor itself is unlabeled, it is good practice in 
mass spectrometry to add a fixed concentration of internal standard to each injected 
sample to increase the accuracy of MS quantification. Preferably this is a deuterated 
version of the marker ligand, which has the same column retention time due to similar 
chemical properties, but can be discerned in MS by its different molecular weight. For this 
purpose, deuterium-labeled DPCPX and ZM-241,385 were synthesized. Subsequently, an 
LC-MS method to quantify pM concentrations of the marker ligands was developed, with 
their deuterium-labeled counterparts as internal standards. 
With the MS quantification method developed, saturation, association, and 
dissociation MS binding assays were performed and validated against radioligand binding 
assays. Furthermore, displacement assays were performed and validated in which the 
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affinity of other ligands can be indirectly measured through their competition with the 
marker ligand. Finally, the MS binding assay was for the first time successfully applied to 
the competition association assay, in which the marker ligand competes with another 
ligand for association to the receptor. This allows for the determination of association and 
dissociation rates of the other ligand indirectly through fitting the association data of the 
marker ligand to the model of Motulsky and Mahan.10 
The necessity to use an internal standard in the mass spectrometry quantification step 
was scrutinized. The internal standard is used to compensate for sources of signal 
distortion in MS quantification. Ligand binding assays typically use multiple measuring 
points to determine affinity and kinetic properties of ligands, and this already leads to a 
certain degree of compensation for deviations of individual points. This aspect of ligand 
binding assays could mean that compensation of MS quantification results by an internal 
standard does not add significantly to their accuracy. Indeed, similar Ki, kon, and koff values 
were obtained from data that was either compensated by internal standard quantification 
and from data without this compensation, indicating that an internal standard is not 
strictly necessary in MS binding assays. Thus, the MS binding assay allows to measure 
affinity and kinetic ligand properties without the need to synthesize any labeled ligand. 
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Future perspectives 
Protein structure elucidation and GPCRs 
The field of GPCR structural biology has been greatly advanced by the elucidation of the X-
ray crystal structures of 30 different types of GPCRs. As to the sodium ion site, the 
elucidation of sodium ion-bound GPCR structures has revealed the molecular details of 
sodium ion binding, adding importantly to the already existing body of pharmacological 
evidence of modulation of GPCRs by sodium ions. The availability of structural information 
inspires new pharmacological studies of the sodium ion site, as exemplified by Chapters 3 
to 5 of this thesis.  
Many GPCRs remain to be crystallized though, as the GPCR family consists of more 
than 800 different receptors. As GPCRs are membrane proteins, they are hydrophobic in 
nature and this is one of the challenges in growing crystals that are viable for X-ray 
diffraction. This has mainly to do with their stability when taken out of their natural 
membrane environment. Except for rhodopsin, GPCR crystal structures could only be 
solved with the help of different protein engineering methods, such as thermostabilizing 
point mutations, insertion of hydrophilic regions obtained from other proteins, and 
deletion of flexible loop and terminus regions.11  Additionally, the resulting engineered 
GPCRs should reach sufficiently high expression levels to produce the large quantities of 
pure protein needed for the crystallization process. One approach to facilitate the 
elucidation of crystal structures of the remaining human GPCRs, is to systematically screen 
all of them for suitable engineered fusion constructs with sufficiently high expression 
levels.12 
A limitation of X-ray crystallography is that it only catches a snapshot of the protein 
structure that is frozen in time. However, GPCRs are dynamic proteins with many different 
possible conformations. The comparison of antagonist (inactive) and agonist (active) 
bound structures may reveal the global movements required for receptor activation, but 
less stable intermediate conformations will be likely missed as the actual activation 
process is not followed. Techniques that allow following protein dynamics in time are in 
full development for GPCRs, for example solid- and solution-state nuclear magnetic 
resonance (NMR) and serial femtosecond crystallography (SFX).  
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NMR allows detecting the dynamics of isotopically labeled amino acids. The study of 
GPCRs by NMR has been primarily focused on GPCR regions due to protein size restrictions 
of this technique.13 However, through isotope labeling of a limited number of amino acids 
spread over the receptor, the global dynamics of the receptor’s backbone can be followed, 
as recently applied to the β1-adrenergic receptor
14 and the adenosine A2A receptor.
15 SFX 
enables to gather data from protein crystals by X-ray free electron laser (XFEL) without 
damaging the proteins, in contrast to X-ray crystallography.16 This allows structural data to 
be obtained at room temperature, thus physiologically more relevant than X-ray 
crystallography, and from smaller crystals, simplifying the crystal growth step. Until now 
SFX has been used to obtain structural GPCR snapshots, for example for the serotonin 5-
HT2B receptor,
17 but it holds the promise of time-resolved structural studies of GPCR 
activation, for example on the conformational changes of rhodopsin induced by light.18 
Advances in molecular dynamics 
The availability of structural information opened the possibility to apply molecular 
dynamics to computationally simulate GPCR dynamics.19 With the captured snapshot from 
a crystal structure as a starting point, molecular dynamics simulates ‘in silico’ the 
subsequent events on an atomic and femtosecond scale. This allows to follow various 
processes, such as structural rearrangements upon receptor activation,20 ligand 
association,21 and ligand dissociation.22 As techniques to follow structural receptor 
dynamics in real-time are still nascent, molecular dynamics may provide a good 
alternative. Even if molecular dynamics is a powerful tool to understand receptor 
dynamics on a molecular scale, it remains a simulation depending on force-fields that only 
approximate actual atomic interactions. This makes it desirable to support conclusions 
drawn from ‘in silico’ molecular dynamics studies by ‘wet lab’ biochemical experiments, as 
demonstrated in Chapters 3 and 4 of this thesis. 
One of the drawbacks of molecular dynamics is the vast amount of computational 
power needed to simulate complex systems such as GPCRs on an atomic scale.19 
Calculations to complete microsecond simulations typically take weeks or months, while 
conformational rearrangements upon GPCR activation may take milliseconds to 
complete.23, 24 Certain ‘tricks’ can be applied to increase calculation speeds and simulation 
lengths, such as reducing energy barriers and temperature accelerated molecular 
dynamics,25 but these also reduce the accuracy of the simulation. However, the availability 
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of computing power keeps expanding exponentially, which continuously enables 
molecular dynamics to tackle more complex systems while decreasing calculation times 
and increasing simulation accuracy. 
Bitopic ligands and their implications 
Next to crystal structures with a sodium ion bound, a few crystal structures with small 
molecule allosteric modulators bound have been elucidated to date, namely of the M2 
muscarinic receptor and the metabotropic glutamate 1 and 5 receptors.26-28 Most of GPCR 
crystal structures have been co-crystallized with high affinity orthosteric ligands, as these 
reinforce protein stability substantially.29 The generally low affinity of allosteric 
modulators for GPCRs is a challenge for acquiring high resolution crystal structures with 
these co-crystallized. Amiloride and HMA are no exception with their affinities in the µM 
range. A crystal structure of the adenosine A2A receptor with an amiloride derivative co-
crystallized would add much information to the findings of Chapters 3 to 5 of this thesis, 
for instance the exact mechanism behind the observed probe dependency and the 
differences in competitive interaction with orthosteric ligands. The results of Chapter 5 
imply the possibility to synthesize a bitopic ligand, which binds in both the allosteric 
sodium ion site and the orthosteric site of the adenosine A2A receptor. The increase in 
possible interactions of such a bitopic ligand upon binding to the receptor would likely 
result in a higher affinity than of an ‘ordinary’ amiloride derivative, making it a viable 
option for co-crystallization with the adenosine A2A receptor.  
Another drawback of amiloride and HMA is their nonselectivity, as they do not only 
bind to many GPCRs but also to other proteins. This makes their application in cell-based 
assays complicated, as it would be hard to pin-point their effects to one target. However, 
cell-based assays are necessary to study the effects of amiloride binding on the receptor 
activation. The recent finding that HMA induces the same conformation of the adenosine 
A2A receptor as a partial agonist emphasizes the value of such a study.
15 A bitopic ligand 
could offer a solution, as it may be more selective through interaction with less conserved 
residues in the orthosteric site. The same interactions with the orthosteric site will 
probably mean that they do not behave as ‘classic’ allosteric modulators, but it would still 
be interesting to study their effects on GPCR signaling in a more physiologically relevant 
system. 
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Mass spectrometry binding without internal standard 
The application of MS binding without the need for a deuterium-labeled internal standard 
in Chapter 6 of this thesis has interesting implications for its further development. 
However, the lack of an internal standard would require a careful control of factors that 
distort mass spectrometry read-outs, i.e. evaporation rates during the elution step, and 
drift and ion suppression during the quantification step. Evaporation rates may be 
reduced by improvements in the elution protocol, for example by incorporating an 
evaporation step and subsequent resuspension of the residue in fixed amounts of elution 
buffer. Improved drift suppression might be reached by ongoing improvements in mass 
spectrometry equipment. Regarding ion suppression, we observed in our work that 
variable ion suppression was mainly caused by the presence of changing concentrations of 
‘cold’ ligand in the elution buffer. For displacement and competition association assays 
this situation is a given, but in saturation, association, and dissociation assays the ‘cold’ 
ligand is inherently absent, thereby removing a substantial source of ion suppression.  
Without the need to synthesize a deuterium labeled internal standard, the development 
of LC-MS quantification protocols for marker ligands would be relatively fast, and this 
would allow to directly determine the KD value and kon and koff rate constants of a series of 
ligands. 
Other mass spectrometry prospects in membrane protein research 
Mass spectrometry is also applied in other ways in membrane protein research. One 
example is endogenous or native mass spectrometry (nMS) which identifies different 
membrane protein-lipid or ligand complexes by their different sizes.30 Differently to the 
MS binding assay, the protein-ligand complex is not denatured before the mass 
spectrometry detection step, so that the intact native membrane protein assembly can be 
probed. To keep the protein intact during the nMS analysis asks for a more complex 
approach than with MS binding, but has the possibility to yield valuable information about 
protein interactions, as endogenous protein ensembles with lipids, peptides, and drugs 
can be detected and identified by their differences in mass. This technique may therefore 
yield great opportunities to find new (endogenous) allosteric modulators of membrane 
proteins and GPCRs in particular. 
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Final note 
This thesis provides a detailed insight in the value of the allosteric sodium ion site for 
GPCR functioning. Inspired by a high resolution crystal structure of the adenosine A2A 
receptor with a sodium ion bound, we explored different aspects of the sodium ion site. 
This resulted in insights into the probe dependency of sodium ions and amilorides, 
evidence for the crucial role of the amino acids of the sodium ion site in receptor signaling, 
and opportunities to design novel bitopic amiloride derivatives that bind in both the 
sodium ion site and the orthosteric site. Furthermore, an unlabeled ligand binding assay 
was developed for the adenosine A1 and A2A receptors by means of mass spectrometry. 
This MS binding assay proves to be an excellent alternative for the conventional 
radioligand binding assay, without the need to synthesize any labeled ligand. 
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The study of allosteric modulation offers new insights in the activation mechanisms of G 
protein-coupled receptors (GPCRs). The sodium ion site is an allosteric site that is well 
conserved among Class A GPCRs. Even though it is well conserved, the allosteric sodium 
ion site is versatile in its allosteric effects and the size of ligands that can bind, from 
sodium ions to 5’-amino and 2-guanidino substituted amilorides (Chapter 2). The 
adenosine A2A receptor was the first GPCR to be crystallized with a sufficiently high 
resolution to reveal a sodium ion bound in the sodium ion site. In this thesis I applied the 
adenosine A2A receptor as a model GPCR for the study of allosteric modulation effected by 
the sodium ion site (Chapters 3 – 5), and together with the adenosine A1 receptor for the 
development of a ligand binding assay based on mass spectrometry (Chapter 6).  
The sodium ion site and the orthosteric site of the adenosine A2A receptor can be 
occupied simultaneously when an antagonist is bound in the orthosteric site, but not 
when an agonist is bound (Chapter 3). Sodium ions seem to stabilize the inactive 
conformation, thereby promoting antagonist binding, but excluding agonist binding at a 
physiologically relevant sodium ion concentration. By binding into the sodium ion site, 
amiloride analogues also exhibit distinct patterns of agonist and antagonist modulation.  
Next to its effect on orthosteric ligand binding, the allosteric sodium ion site facilitates 
receptor signaling (Chapter 4). Mutation of the amino acids that form the sodium ion site 
influenced the affinity of ligands binding to it and to the orthosteric site, but also changed 
the capacity of the receptor as a whole to be activated by agonists. Mutation of the polar 
residues in the sodium ion pocket was shown to either abrogate (D52A2.50 and N284A7.49) 
or reduce (S91A3.39, W246A6.48, and N280A7.45) the negative allosteric effect of sodium ions 
on agonist binding. Mutations D52A2.50 and N284A7.49 completely abolished receptor 
signaling, while mutations S91A3.39 and N280A7.45 elevated basal activity and mutations 
S91A3.39, W246A6.48, and N280A7.45 decreased agonist-stimulated receptor signaling. In 
molecular dynamics simulations D52A2.50 directly affected the mobility of sodium ions, 
which readily migrated to another pocket formed by Glu131.39 and His2787.43. The D52A2.50 
mutation also decreased the potency of amiloride with respect to orthosteric ligand 
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displacement, but did not change orthosteric ligand affinity. In contrast, W246A6.48 
increased some of the allosteric effects of sodium ions and amiloride, while orthosteric 
ligand binding was decreased. 
Amiloride can be extended with substituents at the 5’ position to produce amiloride 
derivatives with different allosteric properties and similar or even higher potencies than 
HMA at the wild-type adenosine A2A receptor (Chapter 5). The potency of a series of 5’-
substituted amiloride derivatives was assessed by their ability to displace orthosteric 
radioligand [3H]ZM-241,385 from both the wild-type and sodium ion site W246A6.48 
mutant adenosine A2A receptors. Of this series, 4-ethoxyphenethyl-substituted amiloride 
12l was found to be more potent than HMA. Similar to amiloride and HMA, the novel 
amiloride derivatives showed significantly higher potencies at the W246A6.48 mutant 
adenosine A2A receptor, implying that Trp246
6.48 hinders the binding of these amiloride 
derivatives. HMA showed the largest allosteric effect on [3H]ZM-241,385 dissociation, 
whereas the most potent novel amilorides 12h, i, k, and l showed reduced or no effects on 
this dissociation process. This indicates that these novel amilorides engage in a more 
direct competition with the orthosteric ligand, and it can be hypothesized that they do so 
by intrusion into the orthosteric pocket. The striking differences in effect on the 
dissociation of [3H]ZM-241,385 between the wild-type and W246A6.48 adenosine A2A 
receptors imply that Trp2466.48 influences the nature of the allosteric interaction by 
amilorides. 
Mass spectrometry is a valid alternative to radioligand detection for the quantification 
of ligand binding to the adenosine A1 and A2A receptors (Chapter 6). Despite the 
robustness of radioligand binding assays, they carry inherent disadvantages in terms of 
safety precautions, expensive synthesis, special laboratory requirements, and waste 
disposal. Mass spectrometry is a method that can selectively detect ligands without the 
need of a label. The sensitivity of mass spectrometry equipment increases progressively, 
and currently it is possible to detect the low ligand quantities that are usually found in 
ligand binding assays. We developed a label-free mass spectrometry ligand binding (MS 
binding) assay for the adenosine A1 and A2A receptors. Radioligand binding assays for both 
receptors are well established, and ample data is available to compare and evaluate the 
performance of an MS binding assay. To prove the feasibility of MS binding on the 
adenosine A1 and A2A receptors we first developed a mass spectrometry detection method 
Summary | 171 
for unlabeled DPCPX and ZM-241,385, which are ligands with high selectivity and affinity 
for the respective receptors. To serve as internal standards, both compounds were also 
deuterium-labeled. Subsequently, we investigated whether the two unlabeled compounds 
could substitute for their radiolabeled counterparts as marker ligands in binding 
experiments, including saturation, displacement, dissociation, and competition association 
assays. Furthermore, we investigated the accuracy of these assays if the use of internal 
standards was excluded. The results demonstrate the feasibility of the MS binding assay, 
even in the absence of a deuterium-labeled internal standard, and provide great promise 
for the further development of label-free assays based on mass spectrometry for other 
GPCRs. 
Chapter 7 concludes this thesis by reflecting on its contents and their place in the 
current state of GPCR research, and on the future perspectives that this field of research 
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Onderzoek naar allostere modulatie leidt tot nieuwe inzichten in het activatiemechanisme 
van aan G eiwitten gekoppelde receptoren (‘G protein-coupled receptors’, of afgekort 
GPCRs). Natriumionen binden aan een allostere bindingsplaats die goed geconserveerd is 
binnen de klasse A van GPCRs. Desondanks laat deze bindingsplaats een grote 
verscheidenheid aan allostere effecten en grootte van liganden die kunnen binden zien, 
van natriumionen tot 5’-amino en 2-guanidino gesubstitueerde amilorides (Hoofdstuk 2). 
De adenosine A2A receptor is de eerste GPCR waarvan een kristalstructuur opgehelderd 
werd met een voldoende hoge resolutie om een natriumion gebonden in de natriumion-
bindingsplaats waar te kunnen nemen. In dit proefschrift wordt de adenosine A2A receptor 
gebruikt als voorbeeldreceptor om de allostere effecten van de natriumion-bindingsplaats 
te onderzoeken (Hoodstukken 3 – 5), en samen met de adenosine A1 receptor om een 
methode te ontwikkelen waarmee ligandbinding aan de receptor gemeten kan worden 
met behulp van massaspectrometrie (Hoofdstuk 6). 
De natriumion-bindingsplaats en de orthostere bindingsplaats van de adenosine A2A 
receptor kunnen tegelijkertijd bezet worden wanneer een antagonist in de orthostere 
plaats gebonden is, maar niet wanneer een agonist gebonden is (Hoofdstuk 3). 
Natriumionen lijken de inactieve toestand van de receptor te stabiliseren, waarmee de 
binding van antagonisten wordt bevorderd, terwijl de binding van agonisten grotendeels 
wordt verhinderd bij een fysiologische concentratie van natriumionen. Amiloride en 
derivaten hiervan laten bij binding in de natriumion-bindingsplaats eveneens verschillen 
zien in de allostere modulatie van agonisten en antagonisten. 
Naast de effecten op de binding van orthostere liganden, is de allostere natriumion-
bindingsplaats ook belangrijk voor de signaaltransductie door de receptor (Hoofdstuk 4). 
Door één voor één de aminozuren die de natriumion-bindingsplaats vormen te muteren, 
kon niet alleen de affiniteit van liganden die op die plaats binden beïnvloed worden, maar 
ook het vermogen van de hele receptor om door agonisten geactiveerd te worden. De 
vervanging van polaire aminozuren door alanine verhinderde de negatieve allostere 
effecten van natriumionen op agonistbinding volledig (D52A2.50 en N284A7.49) of 
gedeeltelijk (S91A3.39, W246A6.48, en N280A7.45). Mutaties D52A2.50 en N284A7.49 schakelden 
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receptoractivatie volledig uit, terwijl S91A3.39 en N280A7.45 de constitutieve activiteit van 
de receptor verhoogden, en S91A3.39, W246A6.48, en N280A7.45 het vermogen van agonisten 
om de receptor te activeren verminderden. In simulaties die de receptordynamiek op 
atomair niveau volgen, had mutatie D52A2.50 een direct effect op het in de kristalstructuur 
in de natriumion-bindingsplaats aanwezige natriumion, dat zich meteen naar een andere 
bindingsplaats bewoog, gevormd door de aminozuren Glu131.39 en His2787.43. Ook 
verlaagde D52A2.50 de potentie van amiloride om orthostere liganden te verdringen, maar 
had deze mutant geen effect op de affiniteit van orthostere liganden. W246A6.48 
daarentegen vergrootte sommige allostere effecten van natriumionen en amilorides, 
terwijl de affiniteit van orthostere liganden verminderde. 
Door amiloride te substitueren op de 5’ positie van het molecuul ontstaan 
amiloridederivaten met afwijkende allostere eigenschappen en gelijke of zelfs hogere 
potentie dan referentiestof HMA op de wild-type adenosine A2A receptor (Hoofdstuk 5). 
De affiniteit van een serie van 5’-gesubstitueerde amiloridederivaten werd vastgesteld 
door hun verdringing van het orthostere radioligand [3H]ZM-241,385 van de wild-type en 
een in de natriumion-bindingsplaats gemuteerde W246A6.48 adenosine A2A receptor te 
meten. Van deze serie was de 4-ethoxyphenethyl-gesubstitueerde amiloride 12l potenter 
dan HMA. Zoals eerder gezien voor amiloride en HMA, hadden de nieuwe 
amiloridederivaten een hogere affiniteit voor de W246A6.48 gemuteerde receptor, wat 
aangeeft dat aminozuur Trp2466.48 hun binding kan verhinderen. HMA had het grootste 
allostere effect op de dissociatiesnelheid van [3H]ZM-241,385, terwijl de meest potente 
nieuwe amilorides 12h, i, k, en l een kleiner of zelfs geen effect op de dissociatie hadden. 
Dit geeft aan dat deze amilorides het orthostere ligand direct kunnen verdringen door de 
orthostere bindingsplaats binnen te dringen. Het grote verschil in het effect op de 
dissociatiesnelheid van [3H]ZM-241,385 tussen de wild-type en de W246A6.48 gemuteerde 
receptor toont aan dat aminozuur Trp2466.48 belangrijk is voor het soort allostere 
interactie dat amilorides teweeg kunnen brengen. 
Massaspectrometrie is een goed alternatief voor de detectie van radioliganden in de 
kwantificering van ligandbinding aan de adenosine A1 en A2A receptoren (Hoofdstuk 6). 
Ondanks dat het meten van radioligandbinding een betrouwbare methode is, heeft het 
ook nadelen, zoals de te nemen veiligheidsmaatregelen, dure synthese, speciale 
laboratoriumvereisten, en afvalverwerking. Met massaspectrometrie kan de aanwezigheid 
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van liganden gemeten worden zonder ze te hoeven labelen met een radio-isotoop. De 
gevoeligheid van massaspectrometrie-apparatuur wordt beter en beter, en met de huidige 
stand van zaken kunnen de lage hoeveelheden van liganden die in bindingsexperimenten 
voorkomen gemeten worden. Dit hoofdstuk beschrijft de ontwikkeling van een label-loze 
massaspectrometrie-gebaseerde methode om ligandbinding te meten (MS-binding) voor 
de adenosine A1 en A2A receptoren. Radioliganden worden veel gebruikt voor de meting 
van ligandbinding aan deze receptoren, waardoor er veel resultaten beschikbaar zijn om 
de MS-bindingsmethode mee te kunnen valideren. Eerst werd een methode ontwikkeld 
voor detectie met de massaspectrometer van ongelabeld DPCPX en ZM-241,385, liganden 
met een hoge selectiviteit en affiniteit voor respectievelijk de adenosine A1 en A2A 
receptoren. Om als interne standaards in de massaspectrometrie-methode te dienen 
werden beide liganden ook gelabeld met deuterium. Vervolgens werd onderzocht of de 
twee ongelabelde liganden hun radio-gelabelde versies konden vervangen in verschillende 
bindingsexperimenten, zoals verzadigings-, verdringings-, dissociatie-, en competitie-
associatie-experimenten. Verder werd onderzocht of het mogelijk was de interne 
standaard niet te gebruiken, zonder de betrouwbaarheid van de resultaten aan te tasten, 
met het doel de MS-bindingsmethode volledig ongelabeld te maken. De resultaten tonen 
aan dat de MS-bindingsmethode goed werkt, zelfs zonder het gebruik van een interne 
standaard, en dit is veelbelovend voor de verdere ontwikkeling van deze label-loze 
methode om ligandbinding te meten op andere GPCRs. 
Hoofdstuk 7 sluit dit proefschrift af met een beschouwing over de inhoud, hoe deze in 
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